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Abstract

Differential effects of endocannabinoid catabolic inhibitors on opioid withdrawal in mice
By Thomas F. Gamage
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013.
Director: Dr. Aron Lichtman, Professor, Department of Pharmacology & Toxicology

The effects of cannabinoids in reducing somatic signs of opioid withdrawal have been
known for some time. In morphine dependent rodents, opioid withdrawal following precipitation
with the mu opioid antagonist naloxone elicits robust withdrawal behaviors including jumps,
paw flutters, head shakes, diarrhea and weight loss. Delta-9-tetrahydrocannabinol has been
shown to reduce this opioid withdrawal in mice via activation of the cannabinoid type-1 (CB1)
receptor and recently it has been shown that inhibition of the catabolic enzymes for
endocannabinoids also reduce somatic signs of opioid withdrawal. Specifically, inhibition the
enzyme fatty acid amide hydrolase (FAAH), the catabolic enzyme for the endocannabinoid Narachidonoylethanolamide (AEA; anandamide) or inhibition of the enzyme monoacylglycerol
lipase (MAGL), the catabolic enzyme for the endocannabinoid 2-arachindonoylglycerol (2-AG)
has been shown to reduce opioid withdrawal in mice. However, FAAH inhibition only reduced a
subset of withdrawal signs in mice and full MAGL inhibition which maximally reduced somatic
withdrawal signs has been shown to produce THC-like effects and dependence potential.
Additionally, the effects of endocannabinoid catabolic inhibitors on other aspects of withdrawal,
xx

such as the negative motivational effects, are not known. The objectives of this dissertation were
to 1) assess the efficacy of dual inhibition of FAAH and MAGL on somatic signs of opioid
withdrawal and 2) determine whether these treatments would produce cannabimimetic effects
(hypomotility, catalepsy, antinociception and hypothermia); 3) develop other behavioral assays
of opioid withdrawal; and 4) determine if endocannabinoid catabolic inhibitors would reduce the
acquisition of opioid withdrawal induced conditioned place avoidance (CPA) as a measure of the
negative motivational consequences of opioid withdrawal. We found that full inhibition of
FAAH with the selective inhibitor PF-3845 and partial inhibition of MAGL with the selective
inhibitor JZL184 reduced withdrawal-related jumps and the expression of diarrhea to a greater
degree than either inhibitor alone and these effects were shown to be CB1 mediated. Additionally,
we tested the novel dual FAAH/MAGL inhibitor SA-57 which has greater potency at inhibiting
FAAH over MAGL and found that it similarly reduced withdrawal signs at doses that only
partially elevated 2-AG while fully elevating AEA; furthermore, SA-57 did not produce
cannabimimetic effects at these doses. We next assessed the effects of morphine withdrawal in
five behavioral assays: marble burying, novelty-induced hypophagia, the light/dark box, a novel
procedure developed to assess “escape behavior” and the CPA procedure. From these studies we
selected the CPA procedure to further evaluate the effects of endocannabinoid catabolic
inhibitors to determine their ability to reduce the negative motivational aspect of opioid
withdrawal. We found that naloxone (0.056 mg/kg) produced robust CPA in morphine-pelleted,
but not placebo-pelleted, mice and that this dose elicited minimal somatic withdrawal signs.
Morphine pretreatment was shown to block withdrawal CPA and withdrawal jumping in mice
while clonidine only blocked withdrawal CPA and these served as positive controls. We found
that THC, JZL184, and SA-57 significantly reduced the percentage of mice that jumped during
xxi

the conditioning session, demonstrating that these treatments blocked the somatic signs of
withdrawal. However, none of these treatments significantly affected acquisition of the
withdrawal CPA. These studies suggest that dual inhibition of FAAH/MAGL has enhanced
effects on attenuating withdrawal-related jumps and diarrhea, but not the negative motivational
aspects of morphine withdrawal as inferred by the Pavlovian CPA experiments.

xxii

Chapter 1: Introduction

1.1. Opioid dependence and addiction in the United States
While opioids are the most potent and efficacious drugs currently available for the
treatment of pain, they possess an abuse potential and dependence liability that limit the safety of
their application. Upon cessation of drug administration, opioid dependence manifests as a
syndrome that includes both physical and psychological withdrawal symptoms. These include
physical aspects such as diarrhea, emesis, dehydration, hypertension, hyperthermia, tachycardia
and body aches as well as affective aspects such as anxiety, dysphoria, and panic attacks (Farrell,
1994; Gossop, 1988; Jasinski, 1981; Wesson et al., 2003). These withdrawal symptoms are
extremely aversive and are considered a primary driver of ongoing drug use (Bart, 2012).
In the United States, non-prescription opioid use has been increasing with approximately
6 million Americans reporting such use in 2009. Dispensed prescriptions for opioids increased
by 50% from 2000 to 2009 (Governale, 2010) and studies suggest that anywhere from 12% to
34% of individuals receiving prescription opioids will abuse them (Chabal et al., 1997; Fishbain
et al., 2008). Emergency room visits involving prescription opioids have more than doubled in
the years between 2004 and 2009 increasing from 198,114 to 477,936 (DAWN, 2010).
Additionally non-medical use of prescription opioids is increasing in the youth (Birnbaum et al.,
2011; McCabe et al., 2005).
The trends are striking and the prognosis for public health in the United States in terms of
opioid abuse and dependence appears even grimmer when other opiates such as heroin are
factored in. While the late 1980s and early 1990s saw a decrease in heroin use, there has been a
1

recent upswing in abuse of heroin since the late 1990s and it still poses a serious threat to public
health (Brown, 2004). Between 2008–2012, heroin use among young adults has remained at peak
rates (0.5-0.6%) and prescription opioids, while still high (7.3%), have slightly declined from the
peak in 2009 (9.2%) (Johnston et al., 2012). Overall, opioid dependence and abuse are becoming
increasingly prevalent and newer and better treatment pharmacotherapies are needed since
currently available treatments (e.g. methadone, buprenorphine, clonidine) are not fully effective
(see section 1.4).
1.2. The endogenous opioid system
Morphine, the prototypical opioid analgesic, and other opioids act upon an endogenous
opioid system. Evidence supporting the existence of opioid receptors came from observations of
stereospecific opiate binding in the central nervous system (Pert et al., 1973). The existence of
multiple subtypes was first suggested by Martin et al. (1976) after studies examining several
opiates (morphine, ketocyclazocine, SKF-10,047) in neurophysiological and behavioral assays.
They observed that the effects of all three drugs could be blocked by naltrexone yet all three
drugs produced distinct physiological effects. While morphine and ketocyclazocine produced
miosis, SKF-10,047 produced mydriasis. Additionally morphine produced bradycardia while
SKF-10,057 produced tachycardia and ketocyclazocine did not affect heart rate. In morphinedependent dogs, morphine would suppress the withdrawal syndrome while ketocyclazocine
would not. From these studies, they proposed three different receptors named for their respective
agonists: mu, kappa, and sigma (Martin et al., 1976). Later, subtypes were discovered and cloned
and included mu (Chen et al., 1993; Min et al., 1994), kappa (Meng et al., 1993), and delta
(Evans et al., 1992; Kieffer et al., 1992) with mu opioid receptors mediating the rewarding and
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analgesic effects (Becker et al., 2000; Dhawan et al., 1996; Matthes et al., 1996; Sora et al.,
1997) of opioids. Mu opioid receptors are members of the class A (rhodopsin) family of
receptors that couple to the pertussis toxin sensitive, heterotrimeric Gi/o proteins (Jordan et al.,
1998) and upon activation inhibit adenylyl cyclase (Sharma et al., 1975b) , inhibit N and P/Q
type Ca2+ channels and activate inwardly rectifying K+ channels (Darlison et al., 1997).
Endogenous ligands for opioid receptors are post-translationally cleaved from peptide
precursors and result in a wide number of peptide ligands. Opioid peptides include 1) endorphins
(Cox et al., 1976)(µ = δ > κ) such as beta-endorphin; derived from proopiomelanocortin; 2)
endomorphins (Zadina et al., 1997)(µ selective); the peptide precursor is yet to be established; 3)
enkephalins (Hughes et al., 1975)(δ >> µ) derived from pro-enkephalin; and 4) dynorphins
(Goldstein et al., 1979)(κ >> µ, δ); derived from pro-dynorphin (Janecka et al., 2004). Naloxone,
the antagonist used for these studies, binds to mu, delta and kappa and has only slightly more
affinity for mu opioid receptors. Since the focus of the present study is on morphine dependence
and withdrawal, the rest of this section will focus on the mu opioid receptor since expression of
naloxone-precipitated morphine withdrawal is dependent on this receptor (Matthes et al., 1996).
1.3. Opioid tolerance, dependence and withdrawal
Opioid dependence encompasses multiple aspects of behavioral and physiological
responses that accompany prolonged drug use and that occur during a specific time frame. The
Diagnostic and Statistical Manual of Mental Disorders IV (American Psychiatric Association,
2000) lists seven primary aspects to drug dependence, of which the presence of three or more is
considered to qualify a patient as dependent. These include: 1) tolerance or markedly
increased amounts of the substance to achieve intoxication or desired effect or markedly
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diminished effect with continued use of the same amount of substance; 2) withdrawal symptoms
or the use of certain substances to avoid withdrawal symptoms; 3) use of a substance in larger
amounts or over a longer period than was intended; 4) persistent desire or unsuccessful efforts to
cut down or control substance use; 5) involvement in chronic behavior to obtain the substance,
use the substance, or recover from its effects; 6) reduction or abandonment of social,
occupational or recreational activities because of substance use; and 7) use of substances even
though there is a persistent or recurrent physical or psychological problem that is likely to have
been caused or exacerbated by the substance.
Of these, tolerance and withdrawal have been intensely studied in mice and are two
separate phenomena, which are produced by similar antecedents (i.e. prolonged exposure to an
opioid agonist). Furthermore, tolerance and withdrawal are distinct phenomena both in how they
are expressed behaviorally as well as in the cellular and molecular changes that underlie those
individual responses. Tolerance to opioids is defined as a loss of effect following repeated
treatments such that a higher dose is required for equivalent effects (Bailey et al., 2005).
Withdrawal manifests as a set of symptoms that occurs following cessation of drug
administration or treatment with an antagonist that abruptly halts receptor activation (Bailey et
al., 2005). In humans, opioid withdrawal symptoms include anxiety, dysphoria, panic attacks,
diarrhea, emesis, dehydration, hypertension, hyperthermia, tachycardia and body aches (Farrell,
1994; Gossop, 1988; Jasinski, 1981; Wesson et al., 2003).
In rodents, opioid withdrawal produces a number of somatic signs including jumping,
paw fluttering, head/body shaking/twitching, ptosis, teeth chattering, weight loss and diarrhea
(Way et al., 1969). Additionally, opioid withdrawal has been shown to produce changes in
behavioral responses in assays described in Chapter 3 of this thesis, used to infer aspects of
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motivation and emotionality including anxiety, aversion, and anhedonia. In rats, opioid
withdrawal has been shown to elicit unconditioned avoidance behaviors in tests such as the
elevated plus maze (Schulteis et al., 1998b; Zhang et al., 2008) where further decreases in the
time spent in the open-arms are observed during withdrawal. These responses are often inferred
to reflect “anxiogenic-like” behavior. Withdrawal from opioids has also been well established to
produce conditioned place avoidance (CPA). In this procedure, injection of naloxone into opioiddependent animals serves as an unconditioned stimulus and the subsequent opioid withdrawal
serves as an unconditioned response. The pairing of naloxone in the opioid-dependent animal
(unconditioned stimulus) with specific contextual cues (conditioned stimulus) leads to a
conditioned response called conditioned place avoidance. It is then inferred from this
conditioned avoidance response that the withdrawal state is aversive (Broseta et al., 2005;
Frenois et al., 2002; Maldonado et al., 2004; Sato et al., 2005; Stinus et al., 2000; Stinus et al.,
1990; Watanabe et al., 2002). CPA is a sensitive measure of opioid withdrawal and is discussed
in further detail in Chapter 3.
Additionally, other behaviors have been assessed during morphine withdrawal, which
involve brain regions that are likely important for affective withdrawal symptoms in humans.
Intracranial self-stimulation (ICSS) is a behavioral procedure in which operant responding by
animals is maintained by electrical stimulation of the brain, typically the medial forebrain bundle.
Drugs of abuse will typically facilitate ICSS and this increase in operant responding for brain
stimulation has been suggested to be a rewarding effect. On the other hand, experimental
manipulations, which suppress operant responding for ICSS are interpreted to indicate a loss of
reward function reflecting anhedonia (Stoker et al., 2011). Rats undergoing opioid withdrawal
exhibit decreases in operant responding for ICSS (Altarifi et al., 2011a; Liu et al., 2004;
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Schaefer et al., 1986; Schaefer et al., 1983; Schulteis et al., 1994). Schulteis et al. (1994)
reported that morphine-pelleted rats (2 x 75 mg subcutaneous morphine pellets) responding for
stimulation of the lateral hypothalamus had marked elevations in current intensity-response
thresholds from baseline following naloxone (0.01 – 0.03 mg/kg) while placebo-pelleted rats
exhibited no such shifts from baseline even when administered a high dose of naloxone (1
mg/kg). In another study, rats trained to respond for electrical stimulation of the left medial
forebrain bundle and receiving daily injections of morphine (3.2 - 18 mg/kg/day over the course
of 4 weeks) became tolerant to the rate decreasing effects of chronic morphine by day 7 of week
4, the week in which they received the highest dose (18 mg/kg/day). The following day, prior to
receiving the daily morphine dose, rats exhibited decreased responding for brain-stimulation
reward as compared to baseline suggesting spontaneous withdrawal produced anhedonic effects.
Furthermore, prior to the sessions, rats did not display somatic withdrawal signs (i.e., diarrhea,
teeth chattering, wet dog shakes), suggesting alterations in ICSS were not due to overt
withdrawal signs (Altarifi et al., 2011a). Alterations in brain-stimulation reward thresholds were
also demonstrated in rats that received repeated injections of morphine (5.6 mg/kg/day) and
tested during spontaneous and naloxone-precipitated withdrawal. Increases in brain-stimulation
reward thresholds were observed in spontaneously withdrawing rats on days 3 and 4, which were
23.5 h following the previous morphine injection. Additionally, 5 min after naloxone (1 mg/kg)
treatment in these same rats, elevations over baseline thresholds were observed on days 1-4,
while naloxone (0.1 and 0.33 mg/kg) resulted in elevated thresholds on day 4. Furthermore,
naloxone (0.1 mg/kg) did not elevate thresholds in mice receiving repeated vehicle injections
suggesting that its effects in morphine-treated mice reflect reward deficits accompanying
precipitated withdrawal. In the case of naloxone (0.1 mg/kg) on day 1, these deficits reflect acute
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withdrawal since the only previous exposure to morphine (5.6 mg/kg) occurred only 4 hours
earlier (Liu et al., 2004). Thus, CPA and ICSS assays are sensitive to morphine withdrawal.
Complex neuroadaptive changes underlie opioid tolerance and dependence (for reviews
see: Bailey et al., 2005; Williams et al., 2001; Williams et al., 2013). The level of tolerance that
develops appears to depend on the intrinsic activity (i.e. relative propensity for a given drugreceptor complex to produce a maximum functional response) of the agonist whereby highly
efficacious mu opioid receptor agonists produce less antinociceptive tolerance than those of low
efficacy. Efficacy of opioids has been calculated from dose ratios following multiple doseresponse curves for the test compounds after increasing doses of beta-funaltrexamine (β-FNA),
the irreversible mu antagonist, in order to reduce the number of spare receptors incrementally.
Mjanger and Yaksh (1991) determined that morphine’s intrathecal antinociceptive dose-ratios
(ED50 post β-FNA / ED50 post vehicle) was much larger than that of sufentanil and DAMGO
(morphine >> sufentanil = DAMGO) suggesting that morphine must have a higher fractional
receptor occupancy to produce a similar effect and thus possesses less intrinsic activity. The
differential effects of intrinsic activity on tolerance have been reported. In a study where 7 days
of continuous intrathecal drug infusion of equieffective doses, as measured by antinociception in
the hot plate test, of either morphine or sufentanil in rats, the antinociceptive tolerance to
morphine resulted in an increase in morphine ED50 value from 0.65 to 30.0 nmol, a roughly 44
fold increase. In contrast, sufentanil ED50 value increased only 3-fold, from 0.07 to 0.21 nmol.
Additionally, when cross tolerance was assessed, sufentanil ED50 value shifted from 0.07 nmol in
saline treated mice to 0.68 nmol in morphine treated mice, roughly 3 fold higher than that
observed in sufentanil treated rats (Sosnowski et al., 1990). These data suggested that morphine
caused greater desensitization and/or internalization of mu opioid receptors than sufentanil,
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which would be consistent with the number of receptors necessary for each to produce their
relative antinociceptive effects, i.e. sufentanil exhibiting properties of a full agonist thus
requiring fewer receptors to produce a given effect than morphine which is a partial agonist.
Continuous infusion of opioid agonists in mice also elicits similar effects on the magnitude of
tolerance depending on the intrinsic activity of the agonist used, however this disparity in level
of tolerance is abolished when equieffective doses are administered intermittently once a day
over a period of 72 h or 7 days which may be due to the phasic stimulation of receptors which
allows for resensitization (Duttaroy et al., 1995; Madia et al., 2009).
Mechanisms of morphine tolerance have not been fully elucidated, however
phosphorylation of the receptor and binding of arrestin are components of this process (Williams
et al., 2001). Opioid agonist-induced desensitization of mu opioid receptors occurs through
phosphorylation of the C terminus primarily by G-protein receptor kinases (GRKs), though
protein kinase C (PKC) has also been suggested as a possible mediator of receptor
phosphorylation (Williams et al., 2013). Phosphorylation of the C-terminus leads to recruitment
of arrestin and uncoupling of the receptor from G-proteins (Bailey et al., 2005). Subsequently,
receptors can be trafficked from the membrane via clathrin-dependent pathway and can then be
either degraded/downregulated or recycled back up to the surface (Bailey et al., 2005; Connor et
al., 2004; Ferguson, 2001; Van Bockstaele et al., 2001; Zastrow et al., 2003).
Phosphorylation and regulation of mu opioid receptors by morphine, on the other hand,
diverges from other agonists such as DAMGO in that phosphorylation is less efficient than full
agonists and morphine leads to minimal receptor internalization (Bailey et al., 2005; Borgland et
al., 2003). Morphine can lead to sustained phosphorylation of the serine-375 residue intracellular
C terminus without the receptor undergoing endocytosis (Schulz et al., 2004) unlike in the case
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of other high efficacy agonists such as DAMGO which causes marked phosphorylation of mu
opioid receptors and subsequent internalization (Zhang et al., 1998). Morphine also differs from
DAMGO in that it recruits only beta-arrestin 2 whereas DAMGO recruits both beta-arrestin 1
and beta-arrestin 2 (Groer et al., 2011). Resensitization of mu opioid receptors is thought to
require receptor endocytosis which occurs with high efficacy agonists such as DAMGO but not
with morphine. The lack of receptor internalization following morphine treatment is thought to
underlie the marked and protracted tolerance that is observed following morphine treatment
(Bailey et al., 2005). This is supported by an increase in the ability of morphine to cause receptor
endocytosis and a reduction in the development of morphine tolerance when animals are also
treated with DAMGO, which itself is known to cause internalization of receptors. Specifically,
spinal cord from rats treated with a low dose of DAMGO (0.01 nmol) and a high dose of
morphine (30 nmol) intrathecally, neither of which produce endocytosis on their own, caused
significant internalization of mu opioid receptors as determined by immunohistochemical
staining of lamina II neurons in spinal cord. Additionally, the same dose of DAMGO (0.01 nmol)
administered twice daily to mice receiving continuous morphine (6 nmol/h) prevented the
development of tolerance to morphine which was suggested to likely be due to its actions on
facilitating internalization of mu opioid receptors (He et al., 2002).
Protein kinase C (PKC) has also been implicated in morphine tolerance. In HEK293 cells
expressing mu opioid receptors and inward rectifying potassium channel (Kir3.1 and Kir3.2
subunits), overexpression of dominant negative mutants of GRK2 reduced the desensitization (as
measured by changes in current amplitude as a percentage of the initial peak current) to
DAMGO (10 µM) but not to morphine (30 µM) suggesting GRK2 is involved in desensitization
of mu opioid receptors following DAMGO, but not morphine. However, exposure of cells to the
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PKC pseudosubstrate inhibitory peptide PKC (19-31) 10 min prior to exposure to morphine or
DAMGO was able to reduce the desensitization caused by morphine (~50%), but not DAMGO.
Additionally, pretreatment of HEK293 cells with the PKC inhibitor GF109203X (1 µM) for 15
min reduced the small but significant increase in mu opioid receptor phosphorylation caused by
30 min exposure morphine, but not DAMGO. Arrestin translocation was also observed following
DAMGO, but not morphine (Johnson et al., 2006). A similar role for PKC was observed in
horizontal slices containing locus coeruleus (LC) neurons in which morphine was shown to
produce desensitization of mu opioid receptors when PKC was activated by either a phorbol ester
or indirectly via activation of M3 muscarinic receptor Gq proteins, as this effect was completely
reversed by PKC inhibition (Bailey et al., 2004). Studies using genetically altered mice also
suggested a role of PKC in antinociceptive tolerance to morphine whereby PKCγ (-/-) mice,
which exhibit similar baseline tail-flick latencies as wild-type mice, showed a decreased degree
of tolerance 96 h following subcutaneous implantation of 75 mg morphine pellets. While the
PKCγ (-/-) and (+/+) mice exhibited similar antinociceptive dose-response curves for morphine
prior to dependence, the ED50 values for morphine following induction of dependence were 6.4
mg/kg (4.8 – 8.4 mg/kg) for PKCγ (-/-) and 14 mg/kg (11 – 18 mg/kg) for PKCγ (+/+) mice. The
role of PKC in desensitization of mu opioid receptors following morphine remains under
investigation.
While phosphorylation/downregulation of mu opioid receptors is believed to play major
contributory roles to the development of tolerance, the mechanisms of dependence involve
compensatory changes of downstream effectors that maintain normal function in the presence of
opioid agonists (Williams et al., 2001). Following mu opioid receptor activation, Gi/o effector
proteins produce the following actions: 1) inhibition of adenylyl cyclase resulting in a decrease
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in cAMP production (Childers et al., 1992) and subsequently a reduction in protein kinase A
(PKA) activity and phosphorylation of cAMP response element binding protein (CREB); 2)
activation of potassium conductance; 3) inhibition of calcium conductance; 4) inhibition of
neurotransmitter release; 5) activation of protein kinase C (PKC); 6) activation of mitogenactivated protein kinase (MAPK) (Williams et al., 2001). Multiple adaptations to these effects of
opioids occur following prolonged activation of mu opioid receptors including increased activity
of adenylyl cyclase (Matthes et al., 1996; Sharma et al., 1975a), upregulation of CREB (Widnell
et al., 1994) and PKA catalytic and regulatory subunits (Lane-Ladd et al., 1997).
Withdrawal occurs following either cessation of opioid exposure (spontaneous
withdrawal) or abrupt halting of signaling via administration of a mu opioid receptor antagonist
(precipitated withdrawal). The resulting reduction in activation of inhibitory G-proteins leads to
a superactivation of upregulated adenylyl cyclase, consequent overshoot of cAMP production
(Sharma et al., 1975a; Watts et al., 2005) and increased signaling downstream of this pathway.
The end result of upregulation of adenylyl cyclase is an increased hyperexcitability of LC
neurons (Aghajanian, 1978; Lane-Ladd et al., 1997). In an early study, recording of LC neurons
in rats implanted with 75 mg morphine pellets exhibited initial reductions in firing rates which
recovered to baseline 48-72 h later. Upon continuous microiontophoretic administration of
naloxone into LC or i.v. administration (0.02 mg/kg), LC neuron firing rates dramatically
increased over baseline in morphine-dependent, but not non-dependent, rats (Aghajanian, 1978).
In a later study using the same dependence induction procedure, LC firing rates were increased 3
min after naltrexone challenge (100 mg/kg, s.c.) roughly 6-fold over baseline and 4-fold over
control animals receiving naltrexone. Furthermore, behavioral time course measurements
corresponded with changes in rates of LC firing. The naltrexone dose used in this study
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(100 mg/kg) was much higher than typically used to precipitate opioid withdrawal, but was
selected because it produces maximal withdrawal behaviors that persist for up to 6 h allowing for
the time course that was conducted (Rasmussen et al., 1990) though such a high dose raises
questions regarding possible off-target effects. Upregulation of adenylyl cyclase appears
dependent upon CREB as increases in levels of immunoreactivity of AC VIII were reduced
following bilateral treatment of CREB antisense oligonucleotides in LC as compared with the
contralateral LC. Morphine withdrawal behaviors were reduced in rats receiving bilateral
infusion of CREB antisense oligonucleotide and increases in firing rates of LC neurons were
reduced (Lane-Ladd et al., 1997). Nestler and colleagues have suggested that increases in firing
of LC neurons is driven by PKA (Nestler, 2001a). Increases in cAMP-dependent PKA activity
have been observed with chronic morphine in the LC (Nestler et al., 1988) and an inhibitor of
PKA, H-89, suppressed naloxone-precipitated morphine withdrawal induced hyperactivity of LC
neurons (Ivanov et al., 2001) and also reduced somatic signs of naloxone-precipitated morphine
withdrawal in rats (Seyedi et al., 2013). The role of PKA in morphine withdrawal has been
suggested to be related to activation of an inward sodium current (Alreja et al., 1993; Nestler,
2001b). Hyperexcitability of LC neurons causes an increased noradrenergic outflow (Crawley et
al., 1979; Van Bockstaele et al., 2008) through efferents which connect widely throughout the
brain to affect cognition, emotionality, anxiety, arousal and stress (Dunn et al., 2004). Thus, the
hyperexcitability of these neurons following withdrawal leading to increased sympathetic
outflow is consistent with the wide range of consequential aversive effects of opioid withdrawal
in humans.
The degree to which LC vs. periaqueductal grey (PAG) neurons contribute to opioid
withdrawal has been questioned (Christie et al., 1997). For example, microinjections of the mu
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opioid antagonists methylnaloxonium (Maldonado et al., 1992) or naloxone (Esposito et al.,
1987) into the LC or PAG were shown to elicit morphine withdrawal signs (teeth chattering,
mastication, rearing, wet dog shakes and jumping) in rats, and electrolytic lesion of LC reduced
withdrawal

severity

following

intracranial

ventricular

(i.c.v.)

administration

of

methylnaloxonium in morphine-pelleted rats (Maldonado et al., 1993) suggesting that the LC is
important for expression of somatic withdrawal signs. In contrast, others have shown that nearcomplete (94%) chemical lesion of noradrenergic neurons in the LC by 6-hydroxydopamine did
not affect naloxone-precipitated (7.5-15 µg/kg) withdrawal-induced CPA in rats implanted with
two subcutaneous 75 mg morphine pellets nor did it affect somatic signs of naloxoneprecipitated (10-1000 µg/kg) morphine withdrawal (Caillé et al., 1999). In addition to PAG and
LC, noradrenergic neurons arising from the bed nucleus of the stria terminalis (BNST) have been
implicated in morphine withdrawal aversion and somatic signs. Chemical lesion of ventral
noradrenergic bundle which projects from the medulla to the BNST attenuated acquisition of
morphine withdrawal CPA, but did not affect somatic signs. In contrast, lesion of the dorsal
noradrenergic bundle projecting from the LC did not affect CPA or somatic withdrawal signs
(Delfs et al., 2000). These data suggest that multiple neural substrates contribute to the
expression of different opioid withdrawal responses.
1.4. Treatment of opioid withdrawal
Currently, there are few available treatment options for opioid dependence. These
medications either 1) act either directly upon mu opioid receptors (substitution therapy), or 2)
target the increased noradrenergic tone that results from hyperexcitability of LC neurons.
Methadone (t1/2 = 28 h), a full mu agonist, and buprenorphine (t1/2 = 37 h), a partial mu agonist,
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are abused in the United States (Cicero et al., 2005) and are not fully effective at combating
withdrawal (Dyer et al., 1999; Kuhlman et al., 1998); thus these treatment strategies have
limitations. Dyer et al. (1999) reported that opioid-dependent patients receiving once daily
methadone maintenance treatment exhibited withdrawal severity that was inversely correlated
with plasma methadone concentrations. Eight hours after subjects received their daily methadone
dose, they reported significant increases in withdrawal severity. Kuhlman et al. reported that
patients receiving buprenorphine (8 mg/day) had elevated withdrawal scores following the end of
the study, peaking on day 5 then gradually returning to baseline by 14 days post-study. A review
of clinical studies suggested that buprenorphine may be a more effective treatment for opioid
dependence than methadone or clonidine as measured by patient retention, possibly because
buprenorphine is associated with fewer adverse effects or because withdrawal symptoms may
have resolved more quickly with buprenorphine (Gowing et al., 2009). Treatment with alpha-2
adrenergic agonists (e.g. clonidine, lofexidine) attenuate the increased sympathetic activity
during withdrawal, but these drugs can produce postural hypotension, sedation and cognitive
impairment, and are not fully effective at attenuating the withdrawal symptoms in all patients
(Gerra et al., 2001; Gossop, 1988; Lobmaier et al., 2010). While current treatment strategies can
ward off some aspects of withdrawal and facilitate patient completion, better medications with
fewer side effects could improve retention rates in detoxification programs and are warranted.
There is clinical evidence suggesting that cannabinoids may be effective at attenuating
opioid withdrawal and improving patient retention in treatment programs. In a study of heroin
abusers who underwent a 9 month drug-free treatment program, cannabis use was associated
with greater retention (Ellner, 1977). Another studied reported that intermittent cannabis use was
associated with decreased percentage of heroin-positive urine during treatment and increased pill
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compliance in patients undergoing naltrexone treatment for opiate-dependence (Church et al.,
2001). Similarly, cannabis use was also associated with greatly improved retention as well as
pill-taking adherence in a naltrexone-treatment program for opioid dependence (Raby et al.,
2009). Additionally, based on pilot data, cannabis use during methadone maintenance treatment
was reportedly associated with decreased withdrawal severity (Scavone et al., 2013b). Cannabis
has also been reportedly used as a substitute for prescription opioids (Lucas et al., 2012).
However, double-blind multi-center studies examining whether cannabinoids actually reduce
opioid dependence are lacking.
1.5. The endogenous cannabinoid system
1.5.1. Cannabinoid receptors
The existence of cannabinoid receptors were first suggested by the ability of
cannabinoids to inhibit adenylyl cyclase activity (Howlett et al., 1984) and the demonstration of
specific binding of [3H]CP55,940 in rat brain (Devane et al., 1988). Subsequently, CB1 (Matsuda
et al., 1990) and CB2 (Munro et al., 1993) receptors were cloned and determined to be Gi/oprotein coupled receptors which upon activation lead to 1) inhibition adenylyl cyclase and L-, Nand P/Q-type voltage-gated calcium channels (Caulfield et al., 1992; Mackie et al., 1992;
Twitchell et al., 1997), and 2) activation of inwardly-rectifying potassium channels (Guo et al.,
2004), and mitogen-activated protein kinase (Derkinderen et al., 2001). In regard to tissue
distribution, CB1 is heterogeneously expressed at high levels in the central nervous system (CNS)
and in peripheral tissue (e.g., liver and adipocytes), while CB2 is localized mainly on immune
cells and microglia and is associated with immune function but is also expressed on neurons
(Galiègue et al., 1995; Gong et al., 2006).
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1.5.2. Endocannabinoids
There are two main endogenous ligands that bind to CB1 and CB2 receptors,
2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995) and
N-arachidonoylethanolamide (anandamide; AEA) (Devane et al., 1992). Several differences exist
between these two endocannabinoids. First, 2-AG levels in the central nervous system are
approximately 100 fold higher than those of AEA (Ahn et al., 2009), though the relative amount
of each endogenous ligand that is actually signaling is likely much more similar. Long et al.
demonstrated via in vivo microdialysis that interstitial levels of AEA and 2-AG are much more
similar than whole brain levels of AEA and 2-AG. Specifically, baseline dialysate 2-AG levels
were 4.6±0.7 nM while AEA levels were 0.54±0.1 nM in contrast to whole brain 2-AG levels in
the nmol/g range in contrast to the pmol/g range for AEA (Long et al., 2009a). Another reported
difference between 2-AG and AEA is that AEA is a partial agonist of CB1 while 2-AG is a full
agonist as determined by increases in intracellular Ca2+ in NG108-15 cells (Sugiura et al., 1999).
Also, AEA is an agonist at TRPV1 (Ross, 2003) and PPARα receptors (Jhaveri et al., 2008).
Other endocannabinoids, which have not been extensively characterized, include noladin ether
(Hanuš et al., 2001), virodhamine (Porter et al., 2002) and N-arachindonyl dopamine (Huang et
al., 2002). Endocannabinoids are not stored in vesicles, but rather are post-synaptically
synthesized and released on demand via cleavage of phospholipids from the cellular membrane
in response to Ca2+ (Ahn et al., 2008).
1.5.2.1. 2-AG biosynthesis and enzymatic regulation
Biosynthesis of 2-AG is activity-dependent (Kano et al., 2009) and is primarily produced
via a two-step process involving phospholipase C (PLC) hydrolysis of membrane phospholipids
resulting in the release of a arachidonic acid-containing diacylglycerol which is then converted
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into 2-AG by diacylglycerol lipase (DAGL) (Gao et al., 2010; Min et al., 2010; Stella et al.,
1997; Tanimura et al., 2010). Two isoforms, DAGLα and DAGLβ, have been identified
(Bisogno et al., 2003). 2-AG is primarily degraded by the pre-synaptically localized (Gulyas et
al., 2004) enzyme monoacylglycerol lipase (MAGL) which breaks down 2-AG into arachidonic
acid and glycerol (Dinh et al., 2002). Minor enzymes that play a role in the hydrolysis of 2-AG
include ABHD6 and ABHD12 (Blankman et al., 2007), the former of which has been shown to
be expressed post-synaptically and to be involved in 2-AG regulation as well as CB1-dependent
long-term depression (Marrs et al., 2010). Additionally, cyclooxygenase-2 and 12- and 15lipoxygenases are known to oxidize both 2-AG and AEA (Matias et al., 2006).
Pharmacological inhibition or genetic deletion of MAGL elevates 2-AG (Long et al.,
2009a; Schlosburg et al., 2010a). Upon repeated administration of JZL184 (40 mg/kg i.p., 6
days), mice became tolerant to its antinociceptive and anti-allodynic effects. MAGL knockout
mice also exhibited tolerance to JZL184’s antinociceptive and anti-allodynic effects. In either
MAGL knockout mice or wild-type mice treated repeatedly with JZL184 (40 mg/kg i.p., 6 days),
decreases in receptor binding by tritiated rimonabant and reductions in CP55,940-stimulated
GTPγS binding were also observed (Schlosburg et al., 2010a). Furthermore, repeated JZL184
treatment also led to dependence as exhibited by marked increases in paw flutters following
rimonabant (10 mg/kg i.p.) challenge.
1.5.2.2. AEA biosynthesis and enzymatic regulation
Biosynthesis of AEA from phospholipid precursors is also activity-dependent (Di Marzo
et al., 1994). AEA is biosynthesized by hydrolysis of N-acylphosphatidylethanolines (NAPEs),
but the specific enzymes involved are less well characterized than those of 2-AG and remains an

17

open area of study. AEA biosynthesis was originally thought to be primarily mediated by NAPEselective phospholipase D (NAPE-PLD) (Wang et al., 2008). However, NAPE-PLD (-/-) mice
possess wild type AEA brain levels, which suggests alternate biosynthetic pathways for this
endocannabinoid (Leung et al., 2006). Proposed pathways include the serine α/β hydrolase 4
(ABHD4) into lyso-NAPE that is converted into AEA either directly by lyso-phospholipase D or
via a two-step process involving further hydrolysis of lyso-NAPE by ABHD4 into
glycerophospho-NAE followed by glycerophosphodiesterase 1 (GDE1) cleavage of the
glycerophosphate group (Simon et al., 2006). However, GDE1 (-/-) mice displayed wild type
levels of AEA, suggesting the involvement of additional enzymatic pathway(s) in AEA
biosynthesis (Simon et al., 2010).
Degradation of AEA is carried out primarily by the post-synaptically localized (Gulyas et
al., 2004) enzyme fatty-acid amide hydrolase (FAAH) resulting in the release of arachidonic acid
and ethanolamine (Cravatt et al., 2001b). Cellular reuptake of AEA may involve the FAAH-like
AEA transporter (FLAT), a truncated and catalytically inactive variant of FAAH that binds AEA
and facilitates its translocation into cells (Beltramo et al., 1997; Fu et al., 2011; Piomelli et al.,
1999). However, a recent study was unable to detect FLAT in mouse brain, spinal cord or L3-L5
dorsal root ganglia and FLAT generated from FAAH via polymerase chain reaction was
characterized and shown to have residual catalytic activity (Leung et al., 2013). Pharmacological
inhibition or genetic deletion of FAAH has also been shown to elevate AEA (Cravatt et al.,
2001b; Fegley et al., 2005; Lichtman et al., 2004).
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1.5.3. Depolarization-induced suppression of inhibition or excitation
Endocannabinoids are involved in a form of CB1-dependent short-term synaptic plasticity
known as depolarization-induced suppression of inhibition (DSI) or excitation (DSE) in which
they are synthesized and released on demand in response to Ca2+ and travel in a retrograde
manner to the presynaptic terminal where they inhibit release of either gamma-Aminobutyric
acid (GABA) (DSI) or glutamate (DSE) (Diana et al., 2004). Complete abolition of this
retrograde inhibitory effect by genetic deletion of DAGLα suggests that this effect is mediated
by 2-AG (Tanimura et al., 2010). Further evidence to support this is that MAGL inhibitors, but
not FAAH inhibitors, augment DSI (Makara et al., 2005) or DSE (Straiker et al., 2005) and that
MAGL knockout mice exhibit prolonged DSI (Pan et al., 2011).
1.6. Interactions between the endogenous cannabinoid and opioid systems
Cannabinoids and opioids have a number of similarities including the effects they
produce (e.g. antinociception, sedation and reward) as well as similar distribution of their
respective receptors and the types of receptors themselves (Vigano et al., 2005). CB1 and mu
opioid receptors are both G-protein coupled receptors that couple with Gi/o proteins and thus
have similar signal transduction pathways. Because of this similarity between these receptors,
their interaction could involve downstream signaling events, including mutual inhibition of
adenylyl cyclase (Childers et al., 1992) via activation of Gi/o proteins (Robledo et al., 2008),
blockade of voltage-dependent Ca2+ channels or activation of GIRK channels. Since both
cannabinoids and opioids can be localized pre-synaptically, they could also interact through
mutual inhibition of neurotransmitter release such as norepinephrine, GABA, dopamine, and
glutamate. Additionally, CB1 and mu opioid receptors can interact through the formation of
heterodimers as determined by fluorescence resonance energy transfer (Hojo et al., 2008).
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CB1 and mu opioid receptors are both found in many areas consistent with the observed
interactions of these two systems in processes related to reward, withdrawal, and antinociception.
CB1 and mu opioid receptors have been colocalized in lamina II interneurons of the dorsal horn
of the spinal cord which may account for some of the interactions between cannabinoids and
opioids in nociception (Salio et al., 2001). In rat caudate putamen, CB1 and mu opioid receptors
are co-localized in somata and dendrites of spiny neurons (Rodrı́ guez et al., 2001). In the nucleus
accumbens (NAc), of immunolabeled presynaptic CB1 receptors localized to terminals,
approximately 3% were coexpressed with mu opioid receptors. Of the presynaptic CB1 receptors
in junctions at dendrites and dendritic spines, 19% (NAc shell) and 13% (NAc core) were
localized with targets containing mu opioid receptors. Presynaptically located mu opioid
receptors, 20% (NAc shell) and 10% (NAc core) were at terminals synapsing onto CB1
immunoreactive dendrites. In dendritic shafts, 21% (NAc shell) and 13% (NAc core) of those
containing CB1 receptors co-localized with mu opioid receptors (Pickel et al., 2004). CB1 and
mu opioid receptors are also co-localized in the PAG with approximately 32% of stained cells
exhibiting immunoreactivity for both receptors (Wilson-Poe et al., 2012). In the locus coeruleus,
electron microscopy of sections stained using immunogold and peroxidase for both CB1 and mu
opioid receptors (i.e. half immunogold-CB1/peroxidase mu opioid receptor; half immunogold mu
opioid receptor/peroxidase CB1) revealed CB1 and mu opioid colocalization in postsynaptic
terminals as well as localization of CB1 receptors presynaptically to postsynaptic mu opioid
receptors (Scavone et al., 2010). Thus, CB1 and mu opioid receptors are localized to brain
regions important for somatic (LC, PAG) as well as negative motivational aspects of opioid
withdrawal (NAc).
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In terms of translational implications, there is evidence to support interactions between
endogenous opioid and endocannabinoid systems in multiple physiological processes. For
example, the increased duration of time spent in the light side of the light/dark box by delta-9tetrahydrocannabinol (THC; 0.3 mg/kg, i.p.), an effect interpreted as “anxiolytic”, was
antagonized by the mu opioid receptor antagonist beta-funaltrexamine (5 mg/kg i.p.) (Berrendero
et al., 2002). Zarrindast et al. demonstrated that naloxone (0.1 mg/kg), which alone had not
effect, reduced the increased time spent in the open-arms of the EPM by the CB1 agonist
arachidonylpropylamide (1.25 and 5 ng/infusion into amygdala) (Zarrindast et al., 2008). In
terms of interactions between cannabinoids and opioids in reward, pretreatment with the mu
opioid antagonist naloxone (2 mg/kg i.p.) blocks conditioned place preference (CPP) produced
by the CB1 agonist CP55,940 (20 µg/kg i.p.) (Braida et al., 2001). Furthermore, naloxone
(2 mg/kg), a dose that did not elicit CPP or CPA alone, blocked CPP to THC (0.75 mg/kg)
(Braida et al., 2004). Likewise, CPP to morphine has a CB1 component (Chaperon et al., 1998;
Martin et al., 2000; Mas-Nieto et al., 2001; Singh et al., 2004). Chaperon et al. demonstrated that
morphine (4 mg/kg) CPP was attenuated by pretreatment of the CB1 antagonist rimonabant
(Chaperon et al., 1998) and Martin et al. demonstrated that morphine CPP (5 mg/kg s.c.) was
absent in CB1 knockout mice (Martin et al., 2000). Mas-Nieto et al. also demonstrated that
rimonabant (5 mg/kg) reduced morphine CPP (3 mg/kg) in mice while rimonabant did not affect
place conditioning on its own (Mas-Nieto et al., 2001). Singh et al. demonstrated in rats that
rimonabant (0.1 mg/kg i.p.) blocked the acquisition of morphine CPP (4 mg/kg s.c.) in rats
(Singh et al., 2004). CB1 antagonists attenuate morphine and heroin self-administration (Caille et
al., 2003; Navarro et al., 2001) and prevent its reinstatement (De Vries et al., 2003; Fattore et al.,
2003). In rats trained to self-administer heroin (0.02 mg/infusion i.v.), the CB1 antagonist/inverse
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agonist rimonabant (0.3 – 3 mg/kg i.p.) pretreatment reduced the number of infusions during a
3 h session under a fixed-ratio 1 schedule of reinforcement and lowered breakpoints for heroin
(0.003 mg/kg/infusion i.v.) reinforcement (Caille et al., 2003). In another self-administration
study, rimonabant (0.25 mg/kg i.p.) reduced the number of morphine (0.002 mg/kg/infusion i.v.)
infusions during a 4 h session in a mouse self-administration paradigm (Navarro et al., 2001).
Additionally, morphine intravenous self-administration (0.001 – 0.004 mg/kg/infusion i.v.) was
reduced in CB1 (-/-) mice as compared to (+/+) controls (Ledent et al., 1999) suggesting this
system is important for the rewarding effects of opioids. Together, these data suggest a strong
relationship in the rewarding and reinforcing aspects of cannabinoids and opioids.
1.7. Cannabinoids and Opioid Withdrawal
Anecdotal evidence for the potential of cannabinoids to be used in treatment of opioid
withdrawal extends to the 19th century when a cannabis tincture was reported as effective at
reducing opium withdrawal in a case study. A man who had been using approximately two
ounces of laudanum (10% powdered opium) daily was suffering from “insomnia, anorexia,
disordered bowels and conscious delusions” and upon being placed on a cannabis tincture the
physician found that it had restored his appetite and improved his sleep (Birch, 1889). Since then,
experimental evidence for the potential of cannabinoids to attenuate opioid withdrawal has been
demonstrated in laboratory animals undergoing morphine withdrawal (see Table 1). It was
demonstrated in the 1970s that THC reduces these somatic withdrawal signs in rats and mice
(Bhargava, 1976; Hine et al., 1975). Specifically, THC (2.5 – 10 mg/kg) administered i.p. 30 min
prior to naloxone-precipitated morphine withdrawal in morphine-pelleted mice significantly
reduced the number of withdrawal jumps (Bhargava, 1976). In rats implanted with a 75 mg
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subcutaneous morphine pellet, THC (5 mg/kg i.p.) reduced naloxone-precipitated (4 mg/kg i.p.;
72 h following pellet implantation) withdrawal induced wet shakes and diarrhea (Hine et al.,
1975). Endocannabinoids have also been shown to possess similar potential. AEA (5 mg/kg)
administered intravenously decreased jumps and body weight loss following naloxone (1 mg/kg)
challenge in morphine (75 mg) pelleted mice 72 h after implantation (Vela et al., 1995). As well,
2-AG (10µg i.c.v.) reduced naloxone (3.2 mg/kg i.p.) precipitated withdrawal signs in mice
following 5 days of morphine (8 – 45 mg/kg s.c. twice daily) injections (Yamaguchi et al., 2001)
though CB1 receptor mediation was not tested in either the Vela et al. nor the Yamaguchi et al.
studies. Furthermore, rapid hydrolysis of endocannabinoids precludes their potential therapeutic
use.
Inhibition of endocannabinoid catabolic enzymes reduces somatic signs of opioid
withdrawal via a CB1 receptor mechanism of action, which supports the notion of
endocannabinoid enzyme inhibition as a strategy to treat opioid withdrawal (Ramesh et al.,
2011). Mice implanted with morphine (75 mg) pellets were administered either the MAGL
inhibitor JZL184 or the FAAH inhibitor PF-3845 and then 2 h later given a naloxone (1 mg/kg
s.c.) challenge immediately prior to a 30 min observation period during which withdrawal signs
were scored. JZL184 (4-40 mg/kg i.p.) significantly reduced the number of jumps while JZL184
(16-40 mg/kg i.p.) reduced the number of paw flutters, amount of weight loss, and percentage of
mice that presented with diarrhea. JZL184’s (40 mg/kg i.p.) effects were all blocked by
pretreatment with the CB1 receptor antagonist rimonabant (3 mg/kg i.p.), but not the CB2
antagonist SR144528 (3 mg/kg i.p.). The FAAH inhibitor PF-3845 (10 mg/kg i.p.) reduced
jumping and paw flutters, an effect that was blocked with rimonabant pretreatment, however
there was no observed effect on weight loss or the presence of diarrhea. These data suggest that
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MAGL inhibition reduced all somatic withdrawal signs while inhibition of FAAH reduced only a
subset, i.e. jumping and paw flutters. Interestingly, both JZL184 and PF-3845 were shown to
reduce the increased contractility of morphine treated ilea following challenge with naloxone
(30 µM), however while PF-3845’s effects were blocked by the CB1 antagonist rimonabant,
JZL184’s effects were not. Nonetheless, all of the in vivo effects of JZL184 and PF-3845 were
blocked by rimonabant suggesting CB1 receptors are necessary for these effects. Aside from
rodent models, a brief report in rhesus monkeys indicated that THC (0.1 – 3 mg/kg s.c.) did not
affect morphine withdrawal signs (Woods et al., 1982) but another study in dogs reported that
THC (2 mg/kg) did reduce morphine withdrawal signs (125 mg/day) (Gilbert, 1981).
In humans, there have been some reports regarding the effects of cannabis use during
treatment for opioid dependence but the results are mixed. A study of opioid-dependent patients
found that concurrent marijuana use did not affect retention in the methadone treatment program
(65% vs. 60%) or the number of continuous weeks of opiate abstinence (8.4±6.5 vs. 8.5±7.2)
(Budney et al., 1998). A retrospective analysis of three clinical trials with heroin-dependent
participants receiving methadone maintenance treatment found no association of cannabis use
with patient retention or heroin use during or after the methadone treatment period (Epstein et al.,
2003). Similar findings reported that cannabis use was not associated with retention rate nor did
it affect any of the psychological measures assessed such as anxiety or mood disorders
(Weizman et al., 2004). Chronic marijuana also has been reported to have no effect on heroin use
prior to treatment and during treatment did not affect the increased HPA axis activity as
measured by increased plasma ACTH. Additionally, during treatment there was no effect of
concurrent marijuana use on withdrawal signs (gooseflesh, mydriasis, vomiting, tremor, profuse
sweating, restlessness, lacrimation, and nasal congestion, uncontrollable yawning, feeling to
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change in temperature, stomach pain, and muscle aching) and no effect on heroin craving (Nava
et al., 2007). In contrast, some studies have reported that cannabis use may have beneficial
effects in opioid-dependent patients undergoing treatment. Intermittent marijuana use was
associated with a decrease in percent of heroin-positive urine samples and an increase in pill
compliance during naltrexone treatment (Church et al., 2001). An association between marijuana
use, but not alcohol use, was associated with improved retention in heroin abusers during a 9
month treatment program and marijuana was also reportedly used as a heroin substitute (Ellner,
1977). Another study similarly reported that intermittent marijuana use was associated with
improved retention in a naltrexone-treatment program and also associated with greater adherence
to pill-taking (Raby et al., 2009). Recently it was reported that when methadone-maintenance
therapy patients were grouped by either low- or moderate-withdrawal severity, cannabis users
were significantly more likely to fall into the low-withdrawal severity group suggesting that
cannabis use may have reduced withdrawal in these patients, although these were preliminary
pilot data (Scavone et al., 2013b).
While the rodent literature suggests that cannabinoids may be effective at reducing opioid
withdrawal, the data available in humans is less convincing. The results from human studies are
based upon reported concurrent cannabis use during treatment rather than controlled studies
looking at cannabinoids directly for their ability to attenuate opioid withdrawal and while some
studies report no effect of cannabis use others do. It will be important to continue studying the
effects of cannabinoids on opioid withdrawal to determine whether they may offer the potential
to reduce withdrawal in humans.
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Table 1. Effects of cannabinoids on opioid withdrawal signs in rodents
Species

Dependence
Induction
75 mg
morphine pellet
(72 h), s.c.
75 mg
morphine pellet
(72 h), s.c.

Withdrawal
type
Naloxone, 4
mg/kg, i.p.

Cannabinoid
agent
THC, 5-10
mg/kg, i.p.

Dependent
measures/outcome
Reduced wet shakes
and diarrhea

Reference

Naloxone, i.p.
(specific doses
not reported)

THC, 2.5-10
mg/kg, i.p.

(Bhargava,
1976)

Guinea
pigs

Slow release
suspension of
morphine, 300
mg/kg (48 h)

Naloxone, 0.1
mg/kg, s.c.

THC, 2 mg/kg,
p.o.

Mice

75 mg
morphine pellet
(72 h), s.c.

Naloxone, 1
mg/kg, i.p.

Mice

Morphine BID,
8-45 mg/kg (5
days), s.c.
Morphine BID,
8-45 mg/kg (5
days), s.c.
Morphine BID,
20-100 mg/kg
(5 days), s.c.

Naloxone, 5
mg/kg, i.p.

THC, 10
mg/kg, i.v. or
AEA, 1-5
mg/kg i.v.
AEA, 0.1-5
mg/kg, i.v.

Naloxone, 3.2
mg/kg, i.p.

2-AG, 1-10µg,
i.c.v.

Spontaneous
withdrawal;
naloxone, 1
mg/kg, i.p.
Naloxone, 1
mg/kg, s.c.

AM404 (AEA
transport
inhibitor), 2-10
mg/kg, i.p.
THC, 1-50
mg/kg, p.o.

Naloxone, 1
mg/kg, s.c.

THC, 0.1-10
mg/kg, p.o.

Naloxone, 1
mg/kg, s.c.

JZL184
(MAGL
inhibitor), 4-40
mg/kg; PF3845 (FAAH
inhibitor), 10
kg/kg; i.p.

Reduced jumping,
defecation, and
rearing; shifted
naloxone ED50
Reduced total
withdrawal score
(jumping, body
shakes, digging,
yawning, ptosis,
diarrhea among)
AEA (5 mg/kg) and
THC (10 mg/kg)
reduced no. jumps and
weight loss
AEA (1-5 mg/kg)
reduced no. jumps and
weight loss
2-AG (10 µg) reduced
no. jumps, paw
tremors
AM404 (2 and 10
mg/kg) reduced no.
jumps in spontaneous
withdrawal; no effect
THC (1, 20, and 50
mg/kg) reduced the
no. mice exhibiting
platform jumping
THC (0.3-10 mg/kg)
reduced paw tremors
and head shakes
JZL184 (4-40 mg/kg)
reduced jumps, (16-40
mg/kg) reduced paw
flutters, weight loss
and diarrhea; PF-3845
(10 mg/kg) reduced
jumps and paw
flutters*

Rats

Mice

Mice

Mice

Mice

Morphine BID,
200-300 mg/kg
(7 days), p.o.

Mice

75 mg
morphine pellet
(72 h), s.c.
75 mg
morphine pellet
(72 h), s.c.

Mice

*CB1 mediation demonstrated
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(Hine et al.,
1975)

(Frederickson
et al., 1976)

(Vela et al.,
1995)

(Vela et al.,
1995)
(Yamaguchi et
al., 2001)
(Del Arco et
al., 2002)

(Cichewicz et
al., 2003)

(Lichtman et
al., 2001a)
(Ramesh et al.,
2011)

1.8. Rationale and Hypothesis
Elevation of endocannabinoids may reduce opioid withdrawal via activation of CB1
receptors on neurons through interactions with mutual second messenger systems shared by both
cannabinoid and opioid receptors or by modulating other systems such as the increased efflux of
norepinephrine during opioid withdrawal. As previously described (see section 1.3), naloxoneprecipitated opioid withdrawal leads to a superactivation of adenylyl cyclase which results in an
overshoot of cAMP production (Avidor-Reiss et al., 1995). Since CB1 receptor activation of Gi/o
proteins leads to inhibition of AC (Matsuda et al., 1990; Vogel et al., 1993) and these receptors
are colocalized with mu opioid receptors in LC, a region important for opioid withdrawal
(Scavone et al., 2010), it is possible CB1 receptor activation could resume inhibition of AC
following opioid withdrawal which would thereby dampen withdrawal effects.
Given the colocalization of CB1 and mu opioid receptors in the LC (Scavone et al., 2010),
PAG (Wilson-Poe et al., 2012) and NAc (Pickel et al., 2004), cannabinoid receptors are
advantageously positioned to compensate for the increased signaling and subsequent
hyperactivity in neurons that are key to the expression of both somatic and motivational aspects
of opioid withdrawal. In LC neurons, CB1 receptors located presynaptically on glutamatergic
afferents could inhibit glutamate release onto noradrenergic neurons, resulting in reduction in
activity and release of norepinephrine (Scavone et al., 2010). Additionally, CB1 receptors located
postsynaptically with mu opioid receptors (Scavone et al., 2010) could inhibit AC and reduce the
cAMP overshoot that occurs during opioid withdrawal. Clonidine has been shown to reduce both
cannabinoid (Lichtman et al., 2001b) and opioid withdrawal (Dehpour et al., 2001; Gold et al.,
1978) signs suggesting that both systems are involved in sympathetic outflow and thus effects of
cannabinoids on opioid withdrawal may involve direct actions on the noradrenergic system. See
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Figure 1 for a diagram of how CB1 receptors may modulate hyperactivity of LC neurons and
how endocannabinoid catabolic inhibitors could indirectly activate CB1 receptors through
elevation of endocannabinoids.
As discussed in the previous section, cannabinoids such as THC as well as inhibitors of
endocannabinoid catabolism reduce somatic withdrawal signs in rodents. Previous work
(Ramesh et al., 2011) examining inhibitors of MAGL and FAAH, JZL184 and PF-3845
respectively, demonstrated that indirect activation of CB1 receptors through elevation of
endocannabinoids reduced somatic withdrawal signs in mice. JZL184 attenuated somatic
withdrawal signs (Ramesh et al., 2011) but also produced cannabimimetic effects (hypomotility,
hypothermia) (Long et al., 2009a), dependence liability and functional CB1 receptor tolerance
after repeated dosing (Schlosburg et al., 2010a). While full FAAH inhibition did not produce
cannabimimetic effects and dependence liability, it only reduced a subset of withdrawal signs in
mice (jumps and paw flutters). There is some evidence to support the possibility of differential
roles of elevating either 2-AG or AEA on opioid withdrawal. While MAGL is localized presynaptically, FAAH is localized post-synaptically (Gulyas et al., 2004) thus inhibition of MAGL
may preferentially elevate levels of 2-AG presynaptically and inhibition of FAAH may
preferentially elevate levels of AEA post-synaptically. As discussed previously, CB1 receptors
have been localized in LC neurons both presynaptically on glutamatergic afferents and postsynaptically alongside mu opioid receptors on LC neurons as well as in the cytoplasm of
somatodendritic profiles (Scavone et al., 2010). It is possible then that 2-AG and AEA are
producing their effects on noradrenergic circuitry via different mechanisms, i.e. 2-AG inhibiting
glutamate release onto LC neurons via pre-synaptic CB1 receptors and AEA inhibiting activation
of LC neurons via post-synaptic CB1 receptors. Considering that full FAAH inhibition reduces a
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subset of opioid withdrawal signs and does not produce cannabimimetic effects and that partial
MAGL inhibition also reduces somatic withdrawal signs without producing cannabimimetic
effects, it’s possible that combined full inhibition of FAAH with partial MAGL inhibition may
reduce somatic signs (jumps, paw flutters, diarrhea) of morphine withdrawal without the adverse
consequences of maximal MAGL inhibition.
While reductions in somatic withdrawal signs by inhibition of endocannabinoid
catabolism signs suggest that these drugs may be attenuating opioid withdrawal, it is important to
examine other aspects of opioid withdrawal. As discussed in section 1.3, motivational
components and somatic signs of withdrawal are dissociable by brain region and naloxone dose
(Frenois et al., 2002; Hand et al., 1988; Stinus et al., 1990) suggesting that distinct regions
mediate the expression of somatic withdrawal signs and aversive aspects of withdrawal. While
endocannabinoid catabolic inhibitors may reduce somatic signs of morphine withdrawal, it is not
known whether they will also reduce the aversive aspects of withdrawal. Therefore, it is
important to establish other behavioral assays sensitive to morphine withdrawal and determine if
endocannabinoid catabolic inhibitors are able to reduce other signs of morphine withdrawal (e.g.
CPA).
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Figure 1. Localization of CB1 and mu opioid receptors, endocannabinoids and their catabolic
enzymes, and targets of endocannabinoid catabolic inhibitors in LC neurons. CB1 receptors have
been colocalized with mu opioid receptors on the same post-synaptic terminals as well as located
presynaptically on glutamatergic afferents of postsynaptic mu opioid receptors in LC neurons
(Scavone et al., 2010). Cannabinoids are hypothesized to reduce hyperactivity of noradrenergic
neurons during opioid withdrawal in LC by either inhibiting glutamate release onto
noradrenergic neurons or compensatory inhibition of cAMP overshoot following opioid
withdrawal in noradrenergic neurons. Catabolic inhibitors elevate levels of 2-AG or AEA by
inhibiting either MAGL or FAAH respectively, thereby indirectly activating CB1 receptors.
AA = Arachidonic acid; 2-AG = 2-arachidonoylglycerol; AEA = arachidonoylethanolamide;
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MAGL = monoacylglycerol lipase, primary catabolic enzyme for 2-AG; FAAH = fatty acid
amide hydrolase, primary catabolic enzyme for AEA; JZL184 = selective MAGL inhibitor; PF3845 = selective FAAH inhibitor; SA-57 = dual FAAH/MAGL inhibitor, more selective for
FAAH than MAGL. [Adapted from (Ahn et al., 2008; Scavone et al., 2013a; Scavone et al.,
2010)]
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1.8.1. Overall Hypothesis
Inhibition of endocannabinoid catabolic enzymes FAAH and/or MAGL will reduce
somatic and negative motivational signs of opioid withdrawal in mice via CB1 mechanism of
action.
1.8.2. Objectives
Our aims for these studies were to 1) assess the efficacy of dual inhibition of FAAH and
MAGL on somatic signs of opioid withdrawal and 2) determine whether these treatments would
produce cannabimimetic effects (hypomotility, catalepsy, antinociception and hypothermia) ; 3)
develop other behavioral assays of opioid withdrawal; and 4) determine if endocannabinoid
catabolic inhibitors would reduce the acquisition of opioid withdrawal induced CPA as a
measure of the negative motivational consequences of opioid withdrawal.
1.8.3. Selection of endocannabinoid catabolic inhibitors
1.8.3.1. MAGL inhibitors
There are several MAGL inhibitors currently available but among them only a few have
sufficient selectivity and potency in vivo for behavioral studies. The MAGL inhibitor URB602
lacks potency (IC50 = 25 µM) and selectivity for MAGL as it was shown to also inhibit AEA
hydrolysis (IC50 = 17µM) (Vandevoorde et al., 2007) whereas the newer inhibitor, JZL184
selectively inhibits MAGL (IC50 = 8 nM), though it can also inhibit FAAH (IC50 = 4,000 nM).
However, JZL184 does not alter AEA acutely and only after repeated administration of JZL184
are elevations of AEA apparent (Long et al., 2009a; Long et al., 2009b). KML29, a new MAGL
inhibitor with greater selectivity for MAGL (IC50 = 15 nM) over FAAH (IC50 > 50,000 nM)
elevates 2-AG without elevating AEA upon repeated treatment, an effect which has been
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observed with JZL184 (Chang et al., 2012). KML29 was reported to produce anti-allodynic and
anti-edamatous effects in mice demonstrating that this compound is effective in vivo
(Ignatowska‐Jankowska et al., 2013). MJN110 is another new MAGL inhibitor with greater
selectivity for MAGL (IC50 = 2.1 nM) over FAAH (IC50 > 50,000 nM) and approximately 100
fold more selective for MAGL than ABHD6 (Niphakis et al., 2013). Since JZL184 acutely
elevates 2-AG and not AEA and has previously been used to assess the effects of MAGL
inhibition of morphine withdrawal in mice (Ramesh et al., 2011) we selected this compound for
these studies.
1.8.3.2. FAAH inhibitors
The irreversible FAAH inhibitor AM374 has marked potency over the non-selective
serine protease inhibitor phenylmethylsulfonyl fluoride at inhibiting AEA hydrolysis, but
AM374 also binds to CB1 receptors (IC50 = 520 nM) (Deutsch et al., 1997). Derivatives of the
sulfonyl fluoride inhibitors have recently been characterized which are approximately 200 fold
more selective for rat FAAH over human MAGL, though these compounds also bind to CB1
receptors in the 100 nM range (Alapafuja et al., 2012). URB597 has been well characterized
though it inhibits other serine hydrolases and carboxylesterases (Lichtman et al., 2004; Zhang et
al., 2007). OL-195, a reversible alpha-ketoheterocycle FAAH inhibitor, has greater selectivity
for FAAH compared to URB597, (Boger et al., 2005). PF-3845 selectively inhibits FAAH (Ahn
et al., 2009) and is more selective than URB597 (Lichtman et al., 2004), and thus is one of the
most potent and selective FAAH inhibitors available. PF-3845 has also previously been used to
investigate the effects of FAAH inhibition on opioid withdrawal (Ramesh et al., 2011) and is
therefore an ideal FAAH inhibitor for these studies.
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1.8.3.3. Dual FAAH/MAGL inhibitors
In addition to the selective FAAH and MAGL inhibitors there are dual inhibitors that can
elevate both AEA and 2-AG. JZL195 was shown to equipotently (IC50 = 2-4 nM) inhibit FAAH
and MAGL and at doses that fully inhibited both enzymes it produced pronounced
cannabimimetic effects (hypomotility, catalepsy, antinociception and hypothermia), THC-like
discriminative stimulus effects (Long et al., 2009c), and spatial learning deficits in the Morris
water maze as measured by path length and escape latency (Wise et al., 2012). AM6701, a nonselective dual FAAH/MAGL inhibitor, provided greater neuroprotective effects than AM6702
which has 44-fold more selectivity for FAAH than MAGL. Excitotoxic damage by kainic acid in
rat hippocampal slice cultures was reduced by AM6701 to a greater degree than AM6702.
Furthermore, AM6701 reduced seizure activity in rats following kainic acid more effectively
than AM6702 and also improved balance and coordination on the rotorod test. The authors
suggested from these data that dual inhibition of FAAH and MAGL has enhanced
neuroprotective effects (Naidoo et al., 2012). Another new dual inhibitor, SA-57, is more
selective for FAAH (IC50 = 10 nM) than MAGL (IC50 = 410 nM) allowing for the partial
inhibition of MAGL while fully inhibiting FAAH (Niphakis et al., 2011).
The mixed FAAH/MAGL inhibitor SA-57 was employed to investigate the effects of full
FAAH inhibition and partial MAGL inhibition as it has significantly greater potency at inhibiting
FAAH over MAGL, allowing for full inhibition of FAAH while only partially inhibiting MAGL
(Niphakis et al., 2011).
1.8.4. Chapter 2: Effects of dual FAAH/MAGL inhibition on somatic signs of opioid withdrawal
In Chapter 2 we investigated the effects of dual inhibition of FAAH and MAGL on
somatic signs of opioid withdrawal in mice. While inhibition of either FAAH or MAGL has been
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shown to reduce somatic signs of opioid withdrawal in mice, FAAH inhibition only attenuated a
subset of withdrawal signs (Ramesh et al., 2011). While MAGL inhibition attenuated all
observed signs of opioid withdrawal, it has also been shown to produce a subset of
cannabimimetic effects (hypomotility, hypothermia, and hyperreflexia) (Long et al., 2009a) and
produce dependence upon repeated treatment (Schlosburg et al., 2010a). We tested the
hypothesis that full inhibition of FAAH and partial inhibition of MAGL would attenuate
morphine withdrawal at doses that do not produce significant cannabimimetic effects.
1.8.5. Chapter 3: Development of behavioral assays of opioid withdrawal
In Chapter 3, we described the development of additional assays for opioid withdrawal in
mice. In order to investigate the ability of endocannabinoid catabolic inhibitors to reduce other
behaviors associated with opioid withdrawal, we examined the effects of opioid withdrawal in
marble burying, novelty-induced hypophagia, the light/dark box, a novel procedure developed to
assess “escape behavior” and the CPA procedure. The light/dark box, novelty-induced
hypophagia, and marble burying assays have been used to assess the effects of anxiolytic drugs
and have been used to infer treatments as “anxiolytic” or “anxiogenic” while CPA has been used
to infer aversive aspects of withdrawal.
1.8.6. Chapter 4: Effects of endocannabinoid catabolic inhibitors on negative motivational
aspects of opioid withdrawal
In Chapter 4, we investigated the effects of endocannabinoid catabolic inhibitors on the
acquisition of CPA to opioid withdrawal in mice. While endocannabinoid catabolic inhibitors
have been shown to reduce somatic signs of morphine withdrawal via CB1 mechanism of action
in mice, this thesis represents the first study examining the effects of cannabinoids on acquisition
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of opioid withdrawal induced CPA. We examined whether inhibition of endocannabinoid
catabolism would block the acquisition of naloxone-precipitated morphine withdrawal CPA and
reduce the percentage of mice that exhibited jumping behavior during the conditioning sessions.
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Chapter 2: Effects of dual FAAH/MAGL inhibition on somatic signs of morphine
withdrawal
2.1. Introduction: Maximal inhibition of MAGL reduces somatic withdrawal signs in mice but
produces cannabimimetic effects
Cannabinoids have been known for almost four decades to reduce somatic signs of opioid
withdrawal (Bhargava, 1976; Hine et al., 1975). Recently it has been shown that a high dose of
the MAGL inhibitor JZL184 reduces somatic measures of morphine withdrawal, including jumps,
paw flutters, weight loss, and diarrhea (Ramesh et al., 2011). However, a problem with JZL184
remains in that it also elicits cannabimimetic (i.e. THC-like) effects, including hypomotility,
hypothermia and hyperreflexia (Long et al., 2009a) and repeated administration of high dose
JZL184 results in cannabinoid dependence and functional CB1 receptor tolerance (Schlosburg et
al., 2010b). Although the antinociceptive and anxiolytic-like effects of JZL184 do not undergo
tolerance following repeated administration of low doses (Busquets-Garcia et al., 2011; Kinsey
et al., 2013; Sciolino et al., 2011), these same low doses of this compound lack effectiveness in
reducing opiate withdrawal responses (Ramesh et al., 2011). Whereas high doses of FAAH
inhibitors do not elicit cannabimimetic side effects and sustained pharmacological inhibition of
FAAH does not lead to CB1 receptor functional tolerance or cannabinoid dependence (Falenski
et al., 2010; Schlosburg et al., 2010b), inhibition of this enzyme prevents only a subset of
withdrawal responses in morphine-dependent mice (Ramesh et al., 2011). Therefore, the primary
objective of these experiments was to determine whether dual inhibition of FAAH and MAGL
would reduce withdrawal signs in morphine-dependent mice, with minimal cannabimimetic side
effects.
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2.1.1. Rationale and hypothesis
Inhibition of endocannabinoid catabolism presents a novel treatment strategy for opioid
withdrawal, but high doses of JZL184 which maximally attenuate somatic withdrawal signs also
produce cannabimimetic effects (Long et al., 2009a), dependence liability and functional CB1
receptor tolerance after repeated dosing (Schlosburg et al., 2010b). Full FAAH inhibition
attenuates a subset of withdrawal signs but is without the cannabimimetic effects and
dependence liability that are observed with high dose JZL184. Thus, combined full inhibition of
FAAH with partial MAGL inhibition may reduce somatic withdrawal signs without the adverse
consequences of maximal MAGL inhibition.
Therefore, we hypothesized that full FAAH inhibition combined with partial MAGL
inhibition would reduce the somatic signs of spontaneous and precipitated morphine withdrawal
and that this treatment would not produce cannabimimetic effects. We tested the efficacy of a
novel combination of low dose of the MAGL inhibitor JZL184 and high dose of the FAAH
inhibitor PF-3845 as well as the novel dual inhibitor SA-57, which is more potent in inhibiting
FAAH (IC50 < 10 nM) than MAGL (IC50 = 410 nM) (Niphakis et al., 2012), in reducing
precipitated and spontaneous morphine withdrawal signs. In addition, endocannabinoid levels
were quantified in whole brain following SA-57 treatment. In these studies, we employed a
spontaneous withdrawal model because it possesses greater face validity than naloxoneprecipitated withdrawal and because somatic signs of spontaneous withdrawal persist for an
extended duration of time (8 h), allowing for time course assessment. Specific withdrawal signs
examined were jumping (platform jumping in the case of spontaneous withdrawal), paw flutters,
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head shakes, diarrhea, and weight loss. To assess cannabimimetic effects, we tested SA-57 in the
cannabinoid tetrad which is a battery of tests that measure locomotor activity, catalepsy, warmwater tail withdrawal, and rectal temperature.
2.2. Methods
2.2.1. Subjects
Male ICR mice (Harlan laboratories; Indianapolis, IN) weighing between 26 and 30 g
served as subjects. The mice were housed 4-5 per cage in a temperature controlled (20-22oC)
environment, in a facility approved by the American Association for the Accreditation of
Laboratory Animal Care. The mice were kept on a 12 h light/dark cycle, with all experiments
performed during the light cycle. Food and water were available ad libitum except while mice
were observed during the withdrawal procedure. The study was performed with the approval of
the Institutional Animal Care and Use Committee at Virginia Commonwealth University in
accordance with the Guide for the Care and Use of Laboratory Animals.
2.2.2. Drugs
Morphine pellets (75 mg), placebo pellets, morphine sulfate, THC, and rimonabant were
obtained from the National Institute on Drug Abuse (Bethesda, MD). Naloxone hydrochloride
was purchased from Sigma Aldrich (St. Louis, MO). JZL184 and PF-3845 were synthesized as
described previously and supplied by Organix Inc. (Woburn, MA) (Ahn et al., 2009; Long et al.,
2009a). SA-57 was synthesized as previously described at The Scripps Research Institute
(Niphakis et al., 2012). THC, PF-3845, JZL184, SA-57 and rimonabant were dissolved in
ethanol, followed by addition of Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and diluted with
0.9% saline to form a vehicle mixture of ethanol, emulphor, and saline in a ratio of 1:1:18.
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Naloxone was dissolved in 0.9% saline and doses calculated by weight of the salt. All injections
were administered in volume of 0.01 ml per 1 g body weight. THC and naloxone were
administered via subcutaneous (s.c.) injection, whereas PF-3845, JZL184, SA-57 and rimonabant
were given via intraperitoneal (i.p.) injection. In spontaneous withdrawal studies, all injections
were given 1 h after pellet removal. For experiments quantifying brain endocannabinoid levels,
SA-57 was administered 2 h before decapitation.
2.2.3. Scoring of somatic signs of morphine withdrawal
For the spontaneous withdrawal experiments, two trained observers (Thomas Gamage
and Divya Ramesh) blinded to the treatment condition live-scored two mice each simultaneously
so that a total of 4 mice were scored per observation session. For the precipitated-withdrawal
studies, one blinded observer (Thomas Gamage) scored the recorded videos. The primary
behavioral signs that were scored were frequency of jumps (either off the platform or within the
observation chamber) and front paw flutters (including single and double paw flutters and
twitches, which are not commonly displayed by naïve mice). The occurrence of diarrhea during
the testing period was noted if liquid feces were present or if fecal boli were soft enough to
“smear” with gentle pressure. All behaviors were recorded as new incidences when separated by
at least 1 s or interrupted by any other normal behavior. In addition, mice were weighed before
and immediately after the 30 min test session to assess body weight loss.
2.2.4. Spontaneous withdrawal
Approximately 72 h after morphine pellet implantation, mice were weighed and assessed
for baseline withdrawal behavior. The mice were then given light isoflurane anesthesia, the
pellets were surgically extracted, and the mice were housed individually in cages that were
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placed on heating pads for 2 h. At 1 h after pellet removal, groups received an injection of drug
or vehicle. The animals were observed for spontaneous withdrawal signs for 15 min intervals at 2,
4, 6 and 8 h post-pellet removal. Spontaneous withdrawal signs were quantified using a
procedure adapted from Way et al. (1969) that included the percentage of mice jumping off a
circular platform (12 cm diameter x 70 cm height), the total number of paw flutter and head
shake incidences, and body weights recorded at each time point. Paw flutters and head shakes
were each pooled across all time points to represent the total number of incidences of the
behaviors observed. The percentage of mice presenting with diarrhea across the 8 h test session
was also recorded. The mice remained singly housed throughout the testing period, and food and
water were available ad libitum, except during the 15 min observation periods.
2.2.5. Pellet implantation surgery
In order to induce opioid dependence, mice were implanted with morphine pellets as
previously described. In brief, anesthesia was induced with 2.5% isoflurane, the fur was shaved,
the skin was disinfected with a sterile betadine swab (Purdue products, Stamford, CT), and a
1 cm horizontal incision was made in the midscapular region, using sterile surgical scissors. A 75
mg morphine sulfate pellet was inserted subcutaneously, and the incision was closed with a
sterile staple. The mice were given a minimum 1 h recovery period in heated home cages for 1 h
after surgery and then returned to the vivarium until testing.
2.2.6. Naloxone precipitated withdrawal
Somatic withdrawal signs were scored, as previously described (Schlosburg et al., 2009).
In brief, mice were placed in white acrylic chambers (20x20 cm), with a clear acrylic front panel
and a mirrored back panel for a 30 min acclimation period. The chambers were enclosed in
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sound-attenuating cabinets that contained an indirect filtered LED light source and fans for air
circulation and white noise. The mice were briefly removed from the chambers for naloxone
administration and immediately returned to the chambers for a 30 min observation period.
Behavior was recorded using a series of Fire-iTM digital cameras (Unibrain, San Ramon, CA),
and the videos were saved using the ANY-mazeTM video tracking software (Stoelting Co., Wood
Dale, IL). Chambers were changed between tests and cleaned at the end of testing with an
ammonia based cleanser and left to dry for two days, to allow for odors to dissipate. The
recorded videos were randomized and scored by a trained observer, who was blinded with
respect to treatment condition. The primary behavioral signs of interest were frequency of jumps
and front paw tremors (including single and double paw flutters and twitches, which are not
commonly displayed by naïve mice). The occurrence of diarrhea during the testing period was
noted. All behaviors were recorded as new incidences when separated by at least 1 s or
interrupted by any other normal behavior. In addition, mice were weighed before and
immediately after the 30 min test session to assess body weight loss.
2.2.7. Cannabinoid tetrad
For this study mice were injected with either vehicle or a dose of SA-57 i.p. (1.25, 2.5, 5,
and 12.5 mg/kg) and tested 2 h later. Locomotor activity was recorded by ANY-maze Software
(Stoelting, Wood Dale, IL) during a 5 min test in which mice were placed in a Plexiglas cage
with black flooring located within a lit sound attenuating chamber equipped with a ventilation
fan. Catalepsy was evaluated using the bar test, in which the front paws of each subject were
placed on a rod (0.75 cm diameter) that was elevated 4.5 cm above the surface. Mice were timed
if they remained motionless with their paws on the bar (with the exception of respiratory
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movements), and the time motionless from 3 attempts to place on the bar were totaled with a
cutoff of 60 s. Hyper-reflexive popping and jumping away from the bar was also scored. In the
tail immersion test, each mouse was placed head first into a small bag fabricated from absorbent
under pads (VWR Scientific Products; 4 cm diameter, 11 cm length) with the tail out of the bag.
The experimenter gently held the mouse and immersed approximately 1 cm of the tip of the tail
into a water bath maintained at 52.0°C. The latency for the animal to withdraw its tail from the
water within a 10 s cutoff time was scored and calculated as percent of maximum possible effect
(%MPE = [(test - control latency) / (100 - control)] x 100). Rectal temperature was determined
by inserting a thermocouple probe 2.0 cm into the rectum and temperature was obtained from a
telethermometer. Before any injections, baseline tail nociceptive latencies and rectal
temperatures were assessed for all tests.
2.2.8. Quantification of endocannabinoids
Mice were treated with vehicle or a dose of SA-57 i.p. (1.25, 2.5, 5, and 12.5 mg/kg).
Two hours after last injection, the mice were decapitated, and brains were harvested and split in
half. Twenty-four h after the last injection, the mice were decapitated, and brains were snap
frozen in liquid nitrogen and stored at -80°C until lipid extraction.
On the day of processing, tissues were weighed and homogenized with 1.4 ml
chloroform/methanol (2:1 v/v containing 0.0348 mg PMSF/ml) after the addition of internal
standards to each sample (2 pmol AEA-d8 and 1 nmol 2-AG-d8). Homogenates were then mixed
with 0.3 ml of 0.73% w/v NaCl, vortexed, and then centrifuged for 10 min at 3220 g (4° C). The
aqueous phase plus debris were collected and extracted two more times with 0.8 ml chloroform.
The organic phases from the three extractions were pooled and the organic solvents were
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evaporated under nitrogen gas. Dried samples were reconstituted with 0.1 ml chloroform and
mixed with 1 ml ice-cold acetone. The mixtures were then centrifuged for 5 min at 1811 g and
4° C to precipitate the proteins. The upper layer of each sample was collected and evaporated
under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed in autosample
vials for analysis.
LC/MS/MS was used to quantify AEA, 2-AG, arachidonic acid. The mobile phase
consisted of (10:90) water/methanol with 0.1% ammonium acetate and 0.1% formic acid. The
column used was a Discovery HS C18, 4.6×15 cm, 3 μm (Supelco, PA). The mass spectrometer
was run in Electrospray Ionization, in positive mode. Ions were analyzed in multiple-reaction
monitoring mode, and the following transitions were monitored: (348>62) and (348>91) for
AEA; (356>62) for AEAd8; (379>287) and (279>269) for 2-AG; and (387>96) for 2-AG-d8. A
calibration curve was constructed for each assay based on linear regression using the peak area
ratios of the calibrators. The extracted standard curves ranged from 0.03 to 40 pmol for AEA and
from 0.05 to 64 nmol for 2-AG.
2.2.9. Statistical Analysis
All data are reported as mean±SEM. In the precipitated withdrawal experiments, the
numbers of jump, head shake and paw tremor incidences were tallied. In the spontaneous
withdrawal experiments, the occurrence of jumps was scored as a binary event for the entire 15min period at each time point. Diarrhea was also scored as a binary event for both spontaneous
and precipitated withdrawal. Weight loss (g) was calculated by subtracting the body weight at
the conclusion of each 15-min observation period from the pre-pellet removal weight. Data were
analyzed using one-way or two-way between measures analysis of variance. Dunnett’s test was
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used to compare drug treatments with vehicle and Newman-Keuls post-hoc test was employed
for comparisons between various treatments. The percentage of mice between groups presenting
with diarrhea and percentage of mice that jumped off platforms were analyzed by the z-test of
two proportions. Differences were considered statistically significant at p<0.05.
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2.3. Results
2.3.1. Withdrawal scoring between observers
Two observers scored the spontaneous withdrawal experiments simultaneously. Both
observers scored pre-recorded withdrawal videos to determine similarities between scoring
criteria and there were positive correlations between both observers for paw flutters [r=0.94,
n=54, p<0.0001], head shakes [r=0.90, n=54, p<0.0001], and jumps [r=0.99, n=54, p<0.0001].
2.3.2. Dual inhibition by combination low dose JZL184 and high dose PF-3845 reduces
naloxone-precipitated somatic withdrawal signs in mice
To evaluate whether combined inhibition of MAGL and FAAH reduces precipitated
opioid withdrawal signs, mice were co-administered a low dose of JZL184 (4 mg/kg, i.p.) or
vehicle and a high dose of PF-3845 (10 mg/kg, i.p.) or vehicle. The combination treatment
blocked the occurrence of withdrawal signs including the frequencies of jumping [F(3, 26) = 4.6;
p <0.01; Figure 2A] and paw flutter incidents [F(3,26) = 5.6; p < 0.01; Figure 2B], as well as
weight loss [F(3,26) = 8.9; p < 0.001; Figure 2C], and diarrhea [Figure 2D].
2.3.3. Dual inhibition by combination low dose JZL184 and high dose PF-3845 reduces
spontaneous somatic withdrawal signs in mice
JZL184 (4 mg/kg) and PF-3845 (10 mg/kg) given in combination reduced the full
spectrum of spontaneous withdrawal signs, while single administration of these drugs reduced
only a subset of withdrawal signs. The combination of JZL184 and PF-3845, but neither drug
alone, significantly reduced jumping at 4, 6, and 8 h after morphine pellet removal [Figure 3A].
The combination as well as each drug given alone significantly reduced the intensity of total
head shakes [F(3,26) = 4.4; p<0.01; Figure 3B] and paw flutters [F(3,26) = 12.3; p<0.001;
Figure 3C]. However, only the combination of JZL184 and PF-3845 significantly ameliorated
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the intensity of weight loss [F(3,26) = 4.8; p<0.01; Figure 3D] and blocked the occurrence of
diarrhea [Figure 3E].
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Figure 2. Combined administration of a low dose of JZL184 (4 mg/kg) and high dose of PF-3845
(10 mg/kg) attenuated the occurrence of the naloxone-precipitated withdrawal jumping and
diarrhea to a greater extent than either inhibitor alone. n=6-8 per group. Data expressed as mean
± SEM for panels A-C. * p<0.05, ** p<0.01. ***p<0.001 vs. vehicle, # p<0.05 compared to
PF-3845 and JZL184 alone.
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Figure 3. Combined administration of a threshold dose of JZL184 (4mg/kg) and high dose of
PF-3845 (10 mg/kg) attenuated the occurrence of the spontaneous withdrawal jumping and
diarrhea to a greater extent than either inhibitor alone. n=7-8 per group. The withdrawal signs
measured include: (A) jumps, (B) headshakes, (C) paw flutters, (D) weight loss, and (E) diarrhea.
n=7–8 per group. Data expressed as mean±SEM for panels B-D. *p<0.05, **p<0.01, ***p<0.001
vs. vehicle, # p<0.05 compared to PF-3845 and JZL184.
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2.3.4. Dual FAAH/MAGL inhibition reduces somatic signs of spontaneous morphine withdrawal
via CB1 receptor mechanism of action
Rimonabant completely prevented all reductions in somatic withdrawal signs by
combined administration of JZL184 (4 mg/kg) and PF-3845 (10 mg/kg) in morphine-dependent
mice following pellet removal, including the occurrence of jumps [Figure 4A], head shakes
[F(1,37) = 4.4; p<0.05; Figure 4B], paw flutters [F(1,37) = 9.9; p<0.01; Figure 4C], weight loss
[F(12,108) = 2.8; p<0.01; Figure 4D], and diarrhea [Figure 4E],
2.3.5. Dual inhibition by the mixed FAAH/MAGL inhibitor SA-57 reduces somatic signs of
naloxone-precipitated morphine withdrawal in mice
To determine the efficacy of a dual FAAH and MAGL inhibitor on morphine-dependent
mice undergoing spontaneous withdrawal, we employed SA-57, which is greater than 100-fold
more potent as a FAAH inhibitor than as a MAGL inhibitor (Niphakis et al., 2012). SA-57 dosedependently reduced the occurrence of platform jumping [Figure 5A], the total numbers of paw
flutters [F(3,32)=18.0; p<0.0001; Figure 5B] and head shakes [F(3,32)=4.34; p<0.05; Figure 5C],
attenuated weight loss at all time points at the 5 mg/kg dose [F(3,32)=5.99; p<0.01; Figure 5D]
and fully blocked the presence of diarrhea at 5 mg/kg [Figure 5E].
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Figure 4. CB1 receptors mediate the effects of combined administration of a threshold dose of
JZL184 (4 mg/kg) and a high dose of PF-3845 (10 mg/kg) in on spontaneous morphine
withdrawal signs. n=10-11 per group. The withdrawal signs measured include: (A) jumps, (B)
head shakes, (C) paw flutters, (D) weight loss, and (E) diarrhea. n=10-11 per group. Data are
presented as mean±SEM for panels B-D. *p<0.05 vs. vehicle, #p<0.05 vs JZL+PF condition
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Figure 5. The dual FAAH/MAGL inhibitor SA-57 reduced all measured signs of spontaneous
morphine withdrawal. The withdrawal signs measured include (A) jumps, (B) paw flutters, (C)
head shakes, (D) weight loss and (E) diarrhea. n=9 per group. Data expressed as mean ± SEM for
panels B-D. *p<0.05, **p<0.01, ***p<0.001 vs. vehicle.
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2.3.6. SA-57 is more potent at elevating AEA than 2-AG in mouse brain
As shown in Figure 6A, 0.125 and 1.25 mg/kg SA-57 did not alter brain 2-AG levels, but
2.5, 5, and 12.5 mg/kg SA-57 elevated brain 2-AG levels respectively by 3-4 fold, 7 fold, and
greater than 10-fold [F(5,24)=305.5; p<0.0001]. SA-57 was considerably more potent in
elevating brain AEA levels (ED50 = 0.4 mg/kg) than 2-AG levels (ED50 = 5.0 mg/kg), with 0.125
mg/kg increasing AEA approximately 3-fold and each of the higher doses producing maximally
elevated brain AEA levels [F(5,24)=49.02; p<0.0001; Figure 6C]. As shown in Figure 6B, 5 and
12.5 mg/kg SA-57 significantly reduced brain AA levels [F(5,24)=10.93; p<0.0001] by 33% and
60%, respectively.
2.3.7. The dual FAAH/MAGL inhibitor SA-57 produces minimal cannabimimetic effects
To evaluate whether dual blockade of MAGL and FAAH would elicit cannabimimetic
effects, we tested SA-57 (1.25-12.5 mg/kg) in the cannabinoid tetrad assay. As shown in
Figure 7, SA-57 produced immobility, catalepsy and hypothermia at only the highest dose tested
(12.5 mg/kg) which maximally elevates both AEA and 2-AG [Figure 6]. Specifically, SA-57
significantly increased [Figure 7A] immobility [main effect of treatment, F(4,30)=4.56, p<0.01]
at the highest dose tested with no main effect for time [p=0.37] or interaction effect [p=0.90].
SA-57 also produced [Figure 7B] catalepsy at 4, 6, and 8 h post-treatment [main effect of
treatment, F(4,124)=6.0, p<0.01; main effect of time, F(4,124)=8.6, p<0.0001; interaction effect,
F(16,124)=3.1, p<0.001]. There was no effect of SA-57 on antinociception at any dose at any
time point [Figure 7C]. Finally, SA-57 produced a significant reduction in rectal temperature at 1,
2 and 4 h [main effect of treatment, F(4,124)=9.5, p<0.0001; main effect of time, F(4,124)=57.6,
p<0.0001; interaction effect, F(16,124)=16.0, p<0.0001; Figure 7D].
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Figure 6. Effects of dual FAAH/MAGL inhibitor SA-57 on whole brain levels of 2-AG,
arachidonic acid, and AEA. The dual FAAH/MAGL inhibitor SA-57 dose-dependently increased
whole-brain levels of (A) 2-AG, and concomitantly decreased (B) arachidonic acid, but was most
potent at elevating (C) brain AEA levels. n=5-7 per group. Data are expressed as mean ± SEM.
*p<0.05, **p<0.05, compared to vehicle.
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Figure 7. Effects of dual FAAH/MAGL inhibitor SA-57 in the cannabinoid tetrad. The dual
FAAH/MAGL inhibitor SA-57 produced (A) immobility, (B) catalepsy and (D) hypothermia
only at the highest dose tested (12.5 mg/kg), but did not produce (C) antinociception. n=5 per
group. Data are expressed as mean ± SEM. *p<0.05, **p<0.05 compared to vehicle.
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2.4. Summary
The major finding of the preceding experiments is that partially blocking MAGL in
combination with full FAAH blockade reduced somatic withdrawal signs at doses that did not
produce cannabimimetic effects. Specifically, combined administration of low dose of the
MAGL inhibitor JZL184 (i.e., 4 mg/kg) and high dose of the FAAH inhibitor PF-3845 (i.e., 10
mg/kg) reduced precipitated [Figure 2] and spontaneous [Figure 3] morphine withdrawal and
these effects were CB1 mediated [Figure 4]. Additionally, dual inhibition with PF-3845
(10 mg/kg) and JZL184 (4 mg/kg) produced greater effects on jumps and diarrhea than either
treatment alone. The dual FAAH/MAGL inhibitor SA-57 [Figure 5] significantly reduced paw
flutters, head shakes, jumps, diarrhea, and weight loss in morphine-dependent mice undergoing
spontaneous withdrawal. Importantly, these studies have shown that dual inhibition of
FAAH/MAGL at doses of SA-57 that only partially elevate 2-AG [Figure 6] do not produce
detectable changes in measures of cannabimimetic activity [Figure 7].
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Chapter 3: Development of behavioral assays of morphine withdrawal
3.1. Introduction
Opioid withdrawal in humans is characterized by a number of physical and affective
components including physical aspects such as diarrhea, emesis, dehydration, hypertension,
hyperthermia, tachycardia and body aches as well as affective aspects such as anxiety, dysphoria,
and panic attacks (Farrell, 1994; Gossop, 1988; Jasinski, 1981; Wesson et al., 2003). As
described in the previous chapters, rodents exhibit a number of withdrawal signs following either
precipitated or spontaneous opioid withdrawal which include jumping, paw fluttering, head/body
shaking/twitching, ptosis, teeth chattering, weight loss and diarrhea (Way et al., 1969). One
concern regarding a drug’s ability to attenuate these withdrawal signs is whether the drug is
having a direct effect on withdrawal or if it is simply suppressing behavior in general, though
this would unlikely be the case for diarrhea. Additionally, it’s been suggested that different
aspects of withdrawal are mediated by different brain regions and while a drug treatment may be
effective at attenuating one subset of withdrawal signs it may be ineffective at reducing others
(Schulteis et al., 1996). A critical component of treating opioid dependence is reducing
withdrawal states which are associated with the maintenance of abuse as continued drug use
serves to avoid the withdrawal state thus serving as a negative reinforcer (Bart, 2012; Koob et al.,
2005). It’s important then to have behavioral models which can effectively assess other aspects
which are related to the aversive internal/affective states of opioid withdrawal. A drug treatment
that only blocks one subset of withdrawal signs would have limited clinical efficacy. Thus, in
order to determine if a drug treatment is differentially affecting aspects of withdrawal, additional
behavioral assays are necessary.
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The purpose of the research presented in this chapter was to examine established murine
behavioral assays thought to be reflective of aversive aspects of opioid withdrawal. We
examined the effects of morphine withdrawal in the marble burying, novelty-induced hypophagia,
and light/dark box tests which have all been suggested to model anxiety. Specifically, anxiolytic
drugs will reduce marble burying, inhibit the suppression of feeding by a novel environment, and
increase the amount of time spent in the light side of the light/dark box. Additionally, we
developed a novel procedure to examine escape behavior in mice to further investigate the
behaviors that we observed following opioid withdrawal in the light/dark box. Finally, we
examined the effects of naloxone-precipitated withdrawal in the conditioned place avoidance
(CPA) procedure which has been used to study the negative motivational aspects of withdrawal.
The objective of this work was to identify a procedure that could be used to infer an aversive
state of withdrawal in order to test endocannabinoid catabolic enzyme inhibitors for their
efficacy to reduce opioid withdrawal.
3.1.1. Elevated plus maze and light/dark box
Several behavioral assays are employed as screening tests for anxiolytic compounds and
among them are the elevated plus maze (EPM) and the light/dark box. Both of these behavioral
procedures utilize a rodent’s innate avoidance of bright/exposed areas to assess the effects of a
treatment on the rodent’s behavior in the assay including measures such as the number of entries
and the amount of time spent in areas of the apparatus. The EPM contains four arms, two of
which are closed off by walls flanking either side creating an “alley” while the other two arms
have no walls leaving them more exposed. The innate avoidance by rodents of the open-arms
was first observed by Montgomery in the 1950s (Montgomery, 1955), who suggested the

58

preference of rats for the closed-arms indicated a difference in the relative amount of “fear”
elicited as compared with the open-arms. He also suggested that both the open and closed-arms
elicit an “exploratory drive” and there is a conflict between the rodent’s motivation to explore
and its avoidance due to the “fear” of the open-arms. Handley and Mithani (1984) used this as
the basis for the development of the elevated-plus maze as a screen for anxiolytic drugs and
found that diazepam (0.5 – 5 mg/kg i.p.) increased the ratio of entries into the open-arms vs.
closed arms but not total entries. Subsequently, Lister (1987) adapted the EPM to be used with
mice and demonstrated that anxiolytic agents chlordiazepoxide (10 mg/kg) and ethanol (1.6 g/kg)
increased the ratio of open-arm entries to total entries, and suggested that the EPM may work to
screen anxiolytic compounds in mice. Furthermore, Lister demonstrated that drugs which are
anxiogenic in humans, caffeine (60 mg/kg) and picrotoxin (2 mg/kg) reduced the ratio of openarm to total entries, suggesting that the procedure has bidirectional drug sensitivity (Carobrez et
al., 2005). The EPM has since been used to assess the effect of various experimental
manipulations (e.g. drug treatments, genetics) on behaviors in this apparatus (e.g. number of
entries to open-arms, time spent in open-arms) and agents which are anxiolytic or anxiogenic in
humans have been shown to increase or decrease the amount of time spent in the open-arms in
this assay respectively (Carobrez et al., 2005; Hogg, 1996).
The light-dark box, first described by Crawley (1981), is constructed of two
compartments, a dark side that is typically one third of the entire apparatus and the light side
which comprises two thirds (though some studies use 1/2 for each side). These two sides are
separated by a wall containing an opening which allows the rodent to ambulate between
compartments. Similar to the EPM, rodents will typically spend much less time in the light side
than in the dark side, an avoidance behavior that is reduced by anxiolytic agents such as
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benzodiazepines (Bourin et al., 2003; Crawley, 1981). Crawley reported that mice treated with
benzodiazepines clonazepam (0.1 – 0.5 mg/kg i.p.), diazepam (0.5 – 5 mg/kg i.p.), flurazepam
(1 – 10 mg/kg i.p.), and chlordiazepoxide (5 – 10 mg/kg i.p.) exhibited increased number of
transitions between sides, suggesting an increased exploratory behavior. This behavior was not
observed with other drugs that do not possess anxiolytic effects in humans suggesting a degree of
pharmacological specificity in this assay. Costall et al. (1989) further characterized the light/dark
box, manipulating light intensity and testing several mouse strains and drug treatments. White
lighting (15 – 40 watts) did not significantly reduce the amount of time on the light side
compared to the dark side in which a red light (60 watt) was placed, however when the white
light was increased to 60 or 100 watts, mice spent significantly less time on the light side and
exhibited shorter latencies to exit to the black side, suggesting that greater light intensity
produces an avoidance response in mice.
The use of behavioral assays typically used to screen for anxiolytic drug effects has also
been extended into studies of drug dependence where rodents undergoing withdrawal exhibit
shifts in behaviors in these assays. For example, in rats, withdrawal from morphine has been
shown to reduce the amount of time spent in the open-arms which is inferred by investigators to
suggest an anxiogenic state (Bhattacharya et al., 1995; Castilho et al., 2008; Harris et al., 1993;
Schulteis et al., 1998b; Zhang et al., 2008). Bhattacharya was among the first to demonstrate that
morphine-dependent (10 mg/kg i.p. b.i.d. for 14 days) rats undergoing spontaneous withdrawal
(24 h following last injection) spent significantly less time in the open-arms of the EPM than did
vehicle-treated rats (9.2±0.9% vs. 24.3±3.6, morphine vs. control) (Bhattacharya et al., 1995).
Subsequently, Schulteis et al. (1998b) demonstrated that rats undergoing both precipitated and
spontaneous morphine withdrawal exhibited decreases in the time spent in the open-arms of the
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EPM. Rats implanted with either morphine (2x75 mg) or placebo pellets for 64 h were tested 8 h
later (72 h post pellet implantation) and morphine-pelleted rats undergoing spontaneous
withdrawal exhibited significant decreases in the percent of time spent in the open-arms. For
precipitated withdrawal, morphine-pelleted rats (2x75 mg; 72 h) received naloxone (0.03,
0.1 mg/kg s.c.) and subsequently exhibited significant reductions in the percent of time spent in
the open-arms (Schulteis et al., 1998b).
Examination of morphine withdrawal effects in the light/dark box is not as well
characterized as morphine withdrawal in the EPM, however Castilho reported that naloxone
(0.1 mg/kg i.p.) significantly reduced the time spent in the light side and the number of entries
into the light side in morphine-dependent, but not non-dependent, rats (Castilho et al., 2008).
These decreases in time spent in the open-arms of the EPM and light side of the light/dark box
are opposite to effects observed with drugs that are known to be anxiety-reducing and mimic
effects of drugs that are known to be anxiety-provoking in humans and experimenters have
therefore inferred that these behaviors are reflecting an anxiogenic state in the animal.
However, opioid-dependent mice undergoing either precipitated or spontaneous
withdrawal display paradoxical behavioral effects in the EPM. Specifically, they exhibit
increases in open-arm time, an effect which would typically be interpreted as anxiolytic-like
(Buckman et al., 2009; Hodgson et al., 2008; Hodgson et al., 2009). The first study to report
increased open-arm time following opioid withdrawal in mice was reported by Hodgson et al.
wherein morphine dependent mice (morphine 10-40 mg/kg s.c. b.i.d., 3 days) were challenged
with naloxone (0.1-0.4 mg/kg) and at each dose mice treated repeatedly with morphine exhibited
a significant increase in open-arm time whereas mice treated with vehicle did not (Hodgson et al.,
2008). Subsequently they demonstrated similar increases in open-arm time following
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spontaneous withdrawal using a slightly longer dependence procedure (morphine 10-40 mg/kg
s.c. b.i.d., 6 days) and mice were tested 2, 4, 8 and 24 h after the last morphine or vehicle
injection. Morphine treated mice exhibited increases in time spent in the open-arms and
increased number of entries into the open arms at the 8 h time point (Buckman et al., 2009).
Additionally, precipitated withdrawal by naloxone (0.2 mg/kg) in opioid-dependent mice
resulted in significantly elevated levels of the stress hormone corticosterone in blood collected
10 min post naloxone treatment (Hodgson et al., 2008). This effect has previously been reported
in mice and rats following morphine withdrawal (Budziszewska et al., 1996; Gonzalvez et al.,
1994). The effects of morphine withdrawal in mice in the light/dark box have not yet been
reported. Here, we examined whether naloxone challenge in morphine-pelleted mice would
cause a decrease in the duration of time in the light side, which would be consistent with the
interpretation that opioid withdrawal produces anxiogenic-like effects.
3.1.2. Escape behavior
Unconditioned defensive behaviors exhibited by rodents have been suggested to include
flight, startle, hiding, freezing, defensive threat, attack and risk assessment (Blanchard et al.,
2003; Rodgers et al., 1997). These defensive behaviors have also been suggested to be controlled
by environmental features such as the availability of escape and the proximity of the threat
(Rodgers et al., 1997). In the mouse defense test battery jumping behavior is scored as attempted
escape. Jumping behavior is also observed during naloxone-precipitated morphine withdrawal in
mice (Way et al., 1969) and this has been termed by some as “escape jumping” (Frederickson et
al., 1976; Noda et al., 2004; Stinus et al., 1990). Observations that mice exhibit an increase in
the amount of time spent in the open-arms of the elevated plus maze during morphine
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withdrawal has been suggested to reflect a shift in defensive behaviors towards escape (Hodgson
et al., 2008). It seems likely that the jumping behavior and the increases in time spent in the
open-arms of the EPM exhibited by mice are closely related. However, it is not clear whether the
jumping or increased time spent in the open-arms of the EPM are directed towards escape. In
order to determine whether morphine withdrawal is increasing escape behavior a procedure is
necessary that allows for rodents to actually escape. Thus, we developed a procedure in which
mice are placed in a novel environment containing an opening through which they can escape.
We hypothesized that naloxone would significantly reduce the latency to escape in morphinepelleted, but not placebo-pelleted, mice.
3.1.3. Novelty-induced hypophagia
Novelty-induced hypophagia is a decrease in food consumption and/or a reduced latency
to begin feeding in a novel environment. Rodents will quickly approach and consume a food in
their home cage if it is 1) familiar and 2) they are food deprived or if the food is highly palatable.
However, if the same food is presented to the animal in a novel environment the latency to
approach and consume the food is increased, the amount consumed is decreased, and this
behavior has been termed “novelty-induced hypophagia” or “hyponeophagia”.
Stephens (1973) and Soubrie (1975) were among the first to demonstrate that rats and
mice treated with benzodiazepines would consume larger quantities of food in a novel
environment than control animals. Stephens reported that food deprived mice receiving
subcutaneous injections of diazepam (0.1 – 62.5 mg/kg), chlordiazepoxide (0.39 – 100 mg/kg)
and nitrazepam (0.1 – 62.5 mg/kg), elicited a dose-dependent increase in wet mash consumption
in a novel environment.
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Variations of the novelty-induced hypophagia task have been developed recently by
Merali et al. (2003) in which animals are not food deprived, but instead are acclimated to a
palatable food and subsequently tested in the home cage and a novel environment. The latency to
consume is recorded in both the home cage and the novel environment and mice exhibit a very
short latency to approach and consume the food in their home cage while taking a significantly
longer amount of time to begin eating the food in a novel environment. Merali et al. evaluated
pharmacological and environmental manipulations in this procedure. Among their findings, the
addition of a predator scent (rat fecal bolus) significantly increased the latency over no scent in
the novel condition. Treatment with diazepam (0.25 mg/kg i.p.) significantly reduced the latency
to approach and consume the palatable food in the novel environment, but did not affect latency
in the home cage suggesting context-specificity of diazepam’s effects. Additionally,
chlordiazepoxide (3 mg/kg i.p.) and propranolol (2 mg/kg i.p.) also reduced the latency to
consume food in the novel condition but not in the home cage.
The novelty-induced hypophagia task has recently been used to examine the effects of
nicotine withdrawal in mice. Turner et al. (2013) examined withdrawal in mice implanted with
osmotic minipumps delivering nicotine (18 mg/kg/day). Fourteen days later, the pumps were
removed to elicit spontaneous withdrawal. Mice were tested 24 h after minipump removal in the
novelty-induced hypophagia test and the withdrawal group exhibited significantly increased
elevations in latency to feed in the novel environment as compared to saline control animals, but
withdrawal did not affect latency in the home cage, suggesting that the nicotine withdrawal state
specifically increases novelty-induced hypophagia. There are presently no published reports of
opioid withdrawal in this model of which we are aware.
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3.1.4. Marble burying
The marble burying test was initially developed as a modified version of the defensive
burying model, but as discussed below this explanation has been challenged. In the defensive
burying model, a nociceptive or predator-related stimulus is presented to the rodent in an
apparatus containing a substrate material (e.g. sand, bedding) which rodents push/kick up
towards the stimulus. This effect was first demonstrated in rats by Pinel and Treit (1978) who
reported that an electrified prod caused rats to bury it, but that rats would not bury another prod
that did not produce a shock. This pattern of findings suggested that the rats were specifically
burying the prod which produced a noxious stimulus and thus the behavior was described as
defensive burying. Ethologically, rodents have been observed emitting this behavior from their
burrows towards snakes (Deacon, 2006). Marble burying is a modified version of the defensive
burying task in which marbles (typically 20-25) are placed in a grid pattern atop the substrate
material and the number of marbles that are buried during the test is taken as an indicator of this
burying behavior, though marble burying as a measure of defensive burying has been challenged
and is now considered an indirect measure of digging behavior rather than defensive burying
(Deacon, 2006). Anxiolytic drugs will reduce the number of marbles buried in the marble
burying procedure (Broekkamp et al., 1986; Njung'e et al., 1991) as will endocannabinoid
catabolic inhibitors (Kinsey et al., 2011).
The effects of opioid withdrawal have been examined in the defensive burying task in
rats. Morphine-dependent rats (10-80 mg/kg i.p. once daily, 11 days) or saline treated controls
were tested 48 h after their last repeated injection and placed in a chamber containing a 3 cm
diameter hole which contained an electric probe with a constant electrical current. Rats that had
received repeated morphine (10 - 80 mg/kg i.p., q.i.d.; 11 days) were tested 48 h after their last
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morphine injection and exhibited significant increases in the latency to begin burying as well as
increased burying duration, suggesting that morphine withdrawal increased the defensive
burying behavior (Harris et al., 1993).
Additionally, morphine withdrawal in mice leads to increases in the number of marbles
buried in the marble burying task. Mice treated repeatedly with morphine (5-20 mg/kg s.c. twice
daily, 10 days) were tested 2, 8, 24, 48 and 96 h post withdrawal in the marble burying task.
Mice were placed in the Plexiglas cage with 5 cm of bedding and 20 marbles placed in a 4x5 grid
pattern and the number of marbles buried at the end of the 30 min session was counted. Mice at 8,
24, and 48 h post withdrawal buried more marbles as compared with saline treated controls
(Umathe et al., 2012). Thus, morphine withdrawal increases both defensive burying in rats and
digging behavior in mice as assessed by the marble burying task.
3.1.5. Conditioned place avoidance
Place conditioning is a Pavlovian paradigm in which the primary motivational properties
of a treatment (e.g. acute drug treatment, drug withdrawal) serve as an unconditioned stimulus
which is paired with specific context that serves as a conditioned stimulus. The conditioned
stimulus (CS) becomes predictive of the unconditioned stimulus (US) such that the CS elicits
either approach (i.e. conditioned place preference) or avoidance (i.e. conditioned place
avoidance). It is then inferred from the animal’s behavior that the treatment is either rewarding or
aversive depending upon the expressed behavior during free access to the entire apparatus after
the conditioning procedure. Test compounds can then be administered prior to the conditioning
sessions to determine their effect on the acquisition of CPA, wherein a reduction of CPA would
suggest the test compound blocked the aversive unconditioned stimulus (Bardo et al., 2000).
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The first published study to examine place conditioning was by Horace Beach (1957)
who developed a procedure in rats based upon early findings by Spragg (1940). Spragg
demonstrated that monkeys would seek a certain colored box that contained a morphine syringe
after the monkeys had been repeatedly treated with morphine from that specific box. Beach
surmised that rats could also learn to associate the effects of morphine with a particular
conditioned stimulus. Using a Y-maze, Beach exposed the rats to the apparatus, allowing them
on repeated trials to enter one arm of the maze or the other but would not allow them to move
backward, thus forcing them to make a “choice”. Rats were then made dependent for 8 weeks
receiving daily morphine injections (5 mg/kg or 1 – 20 mg/kg s.c.) and then conditioned in what
is now termed a “biased” procedure. Following the 8 weeks dependence procedure, rats were
then conditioned for 1 h with saline on their preferred side and then 20 min after this
conditioning session were administered morphine (i.e. the same dose administered daily) and
placed in their non-preferred side. This procedure continued for 12 days until they were tested in
4 trial test sessions where the rats could choose to enter either the morphine paired or saline
paired arms of the Y-maze. The arm selected in each trial was recorded and expressed as a
percentage of total trials. Rats in both treatment groups selected the morphine-paired side more
following conditioning than during pre-conditioning tests. Specifically, rats in the 5 mg/kg
morphine group selected the morphine-paired arm 75% post-conditioning compared to 45.3%
pre-conditioning and rats in the 20 mg/kg group selected the morphine-paired arm 74.4% postconditioning as compared to 43.8% during pre-conditioning. In contrast, saline treated mice did
not change the percentage of arm selection (45% vs. 43.8%) following the procedure. This early
study is possibly the first to demonstrate withdrawal CPA since it could be assumed that rats not
having received their daily morphine injection prior to the saline conditioning session were
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undergoing spontaneous withdrawal. Thus, the selection of the morphine paired arm could also
be interpreted as an avoidance of the withdrawal-paired arm. Beach also demonstrated in the
same paper conditioned place preference to morphine in non-dependent rodents. Morphine (1 – 5
mg/kg i.p.) was conditioned daily for 12 days, reaching the high dose (5 mg/kg) on day five and
being maintained at that dose for the remaining conditioning days. Rats exhibited a greater
percentage of entries into the morphine-paired arm (70.8%) post-training than during pre-training
(46%). These studies by Beach were the first to demonstrate the place conditioning effects of
drugs. Subsequently Rossi and Reid (1976) modified the procedure to examine the amount of
time spent in each context and this measure has been adopted in most place conditioning
procedures.
The negative motivational properties of opioid antagonism were elucidated by Mucha et
al. (1982). Rats conditioned with naloxone (0.1 – 45 mg/kg i.v.) exhibited a CPA behavior
following 4 conditioning sessions for each treatment condition (saline vs. naloxone) and when
morphine-dependent rats were used (75 mg pellets, 72 h prior to first conditioning session),
much lower doses of naloxone (0.004 and 0.0025 mg/kg i.v.) produced CPA in these animals.
This study demonstrated the differential sensitivity to naloxone in morphine-pelleted animals and
therefore naloxone-precipitated morphine withdrawal CPA.
Hand et al. (1988) was the first to demonstrate central mediation of CPA of precipitated
opioid withdrawal. Methylnaloxonium administered intracerebroventricularly (i.c.v.; 200-1000
ng) prior to placement of rats in compartments with distinct contextual cues produced a
significant avoidance behavior to the withdrawal-paired compartment following conditioning in
dependent, but not non-dependent, rats. Methylnaloxonium, which does not readily cross the
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blood-brain barrier, did not produce CPA when administered s.c. in dependent rats at lower
doses and only produced CPA at the highest dose (10 mg/kg), at which point some central
blockade of mu opioid receptors may have occurred. Stinus et al. (1990), using a similar
procedure, determined that the nucleus accumbens followed by the amygdala and periaqueductal
grey were the most sensitive regions to methylnaloxonium, with intracerebral microinfusions of
250 ng (NAc) and 500 ng (amygdala, PAG) producing CPA behavior. Furthermore, the brain
regions which were most sensitive, i.e. nucleus accumbens, amygdala, and PAG, support a role
for multiple loci in the acquisition of withdrawal CPA. Later studies demonstrated that
microinjections of methylnaloxonium into the NAc and amygdala elicited only a subset of
somatic withdrawal signs at relatively high doses as compared to LC and PAG; e.g. (lowest
significant dose; ED50) NAc: mastication (500 ng; ED50 = 5000 ng); Amygdala: mastication (31
ng; ED50 = 112 ng), ptosis (62 ng; ED50 = 94 ng), teeth chattering (250 ng; ED50 = 1024 ng).
These are in contrast to LC and PAG infusions where all withdrawal behaviors were observed. It
is notable that methylnaloxonium (1000 ng) in the LC produced much greater jumping behavior
in comparison to PAG where the effect was 10 fold lower, suggesting a greater role of LC in
withdrawal jumping behavior (Maldonado et al., 1992).
Indeed, higher doses of naloxone have consistently been shown to be required to
precipitate quantifiable somatic withdrawal behaviors as compared with those necessary to
produce CPA (Frenois et al., 2002). In their study, Frenois et al. demonstrated a separation
between naloxone dose and both the behaviors and brain regions activated in morphine-pelleted
rats, thus showing a clear distinction between regions necessary for the expression of somatic
and negative motivational aspects of withdrawal. The calculated ED50 values of naloxone to elicit
withdrawal weight loss (21.2 µg/kg), jumping (30 µg/kg), diarrhea (32.2 µg/kg), and salivation
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(67.3 µg/kg) were higher than the ED50 value to produce CPA (4.7 µg/kg). Furthermore, the
specific brain regions (NAc and amygdala), which Stinus et al. had previously (1990) teased
apart to mediate the negative motivational aspects of withdrawal behaviors, also showed greater
sensitivity to naloxone induced increases in cFos expression than areas thought to mediate
physical withdrawal aspects (e.g. locus coeruleus). While significant increases in cFos
expression were observed at 7.5 µg/kg in the amygdala and 15 µg/kg in the nucleus accumbens,
significant increases in cFos were only observed at doses of 30 µg/kg and higher.
Conditioned place avoidance as a model for the negative motivational aspects of opioid
withdrawal has been well established and is currently used to assess the role of different
neurotransmitter systems and brain regions during this process. Further discussion of opioid
withdrawal CPA is presented in chapter 4, along with experiments examining the impact of
inhibiting endocannabinoid catabolic enzymes in morphine withdrawal CPA.
3.1.6. Rationale and hypothesis
While inhibitors of endocannabinoid catabolism block somatic signs of morphine
withdrawal in mice, it is possible that these effects are due to an overall suppression of behavior
rather than a specific attenuation of withdrawal itself. Furthermore, if these drugs are in fact are
attenuating somatic withdrawal signs via a specific anti-withdrawal mechanism, there are still
multiple components (e.g. somatic signs vs. motivational aspects) to opioid withdrawal in
rodents which involve multiple brain regions (Frenois et al., 2002; Stinus et al., 1990) so
reductions in somatic withdrawal signs do not necessarily indicate a reduction in motivational
aspects. Therefore, in order to determine the extent to which inhibitors of endocannabinoid
catabolism

can

reduce

opioid

withdrawal,
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motivational/affective states are needed. The EPM, light/dark box, and novelty-induced
hypophagia tests have been used to evaluate the potential anxiolytic-like and anxiogenic-like
aspects of various pharmacological manipulations and have therefore been suggested to be
models of affective behaviors, though it is important to ensure that effects in these assays are not
confounded by effects such as locomotor activity. These tests have been used to evaluate drug
withdrawal and are investigated here as potential assays in which to evaluate morphine
withdrawal. Paradoxical effects of morphine withdrawal in the EPM (Buckman et al., 2009;
Hodgson et al., 2008; Hodgson et al., 2009) wherein mice exhibit increases in open-arm time
have been suggested to reflect shifts in defensive behavior towards escaping. Assessment of
mouse behavior during morphine withdrawal in the light/dark box here resulted in a similar
behavior (increases in time spent in the light side) and so a novel procedure was developed to
test the hypothesis that mice are exhibiting escape behavior. We hypothesized that mice
undergoing morphine withdrawal would exhibit 1) decreases in the amount of time in the light
side of the light/dark box; 2) decreases in the latency to escape a novel environment; 3) increases
in digging behavior as assessed in the marble burying task; 4) increases in latency to consume
food in a novel environment in the novelty-induced hypophagia test; and 5) greater conditioned
place avoidance following naloxone conditioning than non-dependent mice.
3.2. Methods
3.2.1. Subjects
Male ICR mice (Harlan, Indianapolis, IN) with a body mass of 27-32 g were used for all
experiments. Mice were group-housed (4 per cage) or single-housed on a 12/12 light/dark cycle
(lights on at 0600 h) and given food and water ad libitum except during the experimental
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sessions for the light dark box, the escape box, marble burying, and the CPA assay. Mice had
access to water and the palatable food during the novelty-induced hypophagia test. All efforts
were made to minimize animal suffering and number of animals used. All animal protocols were
approved by the Virginia Commonwealth University Institutional Animal Care and Use
Committee and were in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal Resources, 2011).
3.2.2. Drugs
Morphine pellets (75 mg), placebo pellets, and morphine sulfate were obtained from the
National Institute on Drug Abuse (Bethesda, MD) and diazepam and naloxone hydrochloride
were purchased from Sigma Aldrich (St. Louis, MO). Naloxone HCl was dissolved in
physiological saline (0.9% NaCl) and drug concentrations were calculated using the weight of
the salt as used previously (Ramesh et al., 2011). Morphine sulfate was dissolved in
physiological saline (0.9% NaCl) and drug concentrations were calculated based upon the free
base. Diazepam was dissolved in ethanol and Emulphor-620 (Rhone-Poulenc, Princeton, NJ) and
then diluted with physiological saline to form a vehicle mixture of ethanol:Emulphor-620:saline
in a ratio of 1:1:18. Diazepam was administered intraperitoneally while naloxone HCl and
morphine were administered subcutaneously. All drugs were administered in a volume of 10µl
per g body mass.
3.2.3. Light/dark box
The light dark box (Bourin et al., 2003) consisted of two distinct compartments: a light
side measuring 20.5×40 cm and a dark side measuring 10×40 cm and walls 34 cm high. The
middle wall separating the two sides contained a 7×7 cm opening in the middle through which
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the mice could travel between sides. The dark side had a UV penetrable lid blocking out the
visible light while the light side had a 60 watt bulb above it. Fire-iTM digital cameras (Unibrain,
San Ramon, CA) recorded video and the videos were analyzed using the ANY-mazeTM video
tracking software (Stoelting Co., Wood Dale, IL)
Mice were implanted with morphine (75 mg/kg) or placebo pellets. Forty-eight hours
later, mice were injected s.c. with naloxone 10 min prior to start of the experiment at which point
they were placed in the front right corner of the light side and time spent on both sides and
general activity were recorded for 5 min.
3.2.4. Escape box
Three variations of the escape box procedure were employed. The first involved opening
the lid of a mouse cage and positioning it so that there was a gap through which mice could
climb through to escape. The second and third procedures used a modified mouse cage in which
a small hole (5×5 cm) was cut out of one end of the lid to narrow the escape route and a small
grid mesh ramp was fitted over the lip to facilitate escape climbing. The height of this mesh lip
was lowered in the third procedure to further facilitate escaping and the scoring of escape
behavior in the absence of jumping.
3.2.4.1. Escape box procedure 1
The test chamber consisted of a standard plastic mouse cage (28×18×11.5 cm; l×w×h)
wiped down with Pinesol (Clorox Co., Oakland, CA) diluted with water (1:10) which served as a
novel odor. The plastic lid covering the cage was left ajar at one end leaving a 2.5 cm opening
through which mice could climb through to escape. Mice were treated s.c. with naloxone and
then 10 min later placed directly in the center of the box and observed for 15 min. Latency for
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the mice to climb up and onto the inverted lid was recorded. Mice that did not escape during the
15 min were considered to not escape and their time was recorded as 900 s.
3.2.4.2. Escape box procedure 2
The test chamber described above was used; however, two modifications were made.
First, the chamber (see Figure 8 for picture) was covered with a plastic lid that contained a
5x5 cm hole centered on one end. Three sides of the exit hole were blocked off by a 5 cm high
plastic lip that prevented mice from climbing onto the top of the cage. The mice were able to
escape from the apparatus by climbing up a grid wire mesh (0.7×0.3 cm) that was located 11.5
cm from the bottom of the cage. The wire mesh formed to a 15.5×4.5 cm ramp (42° from side of
cage) that led down to a clean, escape cage containing fresh bedding and no novel odor. The
apparatus was placed in a sound-attenuating chamber illuminated by an array of white LEDs
(75 lux) and containing a ventilation fan for air circulation and masking noise. Mice were treated
s.c. with naloxone and then 10 min later placed directly in the center of the box. Fire-iTM digital
cameras (Unibrain, San Ramon, CA) captured video and video tracking software (ANY-mazeTM,
Stoelting, Kiel, WI) recorded the latency of the mice to exit out through the escape hole by
detection of mice entering the zone adjacent to the cage. Mice that did not escape during the 15
min were considered to not escape and their time was recorded as 900 s.
3.2.4.3. Escape box procedure 3
The escape box in procedure 2 was modified so that the climbing mesh was extended
lower into the cage (9.5 cm from the bottom) to facilitate escape behavior so that rodents could
escape without jumping. Mice were treated s.c. with the test compound and then 10 min later
placed directly in the center of the box. Fire-iTM digital cameras (Unibrain, San Ramon, CA)
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captured video and video tracking software (ANY-mazeTM, Stoelting, Kiel, WI) recorded the
latency of the mice to exit out through the escape hole by detection of mice entering the zone
adjacent to the cage. Subsequently, videos were observed for jumping behavior and whether
mice jumped or climbed up the wire mesh to escape the cage was recorded. Mice that exhibited
jumping were excluded from a second analysis to determine if jumping behavior was necessary
for reduced latencies.
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Figure 8. The escape box. The escape box is placed within a sound-attenuating cubicle that
contains a fan for ventilation and masking noise. LED lights (75 lux) located on the side wall
provide lighting. Mice are placed within the cage and the lid is closed and the door to the cubicle
is shut. ANY-mazeTM software tracks movement of the mice and once a mouse climbs over the
lip of the cage and the center of the animal has crossed the threshold between the edge of the
cage and the ramp the latency to escape is recorded.

76

3.2.5. Marble Burying
Mice were acclimated to the test room for at least 1 h prior to start of the experiment. For
spontaneous withdrawal experiments, mice were either 1) treated repeatedly with morphine
(6.25 – 50 mg/kg b.i.d.) for 6 days and tested on day 7, 24 h after their last injection or 2)
implanted with subcutaneous morphine (75 mg) or placebo pellets; 48 h later, baseline behaviors
were measured for 20 min, then pellets were removed under light anesthesia (isoflurane), and
mice were again tested at 4 and 8 h post-pellet removal. For naloxone-precipitated withdrawal,
mice were injected with naloxone (0.03, 0.1 and 0.3 mg/kg s.c.) 10 min prior to the start of the
experiment 48 h after pellet implantation. The procedure for assessing marble burying was
adapted from a published protocol (Kinsey et al., 2011; Thomas et al., 2009). The test cage was a
polycarbonate mouse cage (33×21×19 cm; l×w×h) filled with pine wood chip bedding (Harlan
Sani-Chip, Indianapolis, IN) to a depth of 5 cm. The cage was first gently shaken to flatten the
surface of the bedding and then 20 marbles were placed in a 4×5 grid pattern on top of the
bedding. Individual mice were placed in each cage which was subsequently covered with a clear
plexiglass lid containing holes for ventilation. The cage was placed in a sound-attenuating
chamber illuminated by an array of white LEDs (75 lux) and containing a ventilation fan for air
circulation and masking noise. The test lasted for either 20 min (spontaneous withdrawal) or 5
min (precipitated withdrawal), after which the cages were removed and mice were placed back
into their home cages. The session length for precipitated withdrawal was shortened to 5 min due
to control animals burying most of the marbles within the 20 min time limit. The number of
marbles buried was determined by a blinded observer and a marble was counted as “buried” if
half or more of the marble was covered by bedding.
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3.2.6. Novelty-induced Hypophagia
The procedure was adapted from a previously established protocol (Gur et al., 2007).
Mice were single-housed for 1 week prior to the start of food acclimation. Mice were then given
access to 5 peanut butter chips (partially defatted peanuts, sugar; partially hydrogenated
vegetable oil (palm kernel and soybean oil); corn syrup solids, dextrose; reduced minerals whey
(milk), salt; vanillin, artificial flavor; soy lecithin; Reeses®, The Hershey Company, Hershey,
PA) for 15 min each day and the latency to consume the chips and the amount consumed were
calculated until behaviors stabilized to less than 10% variability between days for three days and
this training period occurred over the course of 12 days.
Mice were then implanted subcutaneously with either 75 mg morphine pellet or a placebo
pellet. At 48 h and 72 h post-pellet implantation, mice were tested in either their home cage or a
novel environment, the order of testing being counterbalanced within each treatment group. Mice
received naloxone (0.056 mg/kg) or saline s.c. 10 min prior to the start of the experiment. Home
cage testing occurred on a metal rack in the laboratory where mice had previously been exposed
to the food for 12 days. Novel environment testing was carried out in a separate room within
white cubicles containing a 60 watt overhead light and a ventilation fan for masking noise. Cages
contained no bedding and were wiped down prior to each test with dilute Pinesol (1:10) which
served as a novel odor. Mice were observed and the latency to approach and consume the food
was recorded and the food was weighed before and after to determine the amount consumed.
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3.2.7. Place conditioning
3.2.7.1. Apparatus
The place conditioning chambers (MED Associates, St. Albans, VT, USA) were
comprised of three distinct compartments separated by manual sliding doors. A central grey
compartment with a plastic floor separated a black compartment with a floor comprised metal
bars (0.31 cm) placed in a parallel series and a white compartment with a metal grid mesh floor
(0.625×0.625 cm). The dimensions (w×d×h) of each compartment were as follows: grey
compartment (8.25×12.5×13 cm), black and white compartments (16.5×12.5×13cm).
3.2.7.2. Pre-conditioning and post-conditioning tests
Mice were group housed (4 per cage) with PVC pipe corner pieces placed in the cages for
environmental enrichment for at least 3 days prior to the preconditioning test. Mice were handled
for three days prior to the pre-conditioning test and administered daily saline (s.c.) injections
during this period to acclimate them to the injection procedure.
For all place conditioning procedures, the pre-conditioning and post-conditioning tests
were the same. The mice were placed gently into the central grey chamber with all the doors preopened and mice were allowed to freely ambulate between compartments for 20 min and time
spent in each compartment was recorded by Med-PC (MED Associates, St. Albans, VT, USA).
For the preconditioning test, mice that exhibited a strong unconditioned avoidance (25%) or
preference (75%) for any compartment were excluded from the experiment. For postconditioning tests, the amount of time spent on the treatment-paired side during the preconditioning test was subtracted from the amount of time on that same side during postconditioning

test

(i.e.

post-conditioning

time
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–
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time).
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preference/avoidance scores were calculated so that statistically significant negative scores
compared to control indicated avoidance whereas positive scores indicated preference.
3.2.7.3. Conditioned place preference
Following the pre-conditioning test, mice were counterbalanced to experimental groups
and treatment was assigned to either the black or white side pseudo-randomly. The day following
the pre-conditioning test, mice were injected with either morphine (10 mg/kg s.c.), cocaine (20
mg/kg i.p.) or saline immediately prior to being placed in the respective compartment. The
conditioning session lasted 20 min and afterwards mice were returned to their home cage. The
afternoon conditioning session occurred 4 h later and mice were treated with the opposite
conditioning treatment and placed in the other side of the compartment for 20 min. One half the
mice received their saline condition in the morning session and the other half received it in the
afternoon session. The conditioning period lasted for three days resulting in a total of three saline
conditioning sessions and three drug conditioning sessions (or 6 saline conditioning sessions for
the saline control group). Following conditioning, mice were tested the next day in the postconditioning test.
3.2.7.4. Conditioned place avoidance
Two procedures for CPA were used in these studies. The first procedure, adapted from
Broseta et al. (2005) used repeated morphine injections for the induction of dependence and
three naloxone pairings over a three day period for conditioning. The second procedure was
developed so that morphine pellets could be used for the induction of dependence in order to
provide a separation between the effects of naloxone in morphine dependent and non-dependent
mice. In this procedure naloxone conditioning occurred during two sessions in a single day.
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3.2.7.4.1. Conditioned place avoidance – Procedure 1
This procedure was adapted from Broseta et al. (2005), in which mice were treated twice
daily s.c. (9AM and 7PM) with increasing doses of morphine: day 1 (12.5 mg/kg), day 2 (25
mg/kg) and day 3 (50 mg/kg) and maintained at this high dose for the duration of the experiment.
The experiment began on day 4 with the pre-conditioning test. On day 4, and all subsequent days,
mice were brought into the room and acclimated for at least 45 min prior to testing or
conditioning. The dose of naloxone used for conditioning in this dependence procedure was 0.1
mg/kg s.c. in the first experiment and 1 mg/kg s.c. in the second experiment.
Mice were counterbalanced to treatment groups and the sides on which naloxone was
paired were assigned pseudo-randomly within each group so that approximately half the mice
received naloxone on the black side and half on the white side. After pre-conditioning, the
conditioning phase began and lasted 6 days. On the first day, mice were conditioned to the
saline-paired side 2 h after the morning injection of morphine. Mice were injected s.c. and
immediately placed in the corresponding conditioning chamber for 20 min, after which mice
were returned to their home cage and 24 h later mice were treated with naloxone and placed in
the other compartment for 20 min. This was repeated for four more days, so that mice received a
total of three naloxone conditioning sessions and three saline conditioning sessions (or six saline
conditioning sessions for the saline control group). The day after the final conditioning day mice
were assessed in the post-conditioning test. An initial experiment using this exact procedure
occurred first to assess the dose-response relationship of naloxone (0.1, 0.3 and 1 mg/kg) to
produce CPA on its own. In this experiment, mice did not receive repeated morphine or saline
treatments prior to conditioning.
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3.2.7.4.2. Conditioned place avoidance – Procedure 2
On day 1, and all subsequent days, mice were brought into the room and acclimated for at
least 45 min. The mice were placed gently into the central grey chamber with all the doors preopened and mice were allowed to freely ambulate between compartments for 20 min. Med-PC
software recorded the time spent in each compartment and the number of beam breaks to
estimate locomotor activity. Mice were then returned to their home cage. On day 2 (saline
conditioning; non-withdrawal day), mice were injected s.c. with saline and placed directly in the
chamber designated as the saline side where they remained for 30 min. Mice were returned to
their home cage and remained in the lab until the second conditioning session of the day which
repeated the same procedure 4 h later. On day 3, mice were implanted with a 75 mg morphine
pellet under anesthesia (see section 2.2.4. for pellet implantation surgery). At 48 h post-pellet
implantation, mice were injected with either naloxone or saline (placebo+saline controls) and
placed into the naloxone-designated compartment for 30 min. The naloxone conditioning
procedure was then repeated 4 h later, i.e. 52 h post pellet implantation. On day 6, mice were
tested for the expression of CPA.
In an initial experiment, mice were treated with saline instead of naloxone following
pellet implantation to determine if the presence of the 75 mg morphine pellet could serve as an
unconditioned stimulus to produce conditioned place preference. The results of this experiment
were used to guide subsequent experiments as to whether the modified version of the CPA
procedure was justified. The procedure was developed to have pellet implantation occur after the
saline (non-withdrawal) conditioning out of concern for a potential confound in which it would
be difficult to discern whether the mice exhibited a preference for the side in which mice were
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exposed to morphine from the s.c. implanted pellets or exhibited an aversion to the side in which
they received the naloxone injection.
3.2.8. Somatic withdrawal signs
A naloxone dose response experiment was conducted in mice 48 h after implantation of a
75 mg morphine pellet. Somatic withdrawal signs were scored, as previously described
(Schlosburg et al., 2009). In brief, mice were placed in white acrylic chambers (20x20 cm), with
a clear acrylic front panel and a mirrored back panel for a 30 min acclimation period. The
chambers were enclosed in sound-attenuating cabinets that contained an indirect filtered LED
light source and fans for air circulation and white noise. The mice were briefly removed from the
chambers for naloxone administration and immediately returned to the chambers for a 30 min
observation period. Behavior was recorded using a series of Fire-iTM digital cameras (Unibrain,
San Ramon, CA), and the videos were saved using the ANY-mazeTM video tracking software
(Stoelting Co., Wood Dale, IL). Chambers were changed between tests and cleaned at the end of
testing with an ammonia based cleaner and left to dry for two days, to allow for odors to
dissipate. The recorded videos were randomized and scored by a trained observer, who was
blinded with respect to treatment condition. The primary behavioral signs of interest were
frequency of jumps and front paw tremors (including single and double paw flutters and twitches,
which are not commonly displayed by naïve mice). The occurrence of diarrhea during the testing
period was noted. All behaviors were recorded as new incidences when separated by at least 1 s
or interrupted by any other normal behavior. In addition, mice were weighed before and
immediately after the 30 min test session to assess body weight loss.
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3.2.9. Statistical Analysis
All data are reported as mean±SEM. Data were analyzed using either Student’s t-test,
one-way between measures analysis of variance (ANOVA) for dose response studies and twoway ANOVA for all 2x2 designs. Dunnett’s test was used to compare drug treatments with
vehicle and Newman-Keuls post-hoc test was employed for comparisons between various
treatments. For two-way ANOVAs, Bonferroni’s post-hoc analysis was used. In addition,
planned comparisons were used to compare differences in naloxone CPA between dependent and
non-dependent mice. Differences were considered statistically significant at p<0.05.
3.3. Results
3.3.1. Light/dark box
3.3.1.1. Naloxone increases time spent in the light side of the light dark box in morphine-pelleted,
but not placebo-pelleted, mice
To determine if naloxone-precipitated morphine withdrawal would affect amount of time
in either side of the light/dark box, we examined the dose-response relationship of naloxone in
morphine-pelleted and placebo-pelleted mice. Naloxone produced significant increases in time
spent in the light side [F(4,35) = 13.6; p<0.0001; Figure 9A] while having no effect on distance
traveled [p=0.84; Figure 9B] or any effect on time spent in the light side [p=0.42; Figure 10A] or
distance traveled [p=0.77; Figure 10B] in placebo-pelleted mice.
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Figure 9. Naloxone-precipitated morphine withdrawal increased the amount of time spent in the
light side of the light dark box, but did not affect locomotor activity. Naloxone (0.03, 0.056, or
0.1 mg/kg) administered s.c. in morphine-pelleted mice prior to the start of the session (A)
increased the amount of time spent on the light side of the light dark box but (B) did not affect
distance traveled. n=8 per group. Data are expressed as mean±SEM. **p<0.01, ***p<0.001
compared to saline.
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Figure 10. Naloxone did not affect the amount of time spent in the light side of the light dark box
or locomotor activity in placebo-pelleted mice. Naloxone administered s.c. to placebo-pelleted
mice did not (A) affect the amount of time spent on the light side of the light dark box or (B)
affect distance traveled. n=8 per group. Data are expressed as mean±SEM.
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3.3.2. Escape paradigm
3.3.2.1.Naloxone reduces the latency to escape a novel environment in morphine-pelleted mice,
but not in placebo-pelleted mice
In order to ascertain if changes in preference for sides in the light dark box and increases
in time spent in the open-arms of the elevated plus maze as reported in the literature were related
to escape behavior, we assessed the latency of mice to climb out of an empty clean cage with the
lid ajar 2.5 cm. In morphine-pelleted mice, but not placebo-pelleted mice, naloxone significantly
reduced the latency to escape [F(4,31) = 29.0; p<0.0001; Figure 11].
3.3.2.2. Naloxone reduces the latency to escape a novel environment in morphine-pelleted, but
not placebo-pelleted mice
We designed a modified mouse cage in which a 4x4 cm hole was cut out from one end of
the cage where a climbing mesh was located that led to an exit ramp. This design narrowed the
opening so that random jumping was less likely to result in an escape and provided a means by
which mice could climb up and out via the wire mesh ramp. In morphine-pelleted mice,
naloxone significantly reduced the latency to escape [F(4,35) = 3.7; p<0.05; Figure 12A] but did
not affect escape latencies in placebo-pelleted mice [p=0.29; Figure 12B].
3.3.2.3. Naloxone reduces the latency to escape a novel environment in morphine-pelleted mice
independent of jumping behavior
Because the height of the climbing mesh in the previous experiment was sufficiently high
enough to require that mice had to hop up to reach it, the escape cage was further modified by
extending the climbing mesh lower into the cage to allow mice an option to climb out of the box.
In morphine-pelleted mice, (A) naloxone (0.056 mg/kg) significantly reduced the latency to
escape [t=3.1; p<0.01; Figure 13A]. Exclusion of mice (n=3) that exhibited jumping behavior
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still yielded a significant reduction in escape latency as compared with placebo-pelleted controls
[t=2.8; p<0.05; Figure 13B].
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Figure 11. Naloxone challenge reduced escape latency in morphine-pelleted mice. Mice pelleted
with morphine pellets, but not placebo pellets, exhibited escape behavior as indicated by a
reduced latency to exit a novel cage upon treatment with naloxone (0.03 – 0.1 mg/kg). n=6-8 per
group. Data are expressed as mean±SEM. *p<0.05, compared to placebo+saline mice.
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Figure 12. Naloxone-precipitated morphine withdrawal reduced escape latency. Naloxone
reduced the latency to escape in (A) morphine-pelleted but not (B) placebo-pelleted mice. n=7-9
per group. Data are expressed as mean±SEM. *p<0.05, compared to placebo+saline mice.
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Figure 13. Mice undergoing precipitated-morphine withdrawal exhibit reduced latencies to
escape independent of jumping behavior. Morphine-pelleted (75 mg) mice treated with naloxone
(0.056 mg/kg s.c.) exhibited (A) decreased latencies to escape compared to placebo-pelleted
mice. Exclusion of mice (3 mice) that exhibited jumping behavior did not affect (B) the reduced
latency to escape in morphine-pelleted mice. n=5-8 per group. Data are expressed as mean±SEM.
*p<0.05, **p<0.01 compared to placebo-pelleted mice.
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3.3.3. Marble Burying
3.3.3.1. Mice undergoing spontaneous morphine withdrawal did not exhibit changes in digging
behavior as measured by number of marbles buried during 20 min test.
Mice treated repeatedly with morphine (6.25 – 50 mg/kg s.c. b.i.d.) for 6 days were tested
24 h after their last injection for the effects of spontaneous morphine withdrawal on digging
behavior in the marble burying test. No significant differences were found for the number of
marbles buried between morphine-treated and saline-treated mice [p=0.09; Figure 14].
3.3.3.2. Mice undergoing spontaneous withdrawal from morphine pellets do not exhibit changes
in digging behavior as assessed by marble burying.
Mice implanted with morphine pellets exhibited less digging compared to placebopelleted control mice during baseline and 4 h following pellet removal [main effect of morphine
treatment: F(1,20) = 14.6; p<0.01; Figure 15] but this effect was absent at 8 h following pellet
removal. Mice buried fewer marbles after multiple exposures to the test [main effect of time:
F(2,20) = 6.5; p<0.01; Figure 15] but no interaction effect was observed [p=0.22].
3.3.3.3. Mice undergoing precipitated withdrawal from morphine pellets do not exhibit changes
in digging behavior as assessed by 5 min marble burying test.
In order to prevent ceiling effects with respect to control mice burying most of the
marbles, the test was shortened to 5 min to allow for detection of increases and decreases in the
number of marbles buried. Morphine-pelleted mice treated with naloxone (0.03 – 0.3 mg/kg s.c.)
72 h after pellet implantation did not exhibit differences in digging behavior as assessed in the
marble burying test [Figure 16], nor did placebo-pelleted mice receiving naloxone (0.3 mg/kg
s.c.).
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Figure 14. Mice undergoing spontaneous morphine withdrawal did not exhibit changes in
digging behavior as measured by number of marbles buried during 20 min test. Following
repeated twice-daily injections of morphine (6.25 – 50 mg/kg s.c.) or saline for 6 days, mice
were tested 24 h after their last morphine or saline injection. The number of marbles buried did
not differ between morphine-treated mice and saline-treated mice. n=7-9 mice per group. Data
are expressed as mean±SEM.
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Figure 15. No effect of spontaneous withdrawal on number of marbles buried during 20 min tests.
Mice pelleted for 72 h were tested 4 h and 8 h after pellets were removed. Morphine (75 mg)
pelleted mice initially buried fewer marbles than placebo-pelleted mice but at 8 h there was no
difference between these groups. n=8 per group. *p<0.05 compared to placebo. Data are
expressed as mean±SEM.

94

Figure 16. Naloxone does not affect number of marbles buried in placebo-pelleted or morphinepelleted mice during a 5 min test. Mice implanted with morphine (75 mg) or placebo pellets for
72 h were challenged with naloxone (0.03 – 0.3 mg/kg) and placed in the marble burying
apparatus for 5 min. No differences were detected for any treatment group. n=8 per group. Data
are expressed as mean±SEM.
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3.3.4. Novelty-induced hypophagia
3.3.4.1. Diazepam reduces the latency to consume food in a novel environment
Initially, mice were exposed for 12 days to the peanut butter chips in their home cages
and latency to approach and consume and amount consumed were recorded [Figure 17]. To first
assess a drug which has been shown to produce effects in the novelty-induced hypophagia test,
diazepam (3 mg/kg) was tested as a positive control. Diazepam did not affect the latency to
consume [Figure 18A] or the amount consumed [Figure 18B] during the home cage test;
however, diazepam reduced the latency to consume food [t=2.3; p<0.05; Figure 18C] and
increased the amount consumed [t=3.7; p<0.01; Figure 18D] in the novel cage test.
3.3.4.2. Naloxone does not affect latency or food consumption in placebo or morphine-pelleted
mice in either home or novel cage
To determine if naloxone-precipitated morphine withdrawal would elicit increases in
latency to consume food in a novel environment, morphine-pelleted and placebo-pelleted mice
were challenged with saline or naloxone (0.056 mg/kg s.c). In morphine-pelleted mice, there was
no effect between the familiar and novel test cage [p=0.93], naloxone treatment [p=0.16] or
interaction [p=0.32] on latency to approach and consume food [Figure 19A]. Also, there were no
significant effects of test cage [p=0.27], naloxone treatment [p=0.08] or interaction [p=0.89] on
the amount consumed [Figure 19B]. In placebo-pelleted mice, there was an effect of cage
[F(1,20) = 19.3; p<0.001], but no effect of naloxone treatment [p=0.35] or interaction [p=0.24]
on latency to approach and consume [Figure 19C]. For amount of food consumed, placebopelleted mice consumed less food in the novel cage than the familiar cage [F(1,20) = 52.7;
p<0.0001], but no effects of naloxone treatment [p=0.61] or interaction [p=0.08; Figure 19D]
were detected.
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Figure 17. Baseline latencies and consumption data for mice exposed to peanut butter chips in
their home cage. Mice given access to peanut butter chips in their home cage for 15 minutes
exhibit rapid decreases in (A) latency to approach and consume food and (B) increases in amount
of food consumed during acclimation period over 12 days. n=24 per group. Data are expressed as
mean±SEM.***p<0.001, *p<0.05 compared to day 12.
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Figure 18. Effects of diazepam in the novelty-induced hypophagia test. Diazepam (3 mg/mg i.p.)
did not affect (A) latency or (B) amount of food consumed in the home cage test, but reduced the
(C) latency and increased the (D) amount of food consumed in the novel environment. n=6 per
group. Data are expressed as mean±SEM, or as a percent of animals that exhibited the specified
behavior. *p<0.05, **p<0.01 compared to VEH.
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Figure 19. Effects of naloxone or saline in morphine-pelleted and placebo-pelleted mice in the
novelty induced hypophagia test. There was no effect of naloxone or test cage in morphinepelleted mice on (A) latency to approach and consume food or (B) amount of food consumed. In
placebo-pelleted mice, there was an increase in (C) latency to approach and consume food in the
novel environment and a (D) decrease in the amount of food consumed, but there was no effect
of naloxone in any treatment. n=6-11 per group. Data are expressed as mean±SEM. *p<0.01
compared to saline.
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3.3.5. Conditioned place avoidance – Procedure 1
These experiments sought to establish the place conditioning procedure by validating the
apparatus as unbiased (i.e. mice do not have a preference for the black or white side) and
replicating CPP effects of morphine and cocaine. Additionally, these experiments sought to
replicate a published procedure for producing naloxone-precipitated morphine withdrawal CPA.
We conducted a naloxone dose response curve experiment in non-dependent mice to determine
its propensity to produce CPA on its own. We then selected the naloxone dose for the first CPA
experiment based upon these findings. Upon lack of significant CPA following this dose in mice
treated repeatedly with morphine, we tested a higher dose to see if it would produce greater CPA
in morphine-treated than vehicle-treated mice.
3.3.5.1. Male ICR mice do not have initial preference to white or black side
To determine whether the place conditioning apparatus was biased for either side, time
spent on each side was analyzed from baseline data. Mice showed no preference for the white
side (446.6±11.8 s) vs. black side (441.5±11.7 s), but spent significantly less time in the central
grey chamber (312.0±11.4 s) [F(2,189) = 42.9; p<0.0001; Figure 20].
3.3.5.2. Morphine and cocaine produce conditioned place preference
To ensure that place conditioning would be readily established, an initial study employed
morphine and cocaine as positive controls in the place preference assay. Both morphine and
cocaine produced a significant conditioned place preference [F(2,23) = 4.4; p<0.05; Figure 21A]
and there was no significant effect of conditioning treatment on locomotor activity during the
expression test [F(2,23) = 3.2; p=0.06; Figure 21B].
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Figure 20. Male ICR mice do not exhibit a preference for the white versus black side during 20
min access but spend less time in the central grey chamber. *p<0.05 compared to black side.
n=64 mice per group. Data are expressed as mean±SEM, or as a percent of animals that exhibited
the specified behavior.
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Figure 21. Conditioned place preference to morphine and cocaine. Pretreatment with morphine
(10 mg/kg s.c.) or cocaine (20 mg/kg i.p.) produced (A) conditioned place preference in male
ICR mice but (B) neither group of conditioned mice exhibited a significant change in locomotor
activity during the expression test. n=8-9 mice per group. Data are expressed as mean±SEM.
*p<0.05 compared to saline.
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3.3.5.3. Naloxone produces conditioned place avoidance in naïve mice
To determine whether naloxone would produce CPA in non-dependent mice, a doseresponse study for naloxone was conducted. Naloxone (0.3 and 1 mg/kg) produced significant
CPA [F(3,53) = 5.5; p<0.01; Figure 22A] but there was no effect on locomotor activity during
the expression test [p=0.74; Figure 22B].
3.3.5.4. Low dose Naloxone (0.1 mg/kg) does not produce conditioned place avoidance in mice
given repeated s.c. injections of morphine or saline
Mice that received repeated administration of morphine (12.5 – 50 mg/kg s.c. b.i.d.) or
saline and conditioned with naloxone (0.1 mg/kg) did not exhibit significant CPA [p=0.21;
Figure 23A] but there was a main effect of morphine treatment showing an increase in locomotor
activity during the test session [F(1,56) = 20.2; p<0.0001; Figure 23B].
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Figure 22. Repeated injections of naloxone produces conditioned place avoidance in mice.
Naloxone (0.3 - 1 mg/kg s.c.) produces (A) CPA in mice after 3 conditioning sessions (20 min)
as compared with saline but did not affect (B) locomotor activity during the expression test.
n=13-15 per group. Data are expressed as mean±SEM. *p<0.05 compared to saline.
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Figure 23. Low dose naloxone (0.1 mg/kg) does not produce significant conditioned place
avoidance in mice treated repeatedly with vehicle or morphine. Mice treated repeatedly with
morphine (12.5 – 50 mg/kg s.c. b.i.d.) or saline and conditioned with naloxone (0.1 mg/kg) did
not exhibit (A) CPA behavior; however, mice receiving repeated morphine exhibited significant
(B) increases in locomotor activity during the post-conditioning test. n=8-9 per group. Data are
expressed as mean±SEM.
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3.3.5.5. High dose naloxone (1 mg/kg) produces conditioned place avoidance in mice treated
repeatedly with either escalating doses of morphine or saline
Both morphine-treated (12.5 – 50 mg/kg s.c. b.i.d.) and saline-treated mice conditioned
with naloxone (1 mg/kg) exhibited significant CPA [F(1,35) = 33.0; p<0.0001; Figure 24A], but
there was no effect of morphine treatment [p=0.27] nor was there an interaction effect [p=0.76].
Therefore, no dissociation between naloxone’s effects and precipitated withdrawal could be
inferred. There was a main effect of morphine treatment [F(1,33) = 69.0; p<0.0001; Figure 24B]
on locomotor activity during the expression test but no effect of naloxone [p=0.52] or interaction
[p=0.66].
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Figure 24. Naloxone (1 mg/kg s.c.) produced conditioned place avoidance in mice treated
repeatedly with morphine and saline. Mice treated repeatedly with morphine (12.5 – 50 mg/kg
s.c. b.i.d.) or saline and conditioned with naloxone (1 mg/kg) exhibited (A) CPA behavior. Mice
receiving repeated morphine exhibited significant (B) increases in locomotor activity during the
post-conditioning test. n=8-11 per group. *p<0.05, **p<0.01 compared to saline. Data are
expressed as mean±SEM.
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3.3.6. Conditioned place avoidance – Procedure 2
In the previous CPA procedures, we used repeated injections of morphine (12.5 –
50 mg/kg s.c. b.i.d.) to induce dependence and conditioned mice over the course of 6 days
during which they received one daily conditioning session, either naloxone or saline, for a total
of three conditioning sessions each. The dose of naloxone (0.1 mg/kg) that did not produce CPA
on its own was insufficient to produce CPA in morphine-treated mice. We tested a higher dose of
naloxone (1 mg/kg) in order to precipitate a greater withdrawal response; however, the CPA
produced by naloxone was not significantly different between mice treated repeatedly with
morphine or saline. Thus, the dependence induction procedure used in these experiments was not
sufficient to allow for naloxone to elicit CPA that was contingent upon morphine dependence.
The following studies employed a morphine pellet in order to induce a greater degree of
dependence in mice thus facilitating the separation of naloxone’s effects and those of
precipitated morphine withdrawal. In these studies, mice received two 30 min saline (nonwithdrawal conditioning) sessions on the day prior to pellet implantation and then received two
naloxone conditioning sessions 48 h and 52 h post pellet implantation.
3.3.6.1. 75 mg morphine pellets produce conditioned place preference
In an initial experiment, we tested if implantation of the morphine pellet would elicit a
conditioned place preference. A finding in which morphine alone elicited a place preference
would have important implications for the naloxone precipitated withdrawal place avoidance
experiments. Specifically, morphine in the absence of naloxone might elicit a place preference,
which would confound interpretation of the withdrawal experiments since it would be unclear
whether mice would be expressing avoidance to the side paired with withdrawal or a preference
to the side paired with morphine alone. Accordingly, morphine-pelleted mice were assessed in
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the conditioned place procedure using a similar procedure employed for the withdrawal studies.
Prior to pellet implantation, mice were conditioned on one side of the apparatus and then
following pellet implantation, during what would be the withdrawal conditioning session, each
mouse received a subcutaneous injection of saline. A t-test revealed a significant increase in time
spent on the side paired with the morphine pellet [Figure 25A] suggesting that the continuous
morphine exposure from the pellet produced CPP. There was no effect of morphine pellet on
locomotor activity during the expression test [Figure 25B]. In order to remove the potential
confound of morphine CPP, we implanted the morphine pellets after the saline conditioning
(non-withdrawal) day.
3.3.6.2. Naloxone-precipitated morphine withdrawal produces conditioned place avoidance
behavior at a dose that does not elicit this effect in non-dependent mice
To determine the doses of naloxone that produced CPA in dependent and non-dependent
mice, we examined the dose-response relationship of naloxone (0.03, 0.056, and 0.1 mg/kg) in
morphine- and placebo-pelleted mice. Naloxone (0.056 and 0.1 mg/kg) produced a significant
CPA in morphine-pelleted mice [F(3,74) = 4.3; p<0.01; Figure 26A]. In contrast, only naloxone
(0.1 mg/kg) produced CPA in placebo-pelleted animals [F(3,80) = 4.3; p<0.01; Figure 26B] and
a planned comparison t-test revealed this to be a significantly lower than that observed in the
morphine-pelleted animals [t=2.6, p<0.05]. Additionally, morphine-pelleted mice receiving
naloxone exhibited reduced locomotor activity during the expression test [F(3,74) = 7.2; p<0.001;
Figure 26C] whereas placebo-pelleted mice receiving naloxone showed no change in activity
[p=0.34; Figure 26D]. Since naloxone (0.056 mg/kg) did not produce significant CPA in nondependent mice, this dose was selected for all subsequent studies to ensure that the avoidance
behavior observed was due to morphine withdrawal alone.
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3.3.6.3. Naloxone precipitates somatic withdrawal signs in mice
In morphine-pelleted mice, naloxone elicited significant paw flutters [F(5,26) = 12.0;
p<0.0001; Figure 27A], head shakes [F(5,26) = 12.9; p<0.0001; Figure 27B], jumps [F(5,26) =
17.6; p<0.0001; Figure 27C] and diarrhea [z = -3.4; p<0.001; Figure 27D]. Naloxone (0.3 and
1 mg/kg) produced significant increases in paw flutters, head shakes, and diarrhea whereas
naloxone (0.1, 0.3, and 1 mg/kg) produced significant increases in jumping.
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Figure 25. Conditioned place preference to 75 mg morphine pellet. Presence of a 75 mg
morphine pellet produced (A) conditioned place preference in mice receiving saline but (B) no
effect on locomotor activity during the expression test. n=8-9 mice per group. Data are expressed
as mean±SEM. * p<0.05
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Figure 26. Naloxone-precipitated morphine withdrawal produced conditioned place avoidance
behavior in mice. In (A) morphine-pelleted mice, naloxone (0.056 and 0.1 mg/kg) produced a
significant CPA behavior whereas in (B) placebo-pelleted mice, only naloxone (0.1 mg/kg)
produced CPA. Naloxone conditioning did not have a significant effect on locomotor activity
during the expression test in (D) placebo-pelleted mice. n=16-26 mice per group. Data are
expressed as mean±SEM, or as a percent of animals that exhibited the specified behavior.
* p<0.05, ** p<0.01 compared to Placebo+SAL control.
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Figure 27. Naloxone elicits withdrawal behaviors in mice when administered s.c. 48 h following
implantation of a 75 mg morphine pellet. Behaviors scored were (A) paw flutters, (B) head
shakes, (C) presence of jumping behavior, and (D) presence of diarrhea. n=5-6 per group. Data
are expressed as mean±SEM, or as a percent of animals that exhibited the specified behavior.
*p<0.05, **p<0.01, ***p<0.001
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3.4. Summary
These studies sought to evaluate the effects of morphine withdrawal in multiple
established behavioral tests as well as a novel assay developed to examine escape behavior. In
the light/dark box, naloxone significantly increased the amount of time spent in the light side in
morphine-pelleted [Figure 9] but not placebo-pelleted mice [Figure 10], such that there was
essentially no preference for one side or the other. The finding that naloxone affected only
morphine-pelleted mice suggests that this behavior was the result of naloxone-precipitated
morphine withdrawal rather than naloxone alone. To determine if increases in time spent in the
light side might reflect an escape behavior, we tested the effects of morphine withdrawal in a
novel procedure developed to model escape. In a preliminary study, naloxone significantly
reduced the latency to escape a mouse cage with the lid ajar in morphine-pelleted, but not
placebo-pelleted, mice [Figure 11]. Subsequently, the design of the mouse cage was modified so
that the lid was closed and a 5x5 cm hole was cut out of one end of the lid with a wire mesh
ramp leading out. Naloxone reduced the latency for the mice to escape in this procedure in
morphine-pelleted mice but not placebo-pelleted mice [Figure 12]. To further determine if
escape behavior was a consequence of jumping, the procedure was modified to facilitate
escaping so that mice could easily reach the wire mesh. Morphine-pelleted mice treated with
naloxone (0.056 mg/kg) exhibited significant reductions in escape latency and this effect was
maintained when mice that exhibited jumping were excluded [Figure 13]. These data suggest that
morphine withdrawal led to increases in escape behavior.
In marble burying, neither spontaneous morphine withdrawal [Figure 14 and 15] nor
naloxone treatment in morphine-pelleted mice [Figure 16] affected digging behavior. In the
novelty-induced hypophagia test, diazepam increased the amount of food consumed and
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decreased the latency to consume in the novel environment, but not in the home cage, an effect
that has been previously established thus serving as a positive control [Figure 18]. There was no
effect of naloxone in morphine-pelleted or placebo-pelleted mice. However, implantation of
75 mg morphine pellets resulted in reductions in food consumption during the home cage test as
compared with placebo-pelleted mice [Figure 19].
In place conditioning, mice exhibited no preference for the white vs. black side
[Figure 20] demonstrating an unbiased apparatus. Morphine (10 mg/kg) and cocaine (20 mg/kg)
served as positive controls to establish the general conditioning procedure and both produced
CPP [Figure 21]. An established procedure in which daily conditioning sessions were carried out
for six days was adapted for the initial experiments (Broseta et al., 2005). First, naloxone was
tested alone to determine doses which could produce CPA and naloxone (0.3 – 1 mg/kg)
produced significant CPA [Figure 22]. Using the dependence procedure from a published CPA
protocol (Broseta et al., 2005), we tested the effects of naloxone (0.1 mg/kg) in saline and
morphine treated mice, but found no acquisition of CPA [Figure 23]. The next experiment used
naloxone (1 mg/kg), the dose that was used in the study this procedure was adapted from, but
found that no distinction between CPA in morphine treated and saline treated mice could be
made [Figure 24]. In order to induce a greater level of dependence to facilitate a separation
between naloxone’s effects and those of precipitated morphine withdrawal, we developed a new
procedure in which mice were implanted subcutaneously with 75 mg morphine pellets. Due to
concerns about the presence of morphine during the saline (non-withdrawal) conditioning trials,
we tested whether the presence of 75 mg morphine pellets could serve as an unconditioned
stimulus to produce CPP and found that this was indeed the case [Figure 25]. Thus, the design of
the CPA experiment was modified such that morphine pellets were implanted after the saline
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conditioning (non-withdrawal) sessions. Naloxone (0.03 – 0.1 mg/kg) conditioning trials were
conducted 2 days after morphine pellet or placebo pellet implantation. Naloxone (0.056 mg/kg)
produced significant CPA in morphine-pelleted mice, but did not elicit a preference in placebopelleted mice [Figure 26], suggesting that conditioning to naloxone-precipitated morphine
withdrawal was producing an avoidance behavior in these mice. Finally, to determine the degree
to which these doses of naloxone were precipitating somatic withdrawal signs, we assessed
naloxone (0.03 – 1 mg/kg) during a 30 min session in which behaviors were recorded 48 h after
pellet implantation, which corresponded to the time point of the first conditioning session in
CPA. Naloxone (0.056 mg/kg) produced negligible increases in withdrawal signs [Figure 27].
Based on these studies we selected the CPA procedure to further evaluate the effects of
endocannabinoid catabolic inhibitors on morphine withdrawal.
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Chapter 4: Effects of endocannabinoid catabolic inhibitors on negative motivational
aspects of morphine withdrawal
4.1. Introduction: Conditioned place avoidance to opioid withdrawal in rodents
In Chapter 2 it was demonstrated that dual inhibition of FAAH and MAGL reduces both
spontaneous and naloxone-precipitated morphine withdrawal signs in mice. As well, the effects
of cannabinoids including endocannabinoid catabolic inhibitors have been well established in the
literature in regards to their effects on somatic signs of opioid withdrawal [see Table 1].
However, it remains to be established whether cannabinoids are also reducing the motivational
aspects of opioid withdrawal. In Chapter 3, the effects of morphine withdrawal in a number of
behavioral assays were reported and among them the CPA procedure produced a clear
withdrawal-related effect that has also been well characterized in the literature. From these
experiments the CPA procedure was selected to assess endocannabinoid catabolic inhibitors for
their ability to reduce the negative motivational aspects of morphine withdrawal.
Naloxone-precipitated morphine withdrawal CPA is a highly sensitive measure of
withdrawal with very low doses producing this withdrawal conditioned behavior as compared
with those doses necessary to elicit physical withdrawal signs (Caillé et al., 1999; Frenois et al.,
2002). Early studies in mice (Mucha et al., 1987) and rats (Hand et al., 1988; Mucha et al., 1982)
first demonstrated the phenomena that naloxone produced enhanced CPA in morphine exposed
rodents, suggesting a withdrawal component to this effect. Subsequently the brain regions
important for morphine withdrawal CPA were elucidated by administering microinjections of the
opioid antagonist methylnaloxonium through stereotaxically implanted guide cannulae aimed at
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the nucleus accumbens and amygdala in rats treated repeatedly with morphine (Stinus et al.,
1990).
While both humans and rodents exhibit overt symptoms following opioid withdrawal, e.g.
diarrhea, it is more difficult to ascertain aspects of opioid withdrawal that relate to the aversive
qualities. As discussed in Chapter 1, humans undergoing opioid withdrawal experience both
physical and psychological effects that accompany withdrawal. For example, people have been
reported to experience dysphoria, anhedonia, nausea, anxiety, and panic attacks during
withdrawal from an opioid (Farrell, 1994; Gossop, 1988; Jasinski, 1981; Wesson et al., 2003). In
rodents, the aversive effects of opioid withdrawal can be inferred through behavioral assays
which employ the withdrawal state as an unconditioned stimulus and pair it with a neutral
context (the conditioned stimulus) in a Pavlovian paradigm called conditioned place avoidance
or conditioned place aversion (CPA) (Tzschentke, 2007). Opioid withdrawal serving as an
unconditioned stimulus in this procedure has successfully been modeled in mice (Broseta et al.,
2005; Maldonado et al., 2003; Olson et al., 2006; Sato et al., 2005; Shoblock et al., 2005) and
rats (Gracy et al., 2001; Hand et al., 1988; Parker et al., 1992; Schnur et al., 1992; Stinus et al.,
2000; Stinus et al., 1990; Watanabe et al., 2003).
Comparison of the ability of naloxone to produce CPA and somatic withdrawal signs by
Schulteis et al. (1994) first demonstrated that naloxone was more potent at producing withdrawal
effects in behaviors including disruption of operant responding for food, elevating ICSS
thresholds and producing CPA at doses from 0.004 – 0.01 mg/kg. In contrast 0.01 mg/kg
naloxone, which produced withdrawal-related effects in all measures, did not significantly
increase somatic withdrawal behaviors.
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Since distinct brain regions mediate both the negative motivational and somatic aspects
of withdrawal, our previous work demonstrating that inhibition of endocannabinoid catabolism
reduces somatic signs of morphine withdrawal does not indicate that the aversive aspects of
withdrawal are also being reduced. Thus, we investigated if endocannabinoid catabolic inhibitors
would reduce the negative motivational aspects of opioid withdrawal as assessed in the CPA
paradigm.
4.1.1. Rationale and Hypothesis
The CPA procedure is a well established model of aversive effects of opioid withdrawal
(Broseta et al., 2005; Frenois et al., 2002; Maldonado et al., 2004; Sato et al., 2005; Stinus et al.,
2000; Stinus et al., 1990; Watanabe et al., 2002) and has been shown to be sensitive to
pharmacological treatments (e.g. clonidine) (Kosten, 1994; Schulteis et al., 1998a) which are
known to be effective at reducing opioid withdrawal in humans (Gold et al., 1978; Gossop,
1988). Thus, we selected this procedure to determine if inhibition of endocannabinoid catabolism
would be effective at reducing the negative motivational aspects of opioid withdrawal in mice.
We hypothesized that inhibition of endocannabinoid catabolism would reduce the
acquisition of CPA to naloxone-precipitated morphine withdrawal.
4.2. Methods
4.2.1. Subjects
Male ICR mice (Harlan, Indianapolis, IN) with a body mass of 27-32 g were used for all
experiments. Mice were group-housed (four per cage) on a 12/12 light/dark cycle (lights on at
0600 h) and given food and water ad libitum. All efforts were made to minimize animal suffering
and number of animals used. All animal protocols were approved by the Virginia
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Commonwealth University Institutional Animal Care and Use Committee and were in
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, 2011).
4.2.2. Drugs
Morphine

pellets

(75

mg),

placebo

pellets,

morphine

sulfate,

delta-9-

tetradhydrocannabinol (THC) and clonidine HCl were obtained from the National Institute on
Drug Abuse (Bethesda, MD) and naloxone hydrochloride was purchased from Sigma Aldrich (St.
Louis, MO). JZL184, PF-3845, and SA-57 were provided by the Cravatt laboratory (Scripps, La
Jolla, CA). Naloxone HCl and clonidine were dissolved in physiological saline (0.9% NaCl) and
drug concentrations were calculated using the weight of the salt as used previously (Ramesh et
al., 2011). Morphine sulfate was dissolved in physiological saline (0.9% NaCl) and drug
concentrations were calculated based upon the free base. JZL184, PF-3845, SA-57 and THC
were dissolved in ethanol and Emulphor-620 (Rhone-Poulenc, Princeton, NJ) and then diluted
with physiological saline to form a vehicle mixture of ethanol:Emulphor-620:saline in a ratio of
1:1:18. JZL184, PF-3845, and SA-57 were administered intraperitoneally, THC, clonidine, and
naloxone HCl was administered subcutaneously, and all drugs were administered in a volume of
10µl per g body mass.
4.2.3. Conditioned place avoidance
The place conditioning chambers (MED Associates, St. Albans, VT, USA) were
comprised of three distinct compartments separated by manual sliding doors. A central grey
compartment with a plastic floor separated a black compartment with a floor comprised metal
bars (0.31 cm) placed in a parallel series and a white compartment with a metal grid mesh floor
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(0.625×0.625 cm). The dimensions (w×l×h) of each compartment were as follows: grey
compartment (8.25×12.5×13 cm), black and white compartments (16.5×12.5×13cm).
The conditioning procedure was an unbiased (counterbalanced) design, i.e. mice were
paired with naloxone on either the black or white side. Mice were handled for 3 days prior to
start of the experiment to acclimate them to the experimenter. On day 1, and all subsequent days,
mice were brought into the room and acclimated for at least 45 min. The mice were placed gently
into the central grey chamber with all the doors pre-opened and mice were allowed to freely
ambulate between compartments for 20 min. Med-PC software recorded the time spent in each
compartment and the number of beam breaks to estimate locomotor activity. Mice were then
returned to their home cage. On day 2 (saline conditioning; non-withdrawal day), mice were
injected s.c. with saline and placed directly in the chamber designated as the saline side where
they remained for 30 min. Mice were returned to their home cage and remained in the lab until
the second conditioning session of the day which repeats the same procedure 4 h later. On day 3,
mice were implanted with a 75 mg morphine pellet under anesthesia (see section 2.2.5. for pellet
implantation surgery). On day 5, mice were pretreated either 2 h prior to the first conditioning
session (JZL184, PF-3845, SA-57) or 30 min prior to both conditioning sessions (THC, clonidine,
morphine). At 48 h post-pellet implantation, mice were injected with either naloxone HCl or
saline (placebo+saline controls) and placed into the naloxone-designated compartment for 30
min. The naloxone conditioning procedure was then repeated 4 h later, i.e. 52 h post pellet
implantation. On day 6, mice were tested for the expression of CPA during a 20 min test.
Avoidance scores were calculated by subtracting the amount of time spent on the
naloxone paired side during the pre-conditioning test from the time spent on the postconditioning test. Thus, a negative score indicated that the animal spent less time on that side
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following the conditioning procedure and this value reflected a change from the animal’s initial
preference for that side. Positive scores are considered to reflect CPP and are used to infer the
rewarding effects of drugs while negative scores are considered to reflect an aversive state.
4.2.4. Statistical Analysis
All data are reported as mean±SEM. Data were analyzed using either Student’s t-test or
one-way between measures analysis of variance. Dunnett’s test was used to compare drug
treatments with vehicle and Newman-Keuls post-hoc test was employed for comparisons
between various treatments. The z-test of two proportions was used to analyze jumping data.
Differences were considered statistically significant at p<0.05.
4.3. Results
4.3.1. Morphine reduces both withdrawal jumping and acquisition of naloxone-precipitated
morphine withdrawal conditioned place avoidance
As a positive control, morphine (30 mg/kg) was administered s.c. 30 min prior to each
naloxone conditioning session. Morphine pretreatment significantly attenuated naloxoneprecipitated morphine withdrawal CPA [F(2,23)=9.6; p<0.001; Figure 28A] and withdrawal
jumping [p<0.01; Figure 28B]. There was an effect of conditioning treatment on locomotor
activity during the expression test, with mice that were pretreated with saline, but not morphine,
exhibiting reduced movement counts with respect to placebo mice [F(2,23) = 4.2; p<0.05; Figure
28C].
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Figure 28. Morphine pretreatment blocked both naloxone-precipitated morphine withdrawal
CPA and jumping behavior. Morphine (30 mg/kg) administered 30 min prior to naloxone
conditioning blocked (A) withdrawal CPA and (B) withdrawal jumping. n=6-10 per group. Data
are expressed as mean±SEM, or as a percent of animals that exhibited the specified behavior. **
p<0.01, *** p<0.001 compared to Placebo+SAL control for (A,C) and compared to MOR+NLX
for (B), ### p<0.001 compared with the MOR+NLX group.

123

4.3.2. Clonidine reduces acquisition of conditioned place avoidance to naloxone-precipitated
morphine withdrawal but not withdrawal jumping
We tested whether clonidine, the alpha2 adrenergic agonist would reduce the acquisition
of naloxone-precipitated morphine withdrawal induced CPA. Clonidine (0.1 and 0.3 mg/kg)
pretreatment significantly reduced CPA [F(4,69) = 4.5; p<0.001; Figure 29A], but did not
significantly affect withdrawal jumping [Figure 29B]. Clonidine (0.1 and 0.3 mg/kg) attenuated
the hypomotility during the expression test [F(4,49) = 4.8; p<0.01; Figure 29C].
4.3.3. JZL184 does not produce conditioned place preference or avoidance
To determine if inhibition of MAGL and the resulting elevation of 2-AG might produce
either CPP or CPA on its own, naïve mice were tested with JZL184 (4 or 40 mg/kg) or vehicle.
JZL184 was administered i.p. 2 h prior to the conditioning session. Following conditioning, mice
did not display a significant preference or avoidance to the JZL184-paired side [Figure 30A].
Additionally, conditioning with JZL184 did not affect locomotor activity during the expression
test [Figure 30B].
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Figure 29. The alpha2 adrenergic agonist clonidine reduced naloxone-precipitated morphine
withdrawal CPA, but not withdrawal jumping. Clonidine (0.1 and 0.3 mg/kg) administered s.c.
30 min prior to the first conditioning session reduced (A) acquisition of naloxone-precipitated
morphine withdrawal CPA but did not affect (B) the percentage of mice that exhibited jumping
behavior. Clonidine (0.1 mg/kg) administered prior to conditioning also significantly reduced (C)
hypomotility during the expression test. n=11-20 per group. Data are expressed as mean±SEM,
or as a percent of animals that exhibited the specified behavior. * p<0.05, ** p<0.01, compared
to Placebo+SAL control for (A,C), # p<0.05, compared with the MOR+NLX group.
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Figure 30. JZL184 did not produce conditioned place preference or avoidance in mice. JZL184
(4 or 40 mg/kg i.p.) was administered 2 h prior to the first conditioning session. Upon testing for
expression, mice exhibited no (A) preference or avoidance behavior or (B) differences in
locomotor activity. n=7-8 per group. Data are expressed as mean±SEM.
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4.3.4. JZL184 reduces withdrawal jumping but does not affect acquisition of conditioned place
avoidance to morphine withdrawal
In order to determine if inhibition of MAGL would affect the negative motivational
consequences of morphine withdrawal, JZL184 was tested in the CPA procedure. JZL184 (4 or
40 mg/kg) was administered i.p. 2 h prior to the first conditioning session. Since JZL184
maintains elevated 2-AG for up to 8 h (Long et al., 2009a), only a single injection of the
compound was administered because the second conditioning session occurred 6 h post JZL184
pretreatment which is within this time frame. Naloxone-precipitated withdrawal produced a CPA
response [F(3,49) = 7.4; p<0.001; Figure 31A] which was not affected by JZL184. In contrast to
JZL184’s lack of effects on acquisition of CPA, the high dose of 40 mg/kg significantly reduced
the number of mice that exhibited jumping behavior during the conditioning sessions
[Figure 31B]. Mice that received morphine pellets all had equivalent reductions in locomotor
activity during the expression test [F(3,50) = 6.6; p<0.001; Figure 31C].
4.3.5. PF-3845 does not affect withdrawal jumping nor does it affect acquisition of conditioned
place avoidance to naloxone-precipitated morphine withdrawal
To test whether inhibition of FAAH would affect the negative motivational consequences
of morphine withdrawal, PF-3845 was tested in the CPA procedure. PF-3845 (1, 3 or 10 mg/kg)
was administered i.p. 2 h prior to the first conditioning session. Since PF-3845 maintains
elevated AEA for up to 8 h (Ahn et al., 2009), a single injection of the compound was necessary
since the second conditioning session occurred 6 h after PF-3845 pretreatment. Naloxoneprecipitated withdrawal produced a CPA response [F(4,50)=7.7; p<0.0001; Figure 32A] which
was not affected by PF-3845. Furthermore, PF-3845 (10 mg/kg) did not significantly affect the
number of mice that exhibited jumping behavior during the conditioning sessions [p=0.27;
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Figure 32B]. All mice receiving morphine pellets exhibited reduced locomotor activity during
the expression test [F(4,50) = 9.2; p<0.0001; Figure 32C].
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Figure 31. JZL184 reduced naloxone-precipitated morphine withdrawal jumping but not
acquisition of CPA. JZL184 did not affect (A) acquisition of CPA to naloxone-precipitated
morphine withdrawal but reduced (B) percent of mice that exhibited jumping behavior. There
was no effect of JZL184 on (C) locomotor activity during the expression test. n=9-17 per group.
Data are expressed as mean±SEM, or as a percent of animals that exhibited the specified
behavior. * p<0.05, ** p<0.01 compared to Placebo+SAL control for (A,C) and compared to
MOR+NLX for (B).
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Figure 32. PF-3845 did not affect jumping nor CPA associated with naloxone-precipitated
morphine withdrawal. PF-3845 (1, 3, or 10 mg/kg) did not affect (A) acquisition of naloxoneprecipitated morphine withdrawal CPA and did not significantly reduce (B) the number of mice
exhibiting jumping behavior. Morphine-pelleted mice all exhibited (C) reduced locomotor
activity during expression test. PF-3845 treatment did not result in significant effects on
locomotor activity on test day. n=10-12 per group. Data are expressed as mean±SEM, or as a
percent of animals that exhibited the specified behavior. * p<0.05, ** p<0.01, *** p<0.001
compared to Placebo+SAL control.
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4.3.6. SA-57 reduces withdrawal jumping but does not affect acquisition of naloxoneprecipitated morphine withdrawal conditioned place avoidance
Next we tested whether dual inhibition of FAAH/MAGL would block the negative
motivational aspects of morphine withdrawal in the CPA paradigm. Naloxone-precipitated
morphine withdrawal produced a robust CPA response [F(4,53)=8.0, p<0.0001; Figure 33A], but
this was not affected [p=0.58] by pretreatment with SA-57 (1.25, 5, or 12.5 mg/kg). In contrast,
SA-57 produced a significant reduction in number of mice exhibiting withdrawal jumping
behavior [Figure 33B]. Mice that received morphine pellets exhibited reduced locomotor activity
during the expression test, which was not affected by previous SA-57 treatment [F(4,48) = 7.2;
p<0.0001; Figure 33C].
4.3.7. THC reduces withdrawal jumping but not acquisition of conditioned place avoidance to
naloxone-precipitated morphine withdrawal
To test if a direct agonist of cannabinoid receptors would reduce acquisition of naloxoneprecipitated morphine withdrawal CPA we tested the prototypical phytocannabinoid THC which
has previously been shown to reduce behavioral signs of morphine withdrawal in rats and mice.
Naloxone produced a significant CPA behavior [F(4,23)=8.8; p<0.001; Figure 34A], but THC (1,
3 and 10 mg/kg) did not affect acquisition of CPA. In contrast, THC (3 and 10 mg/kg)
significantly reduced naloxone-precipitated morphine withdrawal jumping behavior in mice
[Figure 34B]. There was no significant effect of THC on locomotor activity [p=0.06;
Figure 34C].
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Figure 33. The mixed FAAH/MAGL inhibitor reduced naloxone-precipitated morphine
withdrawal related jumping, but not CPA. SA-57 (1.25, 5.0, and 12.5 mg/kg) administered i.p,
2 h prior to the first conditioning session did not affect (A) acquisition of naloxone-precipitated
morphine withdrawal CPA but reduced (B) the percentage of mice that exhibited jumping
behavior. SA-57 (1.25 and 12.5) also significantly reduced overall activity during the expression
test. n=9-12 per group. Data are expressed as mean±SEM, or as a percent of animals that
exhibited the specified behavior. * p<0.05, ** p<0.01, *** p<0.001 compared to Placebo+SAL
control for (A,C) and compared to MOR+NLX for (B).
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Figure 34. THC reduced jumping, but not CPA, associated with naloxone-precipitated morphine
withdrawal. THC (1, 3, or 10 mg/kg) did not affect (A) acquisition of naloxone-precipitated
morphine withdrawal CPA but significantly reduced (B) the percentage of mice exhibiting
jumping behavior. Mice pretreated with THC (10 mg/kg) exhibited (C) reduced locomotor
activity during the expression test. n=5-6 per group. Data are expressed as mean±SEM, or as a
percent of animals that exhibited the specified behavior. * p<0.05, ** p<0.01, compared to
Placebo+SAL control for (A,C) and compared to MOR+NLX for (B).
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4.4. Summary
These experiments tested the hypothesis that inhibition of endocannabinoid catabolism
would reduce the negative motivational signs of morphine withdrawal as assessed in the CPA
paradigm. Morphine (30 mg/kg) significantly blocked the acquisition of withdrawal CPA and
significantly reduced the percentage of mice that jumped [Figure 28], serving as the first positive
control. We also found that the alpha-2 adrenergic agonist clonidine (0.1 and 0.3 mg/kg) reduced
acquisition of morphine withdrawal CPA and this served as our non-opioid positive control
[Figure 29]. The MAGL inhibitor JZL184 which elevates the endocannabinoid 2-AG did not
affect CPA but did significantly reduce the percentage of mice that jumped [Figure 31] and had
no effects on place conditioning by itself [Figure 30]. Additionally, the FAAH inhibitor PF-3845
which elevates the endocannabinoid AEA did not affect CPA or the percentage of mice that
exhibited jumping behavior [Figure 32]. We also tested the dual FAAH/MAGL inhibitor SA-57
which more potently inhibits FAAH than MAGL but found that even the highest dose tested
(12.5 mg/kg), which maximally elevates 2-AG and AEA, did not affect CPA; however, SA-57
reduced the percentage of mice that jumped [Figure 33]. We also tested whether THC, the
cannabinoid partial agonist, would block the acquisition of morphine withdrawal CPA. We found
that while THC did not affect CPA it reduced the percentage of mice that jumped [Figure 34].
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Chapter 5: Discussion
It is well established that drugs acting upon the endocannabinoid system are effective at
reducing somatic withdrawal signs in rodents (Bhargava, 1976; Hine et al., 1975; Ramesh et al.,
2011; Vela et al., 1995; Yamaguchi et al., 2001) and recent data suggest that cannabis use during
methadone maintenance treatment is associated with lower withdrawal severity (Scavone et al.,
2013b). However, direct acting agonists, e.g. THC, have been reported to elicit dysphoria and
anxiety in humans (Martin-Santos et al., 2012) and also elicit behavioral/physiological effects in
mice including hypomotility, catalepsy and hypothermia (Varvel et al., 2005). Inhibition of
FAAH and MAGL reduces somatic signs of opioid withdrawal in mice, but only full inhibition
of MAGL produces maximally efficacious reductions in all withdrawal measures (Ramesh et al.,
2011). Additionally, the high dose of the MAGL inhibitor JZL184 that produces these
pronounced effects also elicits a subset of cannabimimetic effects (hypomotility, hypothermia)
(Long et al., 2009a) and upon repeated administration leads to dependence liability and
functional CB1 receptor tolerance (Schlosburg et al., 2010b). Since full FAAH inhibition is
without cannabimimetic effects (hypomotility, catalepsy, hypothermia) and does not lead to
functional tolerance or cannabinoid dependence (Falenski et al., 2010; Long et al., 2009c;
Schlosburg et al., 2010b), we sought to determine if full FAAH inhibition combined with partial
MAGL inhibition would reduce morphine withdrawal signs without eliciting cannabimimetic
effects.
While inhibition of endocannabinoid catabolism reduces the somatic signs of opioid
withdrawal, it is not established whether these effects extend to negative motivational aspects of
withdrawal. As previously discussed, the motivational and somatic aspects of withdrawal are
dissociable by brain region and naloxone dose (Frenois et al., 2002; Hand et al., 1988; Stinus et
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al., 1990) suggesting that distinct regions mediate the expression of somatic withdrawal signs
and aversive aspects of withdrawal. While endocannabinoid catabolic inhibitors may reduce
somatic signs of morphine withdrawal, it is not known whether they will also reduce the aversive
aspects of withdrawal. In order to determine the extent to which inhibition of endocannabinoid
catabolism reduces opioid withdrawal, other behavioral assays are necessary that reflect these
states. In Chapter 3, we examined the effects of opioid withdrawal in several behavioral assays
that have been suggested to reflect affective/aversive states, including the light/dark box, a novel
escape procedure, the marble burying test, the novelty-induced hypophagia test and the
conditioned place avoidance (CPA) procedure. The morphine withdrawal CPA assay resulted in
a reproducible and robust conditioned measure of withdrawal-related effects and this behavioral
procedure was selected to evaluate the endocannabinoid catabolic inhibitors.
Thus, these studies tested the hypothesis that inhibition of FAAH and/or MAGL would
attenuate somatic signs as well as the development of CPA to morphine withdrawal in mice.
5.1. Dual inhibition of endocannabinoid catabolism attenuates signs of opioid withdrawal
without producing cannabimimetic effects
We demonstrated that partially blocking MAGL in combination with full FAAH
blockade produced an enhanced reduction in a subset (jumps and diarrhea) of somatic opioid
withdrawal signs than either of these inhibitors elicited alone. Specifically, combined
administration of low dose of the MAGL inhibitor JZL184 (i.e., 4 mg/kg) and high dose of the
FAAH inhibitor PF-3845 (i.e., 10 mg/kg) reduced precipitated [Figure 2] and spontaneous
[Figure 3] somatic morphine withdrawal signs and these effects were CB1 mediated [Figure 4].
Additionally, the dual FAAH/MAGL inhibitor SA-57 [Figure 5] significantly reduced paw
flutters, head shakes, jumps, diarrhea, and weight loss in morphine-pelleted mice undergoing
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spontaneous withdrawal. Importantly, these studies have shown that dual inhibition of
FAAH/MAGL at doses of SA-57 that only partially (3-5 fold) elevated 2-AG [Figure 6] did not
produce detectable changes in measures of cannabimimetic activity [Figure 7].
High dose JZL184 (40 mg/kg) significantly blocked measured somatic opioid withdrawal
signs, while high dose PF-3845 (10 mg/kg) reduced only a subset of these effects (Ramesh et al.,
2011). Problematically this high dose of JZL184 produces a subset of cannabimimetic effects
(hypomotility, hypothermia) (Long et al., 2009a). Although FAAH inhibitors do not elicit
observable cannabimimetic side-effects, PF-3845 was less efficacious than JZL184 in reducing
spontaneous and naloxone-precipitated opioid withdrawal signs (Ramesh et al., 2011). Taken
together, these results suggest that FAAH and MAGL are both potential targets for treating
opioid dependence. However, selective inhibitors of these enzymes are associated with
respective challenges related to efficacy and potential side effects. In order to circumvent these
limitations, we investigated whether a combination of partial MAGL inhibition and complete
FAAH inhibition would achieve enhanced efficacy in attenuating opioid withdrawal signs,
without cannabimimetic side effects associated with simultaneously and completely blocking
both endocannabinoid catabolic enzymes (Long et al., 2009c). The reduction in somatic
morphine withdrawal signs by this combination coupled with the lack of cannabimimetic effects
are important findings supporting further development of dual FAAH/MAGL inhibitors. Notably,
the dual inhibitor SA-57, which much more potently inhibits FAAH (IC50 < 10 nM) than MAGL
(IC50 = 410 nM) (Niphakis et al., 2012), displayed differential potency in elevating brain AEA
(ED50 = 0.4 mg/kg) and 2-AG (ED50 = 5.0 mg/kg) levels [Figure 6] and dose-dependently
prevented spontaneous withdrawal in morphine-pelleted mice [Figure 5].
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Importantly, SA-57 did not produce cannabimimetic effects at doses that reduced opioid
withdrawal signs [Figure 7]. Specifically, SA-57 (1.25 – 5 mg/kg) did not produce hypomotility,
catalepsy, antinociception, or hypothermia during an 8 h period which corresponds to the period
of time spontaneous opioid withdrawal signs were scored. The relative increase in brain AEA
and 2-AG levels at 2.5 and 5 mg/kg SA-57 were similar to those obtained by combined
administration of high PF-3845 (10 mg/kg) and low JZL184 (4 mg/kg) (Ramesh et al., 2013).
SA-57 at 2.5 and 5 mg/kg elevated 2-AG levels approximately 3- and 7-fold respectively
whereas the combination of PF-3845 and JZL184 elevated 2-AG levels approximately 4-fold
while both treatments fully elevated AEA. Additionally, the combination of high PF-3845 and
low JZL184 did not produce cannabimimetic effects in the tetrad (Ramesh et al., 2013). The lack
of effects of combined JZL184 and PF-3845 or SA-57 (1.25 – 5 mg/kg) in the cannabinoid tetrad
are in agreement with other published findings. First, complete FAAH blockade does not
produce THC-like effects in drug discrimination and does not elicit hypothermia, catalepsy, or
hypomotility (Ahn et al., 2008; Long et al., 2009c). Additionally, low dose JZL184 (4 mg/kg)
produces minimal THC-like effects, while full blockade of MAGL elicits hypomotility and full
inhibition of both FAAH and MAGL elicits robust cannabimimetic effects (hypomotility,
catalepsy, hypothermia, and antinociception) (Long et al., 2009c).
Although FAAH and MAGL are well established to be the primary hydrolytic enzymes
of AEA (Cravatt et al., 2001b) and 2-AG (Dinh et al., 2002) respectively, non-endocannabinoid
substrates of these enzymes and their receptor targets are also affected by inhibitors of these
enzymes. In particular, MAGL plays a major role in the biosynthesis of free arachidonic acid in
brain from its precursor, 2-AG (Nomura et al., 2011). Also, FAAH metabolizes other bioactive
fatty acid amides, including N-palmitoyl ethanolamine, N-oleoyl ethanolamine, and oleamide
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(Cravatt et al., 2001a; Cravatt et al., 1996), as well as N-acyl taurines (Leung et al., 2006), which
activate various TRP channels and PPARα receptors (Jhaveri et al., 2008; Marzo et al., 2010;
Smart et al., 2000). Thus, combined blockade of FAAH and MAGL produces many
neurochemical alterations that could affect morphine withdrawal responses. Nonetheless, the
observation that the CB1 antagonist rimonabant completely prevents all reductions of somatic
withdrawal signs produced by combined administration of JZL184 and PF-3845 in morphinepelleted mice indicates that endocannabinoid activation of CB1 receptors plays a necessary role
in these actions. Similarly, rimonabant, but not the CB2 receptor antagonist SR144528, prevented
the protective effects of JZL184 on naloxone-precipitated withdrawal signs in morphine-pelleted
mice (Ramesh et al., 2011).
Although compelling evidence supports the idea that AEA and 2-AG play pivotal roles in
mediating the reduction in somatic withdrawal signs elicited by dual inhibition of their primary
catabolic enzymes, the manner by which these two endocannabinoids interact remains to be
established. One explanation is that dual enzyme inhibition produces enhanced reductions in
somatic withdrawal signs (jumps and diarrhea) by increasing total endocannabinoid brain levels
to stimulate CB1 receptors. While the observation that 2-AG levels in brain are at least 200-fold
higher than AEA brain levels (Ahn et al., 2009; Long et al., 2009a) could argue against this idea
of mass action, the difference in relative levels of AEA and 2-AG in interstitial space is more
narrow. Long et al. reported baseline NAc interstitial levels of AEA and 2-AG in C57BL/6 mice
as 0.5±0.1 nM and 4.6±0.7 nM respectively (Long et al., 2009a). Thus, additive effects of
elevated 2-AG and AEA might account for the enhanced effects on somatic withdrawal signs.
Alternatively, it is plausible that simultaneous inhibition of MAGL and AEA may produce
augmented effects because distinct CB1 receptor-mediated circuits are activated by the respective
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endocannabinoids. Consistent with this idea is that FAAH is predominantly expressed on postsynaptic terminals (Gulyas et al., 2004) and MAGL is expressed on presynaptic terminals (Dinh
et al., 2002). Considering the localization of CB1 receptors in LC both presynaptically on
glutamatergic afferents and post-synaptically with mu opioid receptors (Scavone et al., 2010), it
is possible elevating either 2-AG or AEA by inhibition of their catabolic enzymes may
preferentially activate these pools of CB1 receptors. Furthermore, while phasic endocannabinoid
signaling is mediated by 2-AG, tonic endocannabinoid signaling involves both 2-AG
(Hashimotodani et al., 2007) and AEA (Kim et al., 2010). Also, as discussed above, other
consequences of enzyme inhibition may further contribute to the reduction in somatic withdrawal
signs (e.g., decreased brain levels of arachidonic acid or increased brain levels of noncannabinoid fatty acid amides). Indeed, phospholipase A2, cyclooxygenase-1, cyclooxygenase-2,
and 5-lipoxygenase inhibitors were shown to decrease naloxone-precipitated opioid withdrawal
induced contractions of guinea-pig isolated ileum, suggesting arachidonic acid and its
metabolites (e.g. prostaglandins and leukotrienes) are involved in the expression of opioid
withdrawal (Capasso et al., 1997).
While these results highlight the potential of the endocannabinoid catabolic enzyme
inhibitors to treat opioid withdrawal, it will be important to assess this strategy on other
components of opioid addiction, including self-administration of opioids, extinction, and
reinstatement. The CB1 receptor antagonist rimonabant attenuates heroin self-administration
(Navarro et al., 2001) and reinstatement of heroin self-administration in rats (Fattore et al., 2005),
while CB1 receptor agonists such as CP55,940 and WIN55,212-2 restore heroin selfadministration in rats (Fattore et al., 2003). Thus, it will be important to determine the degree to
which elevating endocannabinoids may affect resumption of opioid self-administration.
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Furthermore, although somatic withdrawal signs represent an important component of opioid
withdrawal, it remains to be established whether manipulations of the endocannabinoid system
also attenuate the negative motivational aspects of opioid withdrawal (Frenois et al., 2002).
Chapter 4 followed this line of investigation by assaying for behaviors indicative of negative
motivational aspects of opioid withdrawal using the CPA paradigm.
5.2. Morphine withdrawal produces conditioned place avoidance but paradoxical effects in the
light/dark box
Inhibitors of endocannabinoid catabolism reduce somatic signs of morphine withdrawal
in mice suggesting that these drugs may be effective at reducing opioid withdrawal in clinical
setting. It is not known whether endocannabinoid catabolic inhibitors reduce other aspects of
opioid withdrawal such as those related to negative motivational or aversive aspects.
Additionally, it might be argued that reductions in somatic withdrawal signs may be subject to
non-specific behaviorally disruptive effects of drugs and not fully reflect whether treatment is
reducing opioid withdrawal. Thus, it is important that the extent to which endocannabinoid
catabolic inhibitors reduce other aspects of opioid withdrawal be established. These experiments
investigated the effects of morphine withdrawal in five distinct in vivo assays in order to develop
behavioral procedures sensitive to opioid withdrawal that may be used to infer the internal
emotional state of the animal. Specifically, we examined the effects of morphine withdrawal in
the marble burying test, the novelty induced hypophagia test, the light/dark box, a novel test for
escape behavior, and CPA.
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5.2.1. Light/dark box
We investigated the effects of naloxone-precipitated morphine withdrawal on mouse
behavior in the light/dark box. Naloxone significantly increased the amount of time spent in the
light side in morphine-pelleted [Figure 9] but not placebo-pelleted [Figure 10] mice. Furthermore,
morphine-pelleted mice that received the highest dose of naloxone (0.1 mg/kg) spent more time
in the light side than placebo-pelleted mice receiving the same naloxone dose. However, it must
be noted that these mice did not exhibit a preference for one side or the other as approximately
half the time was spent in the light side and half in the dark. These data are in contrast to the
effects of morphine withdrawal observed in rats in the light/dark box where reductions in time
spent in the light side were observed (Castilho et al., 2008). Rats treated twice daily with
ramping doses of morphine (10 – 50 mg/kg) for 10 days were challenged with naloxone (0.1
mg/kg) and tested in the light/dark box for 10 min. Rats undergoing precipitated-morphine
withdrawal exhibited a significant decrease in the time spent on the light side (~150 s) compared
to saline control animals (~250 s) as well as decreased transitions from the dark to light side (~6
transitions vs. 10 transitions). Furthermore, similar effects were observed in the EPM where
naloxone-precipitated withdrawal decreased the amount of time spent in the open-arms (~12%)
as compared to control rats (~26%).
While there are minimal published data regarding the effects of opioid withdrawal in the
light/dark box, several studies have examined the effects of opioid withdrawal in the EPM,
though the majority of these studies have been conducted in rats. Similar to the effects of
morphine withdrawal in the light/dark box reported by Castilho where decreases in the amount of
time spent in the light side were observed, decreases in the time spent in the open-arms of the
EPM in rats have also been reported (Bhattacharya et al., 1995; Castilho et al., 2008; Schulteis et
142

al., 1998b; Zhang et al., 2008). In contrast, similar to the effects we observed in the light/dark
box, mice have been reported to exhibit increases in the amount of time spent in the open-arms
following morphine withdrawal (Buckman et al., 2009; Hodgson et al., 2008; Hodgson et al.,
2009). Increased time in the open-arms is typically observed following acute treatment with
anxiety-reducing compounds such as benzodiazepines and is therefore interpreted by
investigators as an anxiolytic-like effect. Observations of rats undergoing morphine withdrawal
in the EPM exhibiting decreases in the amount of time in the open-arms suggests an anxiogeniclike effect which is in accord with the reported increased anxiety in humans as well as the
elevations in stress hormones that accompany withdrawal in both rats (Budziszewska et al., 1996;
Gonzalvez et al., 1994) and humans (Gil-Ad et al., 1985). Mice also exhibit increases in plasma
corticosterone following morphine withdrawal (Hodgson et al., 2008; Rabbani et al., 2009)
which makes the increases in time spent in the open-arms of the EPM and the light side of the
light/dark box surprising. Since mice treated with anxiolytic compounds typically exhibit
increases in the time spent in the open-arms (Lister, 1987) of the EPM or light side of the
light/dark box (Crawley et al., 1979), the observation that morphine withdrawal increases time in
the open-arms of the EPM or light side of the light/dark box in mice is paradoxical. Since
morphine withdrawal appears to produce species-dependent effects in both the EPM and
light/dark box, these data raise questions regarding the interpretation of behavior in these
paradigms.
Hodgson et al. (2008) were the first to report that naloxone-precipitated morphine
withdrawal increased time spent in the open-arms of the EPM in mice and suggested that these
increases in time spent in the open-arms might reflect shifts in defensive strategies due to an
increased motivation to escape. This would cause a decrease in the inhibitory avoidance
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exhibited by rodents toward the open-arms of the EPM and thus increased time spent in this area
of the apparatus. The suggestion that mice may be exhibiting increases in escape behavior led to
the development of the escape assay in Chapter 3 in order to test the hypothesis that morphine
withdrawal increases escape behavior in mice.
5.2.2. Escape box
The escape box was designed to examine mouse behavior during morphine withdrawal in
an environment in which mice can escape. In an initial experiment, a clear plastic mouse cage
was set on top the lab bench where the experimenter could observe the animal’s behavior. The
cage lid was left ajar in order to allow mice to exit the cage at one end. Morphine-pelleted and
placebo-pelleted mice were then challenged with naloxone to precipitate withdrawal and the
latency for them to exit the cage was recorded. Control animals did not escape during the 15 min
test session, however morphine-pelleted mice receiving naloxone (0.03 – 0.1 mg/kg) did escape
[Figure 11]. However, the height of the edge of the cage required that mice jump up to climb out
and because mice undergoing precipitated morphine withdrawal exhibit jumping behavior in the
absence of an opening through which they can escape, it is possible that escaping was simply a
consequence of increased jumping. To facilitate escape behavior in mice and narrow the opening
to prevent random escape via non-directed jumping, a second apparatus was designed that
contained a 5x5 cm opening at one end with a wire mesh ramp recessed over the lip of the cage
so that mice could climb out much easier. This design resulted in control mice exhibiting escape
behavior as well suggesting that the resulting jumping behavior of morphine withdrawal was not
necessary for mice to escape. Additionally, naloxone-precipitated morphine withdrawal further
lowered this latency [Figure 12] suggesting that morphine withdrawal was facilitating escape in
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this procedure. In an effort to optimize the likelihood that the escape behavior was not simply a
consequence of withdrawal-induced jumping, the procedure was slightly modified so that the
wire mesh extended further (2 cm) into the cage so that mice could easily climb out and further
reduce the chances that jumping behavior was contributing to this effect. Mice were closely
observed during the procedure and scored as to whether any jumping behavior was exhibited.
Naloxone (0.056 mg/kg) significantly reduced the escape latency in morphine-pelleted mice as
compared to placebo-pelleted controls and when mice that exhibited any jumping during the
session were excluded (n=3), the effect remained statistically significant [Figure 13]. This last
experiment suggested that mice undergoing morphine withdrawal would indeed escape with a
lower latency than control mice and that this behavior was not dependent upon the presence of
jumping behavior. These experiments taken together suggest that morphine withdrawal decreases
the latency of mice to escape from a novel cage independently of effects on jumping behavior.
Previous morphine withdrawal studies have characterized jumping behavior in rodents as
an “escape behavior” (Frederickson et al., 1976; Noda et al., 2004; Stinus et al., 1990). The
results of the present study support this interpretation by demonstrating that mice during
morphine withdrawal are exhibiting a goal-directed behavior (i.e. they are actively escaping
rather than simply emitting a jumping behavior). While it seems likely that the increased
jumping behavior during opioid withdrawal is directly related to the escape behavior as we have
defined it in our study, the observation that naloxone-precipitated morphine withdrawal results in
mice exiting a novel environment more rapidly than control mice lends support to the notion that
increases in time spent in the open-arms of the EPM and light side of the light/dark box reflect an
escape response rather than an anxiolytic effect. Further characterization of this experimental
procedure is warranted including assessment of known anxiolytic (e.g. benzodiazepines) and
145

anxiogenic compounds (e.g. kappa agonists, GABA antagonists), manipulations of the
environment (stressors) and testing in home cage vs. novel cage to determine their effects on
escape behavior.
5.2.3. Marble Burying
It has previously been shown that morphine withdrawal increased the number of marbles
buried by male albino Swiss mice (Umathe et al., 2012). The present studies sought to determine
if morphine withdrawal would produce similar increases in digging behavior as measured by
marble burying in male ICR mice. Spontaneous morphine withdrawal following six days of
morphine treatment (6.25 – 50 mg/kg s.c., b.i.d.) did not produce significant changes in the
number of marbles buried during a 20 min test [Figure 14]. Following that study, a second
experiment was conducted in which mice were implanted with subcutaneous morphine (75 mg)
pellets for a greater induction of dependence. During the baseline test (72 h post pellet
implantation), morphine-pelleted mice buried fewer marbles than placebo-pelleted mice did,
suggesting the presence of morphine was reducing digging behavior in these mice [Figure 15].
Subsequently, pellets were removed and mice were retested at 4 h and 8 h after pellet removal.
The difference between number of marbles buried between morphine treated and placebo treated
mice persisted at 4 h post pellet removal, but by 8 h placebo-pelleted mice were burying fewer
marbles and this difference between groups was no longer present [Figure 15]. The effects of
morphine on marble burying represented a challenge to the interpretation of these results since
there were baseline differences between morphine-pelleted and placebo-pelleted mice. It is
possible that mice habituated to the marble burying apparatus and thus were less active and
buried fewer marbles, yet mice that were morphine-pelleted did not exhibit any significant shifts
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in digging behavior as measured by number of marbles buried following pellet removal.
Increases in the number of marbles buried might have been apparent at the later time point had
the animals not acclimated to the test cages, but the relative high number of marbles buried by
the placebo animals likely would have precluded detection of shifts in this direction. Thus, the
next experiment was modified to reduce the number of marbles buried by control animals by
shortening the test session length. In this experiment, we assessed a wide range of doses of
naloxone in order to test whether it produced a dose-related effect on marble burying in
morphine-pelleted mice. Mice were implanted with morphine or placebo pellets and tested 72 h
later following treatment with either saline or naloxone (0.03 – 0.3 mg/kg, s.c.). Placebo-pelleted
mice buried fewer marbles during the 5 min test than in previous experiments using the 20 min
session length, providing a window for detection of either increases or decreases in digging
behavior. However, naloxone did not significantly affect the number of marbles buried at any
dose tested and both morphine and placebo-pelleted mice buried a similar number of marbles
[Figure 16].
To date, only one study has reported the effects of opioid withdrawal on marble burying
in mice. Umathe et al. (2012) reported that in male Swiss mice (24-30 g) repeatedly treated with
morphine (5 – 20 mg/kg, s.c., b.i.d.) for 10 days exhibited significant increases in the number of
marbles buried at 8 h, 24 h, and 48 h following their last morphine injection. We examined
marble burying at 8 h post-pellet removal but did not observe this increase in marble burying but
this could be due to the dependence induction procedure. It is notable, however, that control mice
in the Umathe study buried very few marbles (~10 marbles out of 20) during the 30 min test
session as compared with the ICR mice in the present study during the 20 min test. In order to
facilitate a detection of increases in marble burying, the test session was shortened to 5 min and
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the precipitated withdrawal model was employed to induce withdrawal to varying degrees,
however this did not yield significant effects of morphine withdrawal. Thus, the marble burying
assay under the conditions we tested was not sensitive to alterations in digging behavior by
morphine withdrawal. Future studies could further modify the marble burying procedure to
reduce the number of marbles buried. Acclimation is one possible means to reduce the number of
marbles buried, however when tested at 8 h post pellet removal, morphine withdrawn mice did
not exhibit even a slight trend for an increase in this behavior although control animals exhibited
a reduction in the number of marbles buried as compared to baseline. Further shortening the time
of the procedure may reduce the number of marbles buried but it is unlikely large changes in
digging behavior could be observed in such a short time period. The difference in numbers of
marbles buried between these studies and those published by Umathe et al. is the primary
concern regarding translation of morphine withdrawal effects since the differences in baseline
behavior are so different that it may reflect a strain dependent effect. Other groups using the
Swiss mouse and the same 30 min marble burying procedure (non-dependence procedures) have
also reported that control mice bury approximately 10 marbles (Li et al., 2006; Uday et al., 2007).
In contrast, some studies using ICR mice have reported more marble burying under control
conditions. Ichimaru et al., using male ICR mice in a 30 min procedure with a total of 25 marbles,
reported that the median number of marbles buried under control conditioned was 22 (Ichimaru
et al., 1995). Another study reported that baseline marble burying was approximately 70% buried
(out of 25 marbles) during a 30 min test, equaling approximately 18 marbles (Young et al., 2006).
In another study using 20 marbles, control ICR mice buried approximately 15 marbles after 20
min (Sugimoto et al., 2007). Though some these studies used longer session times, it is possible
that strain differences on baseline digging behavior may account for lack of effects of morphine
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withdrawal in these studies, since the experimental design (aside from test length), size of the
mice, and time of day were similar between our studies and those of Umathe et al. A previous
study examined multiple inbred strains of mice and found that marble burying did indeed vary
across strains but did not correlate with other behavioral measures typically interpreted as
anxiety-like. Mice of the 129S6 strain buried the fewest marbles (~6) whereas CBA mice buried
the most (~15-16) during a 30 min period in which 20 marbles were present (Thomas et al.,
2009). This study suggested that strain does indeed play a role in digging behavior and also
demonstrated that digging was not affected by the presence of marbles as compared to control
tests where marbles were absent, thus supporting the argument that the marble burying assay is a
measure of digging behavior rather than marble burying.
Another difference which may account for differences in marbles buried is the scoring
criteria. We used a procedure that has previously been published from our lab (Kinsey et al.,
2011) which was adapted from an established procedure (Thomas et al., 2009). In this procedure,
marbles are scored as buried if >50% of the marble is covered by bedding whereas other studies
have typically used the criteria of 2/3 buried. Thus, differences in scoring of the number of
marbles buried might reflect the higher scores in our studies since the threshold for being “buried”
is lower. Though this difference exists it is such a small difference that it seems unlikely to
account for lack of effects observed following morphine withdrawal but it cannot be completely
discounted.
Digging behavior aside from defensive burying has been observed in rats during
withdrawal. Rubino implanted morphine (75 mg) pellets daily into rats for 5 days then
administered naloxone (10 mg/kg i.p.) and observed increases in digging behavior in morphinepelleted but not placebo-pelleted rats (2000) and Rasmussen et al. reported increases in digging
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during a naltrexone-precipitated (10 mg/kg s.c.) morphine (2x75 mg pellets) withdrawal during a
60 min observation period in which withdrawal behaviors were scored while rats were observed
in clear plastic cages lined with wood shavings (2005). It is notable that in both of these studies
there was also a significant increase in jumping behavior in the withdrawal group which suggests
that increases in one behavior did not limit the emergence of other behaviors through response
competition. In summary, the lack of effects of morphine withdrawal on marble burying in our
assay may be due to mouse strain or the dependence procedure and because there was no effect
of withdrawal we chose not to pursue this behavioral procedure.
5.2.4. Novelty-induced hypophagia
The novelty-induced hypophagia protocol was adapted from an established procedure
which is sensitive to nicotine withdrawal (Gur et al., 2007). Initially, mice were acclimated to the
novel food in their home cages over 12 days [Figure 17] and an initial control experiment tested
the benzodiazpine diazepam. Typically, mice will show an increased latency to consume this
food in a novel environment, but benzodiazepines and other drugs that produce anxiolytic-like
effects decrease latency to consume the food and increase the amount of food consumed in a
novel environment [Figure 18]. This established the procedure and demonstrated that diazepam
produced effects that have been previously reported (Merali et al., 2003). We next assessed the
effects of naloxone in morphine-pelleted and placebo-pelleted mice in this procedure. When
tested in the home cage, morphine-pelleted mice exhibited a decrease in the amount of food
consumption as compared to placebo-pelleted mice [Figure 19] but there was not an effect of
naloxone on the amount of food consumed and or the latency to consume food. The suppressive
effects of morphine on latency and food consumption predominated in this experiment and made
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conclusions regarding withdrawal effects difficult. Future studies might use a longer dependence
period following pellet implantation to allow for the anorectic effects of morphine to undergo
tolerance or use a repeated dosing procedure to avoid the inhibitory effects of morphine on food
consumption. Thus the suppressive effects of morphine on food consumption occluded any
possible effects of naloxone-precipitated withdrawal and further studies would have to assess the
effects of withdrawal in rodents in which morphine does not suppress feeding during control
tests. The duration of time between pelleting and testing could be lengthened so that the animals
are tested once the food consumption of the morphine treated group matches that of the placebopelleted group. In summary, naloxone-precipitated morphine withdrawal did not produce effects
that could be interpreted as withdrawal related in this procedure.
5.2.5. Conditioned place avoidance
The place conditioning paradigm employed in our studies used an unbiased apparatus.
This was first established following examination of baseline preferences which demonstrated
that mice did not prefer the white or the black side [Figure 20]. An initial experiment replicating
CPP to morphine and cocaine served to establish the basic conditioning procedure. Both
morphine (10 mg/kg) and cocaine (20 mg/kg) produced a significant CPP in ICR mice
demonstrating that the basic methodology (i.e. handling, conditioning apparatus) was sufficient
to produce an established CPP effect [Figure 21]. The next set of experiments sought to replicate
an established procedure (Broseta et al., 2005) for producing CPA to morphine withdrawal. First,
a dose-response experiment for naloxone was conducted in order to determine the potential for
naloxone to produce CPA on its own which is an effect that has previously been reported (Mucha
et al., 1987). Naloxone (0.3 and 1 mg/kg) produced a significant CPA effect in ICR mice
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[Figure 22]. Thus, for the first experiment, naloxone (0.1 mg/kg) was selected as the dose to
precipitate morphine withdrawal. Mice were treated repeatedly with morphine (12.5 – 50 mg/kg
s.c. b.i.d.) and conditioned with naloxone (0.1 mg/kg) on one side and saline on the other side.
Naloxone did not yield a significant CPA effect in either morphine or saline treated mice
[Figure 23]. A follow up experiment was conducted in which the naloxone dose was increased in
order to produce a greater degree of morphine withdrawal and thus a more robust unconditioned
stimulus. Naloxone (1 mg/kg) produced a significant CPA in both saline treated and morphine
treated mice but no significant difference in the degree of CPA was observed between these two
groups [Figure 24]. Thus, the conditions used in this experiment did not lead to precipitated
morphine withdrawal effects. This was problematic in terms of being able to assess the effects of
endocannabinoid catabolic inhibitors on acquisition of naloxone-precipitated morphine
withdrawal CPA. The naloxone dose in these studies appeared less important in terms of
acquisition of naloxone-precipitated morphine withdrawal CPA than the dependence induction
procedure. Accordingly, the next set of experiments sought to determine if acquisition of
naloxone-precipitated morphine withdrawal CPA would occur in animals implanted with
subcutaneous morphine pellets. The use of morphine pellets was selected because it would
produce a greater degree of dependence in these animals and because it was also the method to
produce dependence in our previous studies (Ramesh et al., 2011). While other studies have
implanted morphine pellets prior to conditioning (Mucha et al., 1982; Schulteis et al., 1994;
Watanabe et al., 2002) we were concerned that the constant presence of the morphine pellet
presented a potential pitfall in that morphine could potentially be serving as an additional
unconditioned stimulus in these rodents. Specifically, if morphine pellets were implanted prior to
saline (i.e. non-withdrawal) conditioning sessions, the rewarding effects could possibly be paired
152

with the non-withdrawal side. This would confound the interpretation of our data as the mice
could either be exhibiting CPP to morphine or CPA to morphine withdrawal. Indeed, morphine
pellets alone produced CPP when present during conditioning on only one side of the apparatus
[Figure 25]. It has been shown that treatment with the conditioning compound prior to the
expression test can facilitate either CPP (in the case of morphine) or CPA (in the case of
naltrexone) (Bespalov et al., 1999). It is possible that if morphine pellets were removed prior to
the expression test that mice may not have exhibited CPP, however we did not test this condition.
Nonetheless, the observation that morphine pellets could produce CPP suggested that presence of
the morphine pellet during saline (i.e. non-withdrawal) conditioning could confound our
interpretations since increases in time spent in the saline (i.e. morphine-pelleted) side compared
to decreases in the naloxone (i.e. withdrawal) side could be attributed to either avoidance to
withdrawal or preference to morphine. Thus, we concluded that morphine pellets should not be
present during the “non-withdrawal” conditioning session and performed pellet implantation the
day following the saline/“non-withdrawal” conditioning sessions.
We next demonstrated that naloxone produced CPA in morphine-pelleted mice at doses
that did not produce CPA in placebo-pelleted mice [0.056 mg/kg naloxone; Figure 26].
Furthermore, planned comparison Student’s t-test revealed that the CPA response of morphinepelleted mice following naloxone (0.1 mg/kg) conditioning was greater than in placebo-pelleted
mice, suggesting withdrawal contributed to the behavior rather than being solely a naloxone
effect. Differences in locomotor activity were observed where morphine-pelleted mice, but not
placebo-pelleted mice, exhibited reduced locomotor counts during the expression test [Figure
26C and 26D]. Additionally, CPA occurred in morphine-pelleted mice at doses that produced
minimal somatic signs of opioid withdrawal [Figure 27]. The effects of naloxone by itself in
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placebo-pelleted mice were consistent with a previous report in which naloxone (0.1-10 mg/kg)
produced CPA in naïve CD-1 mice to a similar degree. The effects of naloxone on CPA in naïve
animals is mediated by mu opioid receptors as mu opioid receptor knockout mice do not exhibit
CPA following naloxone (10 mg/kg s.c.) as compared with wild-type controls (Skoubis et al.,
2001). In morphine (2 x 75 mg) pelleted rats, naloxone (1 mg/kg) produced a roughly 2-fold
increase in the CPA effect as compared to placebo-pelleted rats (Mucha et al., 1987). This is
similar to the CPA observed in our study where morphine-pelleted mice exhibited an avoidance
score approximately twice that of placebo-pelleted mice following naloxone (0.1 mg/kg) [Figure
26].
The doses of naloxone that produced CPA were considerably lower than those necessary
to produce somatic withdrawal signs in mice. Indeed, naloxone (0.056 mg/kg) did not produce
statistically significant increases in withdrawal behaviors as compared with control animals
[Figure 27]. While 50% of the mice exhibited jumping behavior following naloxone
(0.056 mg/kg), the average number of jumps was very low (3±1.4, mean±SEM) which was not
statistically significant from controls. In fact, naloxone (0.3 mg/kg) was the lowest dose that
significantly increased number of jumps.
These data taken together suggest that naloxone is more potent at producing CPA than it
is at eliciting somatic withdrawal signs. The naloxone-precipitated morphine withdrawal CPA
procedure produced a clear withdrawal effect which has been well established in the literature
and used to evaluate the negative motivational consequences of opioid withdrawal (Broseta et al.,
2005; Frenois et al., 2002; Maldonado et al., 2004; Sato et al., 2005; Schulteis et al., 1998a;
Stinus et al., 2000; Stinus et al., 1990; Watanabe et al., 2002). Thus, we chose this procedure to
further evaluate the endocannabinoid catabolic inhibitors on opioid withdrawal.
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5.3. Inhibition of endocannabinoid catabolism reduces jumping, but not conditioned place
avoidance of morphine withdrawal
These experiments tested the hypothesis that inhibition of endocannabinoid catabolism
would reduce the negative motivational aspects of morphine withdrawal as assessed in the CPA
paradigm. Morphine and clonidine were tested as positive controls to determine if the CPA assay
was sensitive to drug treatments that are effective in clinical settings. Thus, morphine
pretreatment might represent what could be considered a replacement therapy used in the clinic,
which involves treatment with a direct agonist such as methadone or buprenorphine (Lobmaier et
al., 2010). We hypothesized that morphine sulfate would block both acquisition of CPA and
somatic withdrawal signs as assessed by recording the percentage of mice that exhibited
spontaneous jumping behavior, a typical behavioral sign that accompanies opioid withdrawal.
This behavioral observation during conditioning was used as a secondary measure of drug effects
for all experiments to ensure that previously efficacious doses of the endocannabinoid catabolic
inhibitors were effective at reducing somatic aspects which could be used to rule out
experimental problems as a cause for lack of effect on CPA.
As expected, morphine (30 mg/kg) blocked naloxone-precipitated withdrawal jumping
[Figure 28]. Previously, morphine (25.6 mg/kg) was shown to inhibit withdrawal jumping
approximately 80% following a very large dose of naloxone (25 mg/kg i.p.) in mice treated
repeatedly with morphine (Iorio et al., 1975) and a morphine dose of 40 mg/kg shifted the
naloxone ED50 value for precipitating withdrawal jumping from 0.1 mg/kg to 0.5 mg/kg (Suzuki
et al., 1989). Our morphine dose was much higher relative to our naloxone dose compared to the
Iorio study in which the morphine and naloxone doses were similar. We selected a high
morphine dose to ensure that we blocked both the withdrawal jumping and CPA since there is no
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data on morphine doses necessary to block naloxone-precipitated morphine withdrawal CPA.
Importantly, morphine prevented acquisition of naloxone-precipitated withdrawal CPA. The
effect of morphine on withdrawal CPA demonstrates that the CPA paradigm is at the very least
capable of detecting reductions in withdrawal responses as would be accomplished using a
model of substitution therapy.
We also tested if clonidine was effective at reducing CPA in our procedure, as it is used
clinically for the treatment of opioid withdrawal (Gold et al., 1978; Gossop, 1988) and has been
shown to reduce CPA to morphine withdrawal in rats (Kosten, 1994; Schulteis et al., 1998a).
Clonidine (0.025-0.4 mg/kg) when administered immediately prior to conditioning, was
previously shown to significantly reduce CPA to morphine withdrawal (Schulteis et al., 1998a)
so we tested a similar range of doses. We found that clonidine (0.1 and 0.3 mg/kg) significantly
reduced the acquisition of CPA to morphine withdrawal [Figure 29]. Previously, clonidine
(0.05 mg/kg i.p.) has been shown to produce CPA in mice but not at lower doses (Zarrindast et
al., 2002) thus it is unlikely that clonidine masked naloxone-precipitated morphine withdrawal
CPA by producing CPP on its own. Surprisingly, none of these doses (0.03-0.3) affected
morphine withdrawal jumping. In the present study the jumping was scored as a nominal
measure rather than counting the total number of jumps, so it is likely that our measure lacked
the ability to detect changes in the number of jumps. Clonidine may reduce the number of jumps,
but not necessarily its occurrence. Thus, this measure mainly served as a confirmation if drug
treatments had a detectable effect on somatic withdrawal signs. Indeed, clonidine (0.01-0.16
mg/kg) has been shown at similar doses to reduce morphine withdrawal-induced body shakes,
jumping, and paw tremors (Dehpour et al., 2001; Fielding et al., 1978; Valeri et al., 1989).
Interestingly, others have reported that while clonidine reduces the height of naloxone156

precipitated withdrawal jumps, it does not affect the number of jumps (Alguacil et al., 1989).
Thus, it is plausible that clonidine may reduce other aspects related to naloxone-precipitated
jumping behavior that were not assessed in the current study. Importantly, clonidine significantly
reduced withdrawal CPA and to our knowledge this is the first time clonidine has been shown to
reduce CPA to morphine withdrawal in mice.
JZL184 (40 mg/kg) did not affect acquisition of naloxone-precipitated morphine
withdrawal CPA [Figure 31]. While it reduced the percentage of mice that jumped, this lack of
effect on CPA gave an early indication that elevation of endocannabinoids may lack efficacy in
ameliorating the negative motivational aspects of withdrawal. Additionally, inhibition of FAAH
with PF-3845 did not affect withdrawal jumping or CPA [Figure 32] and PF-3845 has been
shown to be less effective than JZL184 at reducing withdrawal jumping (Ramesh et al., 2011).
As previously mentioned in regards to the lack of effects of clonidine on jumping, it may be that
potential effects of PF-3845 are not detectable when jumps are scored nominally.
We next assessed the dual FAAH/MAGL inhibitor SA-57 on naloxone-precipitated
morphine withdrawal CPA. SA-57 (5 and 12.5 mg/kg) reduced the percentage of mice that
jumped during conditioning but did not affect withdrawal CPA [Figure 33]. These data suggest
that maximal elevation of AEA and 2-AG, which occurs at the 12.5 mg/kg dose [Figure 6], is not
sufficient to block the acquisition of CPA to morphine withdrawal.
Finally, we tested direct agonism of the CB1 receptor with the phytocannabinoid THC,
which is well-established to attenuate opioid withdrawal signs (Bhargava, 1976; Hine et al., 1975;
Ramesh et al., 2011). THC reduced jumping associated with naloxone-precipitated morphine
withdrawal but did not affect CPA. In this experiment, morphine-pelleted mice receiving vehicle
pretreatment and the low dose of THC (1 mg/kg) did not exhibit reduced locomotor activity
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unlike other experiments. The placebo-pelleted mice exhibited locomotor counts around 1500
which is slightly less than in previous experiments. Low doses of THC have been shown to
produce CPP (Braida et al., 2004; Ji et al., 2006) while higher doses (e.g. >=5 mg/kg) have been
shown to produce CPA (Braida et al., 2004; Cheer et al., 2000; Hutcheson et al., 1998; Zimmer
et al., 2001). Braida et al. showed in rats that THC administered i.p. 10 min prior to conditioning
produces CPP at 0.075 – 0.75 mg/kg, no effect at 1 or 3 mg/kg but produces CPA at 6 mg/kg
(2004). In mice, Zimmer et al. (2001) reported that THC (5 mg/kg) produced CPA and Valjent et
al. reported that the same dose of THC produced CPA in mice as well (2000). Similarly, THC
(5 mg/kg) was reported to produce CPA in mice while a lower dose of 1 mg/kg produced CPP
(Soria et al., 2004). Previously our lab published that THC (1 – 3 mg/kg) attenuated paw flutters
and weight loss following naloxone-precipitated morphine withdrawal and near full blockade
was observed at 10 mg/kg (Ramesh et al., 2011). While the range of doses we tested against
withdrawal CPA is the same that significantly attenuated somatic withdrawal signs, they do fall
within the range of doses that produce CPA. Thus, it is possible that any effect of THC on
reducing the CPA of morphine withdrawal may have been masked by this aversive effect of
THC alone. However, 40 mg/kg JZL184 which was shown to be nearly as efficacious as THC
(10 mg/kg) at reducing somatic withdrawal signs via CB1 mechanism (Ramesh et al., 2011) did
not affect morphine withdrawal CPA and alone did not elicit CPP or CPA [Figure 30].
We proposed that endocannabinoid catabolic inhibitors would reduce naloxoneprecipitated morphine withdrawal CPA based on interactions between the opioid and
endocannabinoid systems in the nucleus accumbens and amygdala, regions important for opioid
withdrawal CPA. Specifically, Zarrindast et al. reported that injection of naloxone into the
central nucleus of the amygdala reduced the anxiolytic effects of the CB1 agonist
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arachidonylpropylamide (Zarrindast et al., 2008) and FAAH has been localized with CB1
receptors in the amygdala (Egertova et al., 2003). This is an important region for opioid
withdrawal CPA as injection of mu opioid antagonists into the amygdala have been shown to
produce CPA and mild somatic withdrawal signs in morphine-dependent rodents (Maldonado et
al., 1992; Stinus et al., 1990). It’s also been shown that CB1 and mu opioid receptors are
colocalized in LC neurons (Scavone et al., 2010), which would be consistent with the effects of
cannabinoids on somatic signs of opioid withdrawal, however colocalization of CB1 receptors
with mu opioid receptors in amygdala is not as well established. There is some evidence
suggesting the interactions of cannabinoids and opioids in the central nucleus of amygdala.
Rezayof et al. (2011) demonstrated that injection of arachidonylcyclopropylamide, a synthetic
CB1 agonist, into the central nucleus of the amygdala enhanced morphine CPP and injection of
the CB1 antagonist AM251 into the central nucleus of the amygdala produced CPA and blocked
morphine CPP, suggesting CB1 receptors in the amygdala are important for morphine reward.
While the research presented in Chapter 4 is the first known investigation of cannabinoid
effects on naloxone-precipitated morphine withdrawal CPA, other work has studied the
interaction of opioid and endocannabinoid systems in CPP. Specifically, the full CB1 agonist
CP55,940 (0.02 mg/kg) produced CPP which was blocked by pretreatment with naloxone
(Braida et al., 2001). THC produced CPP at doses of 0.075 – 0.75 mg/kg which was fully
blocked by naloxone (2 mg/kg i.p.) at a dose that did not produce CPA on its own (Braida et al.,
2004). Furthermore, the CB1 receptor antagonist rimonabant (0.1 mg/kg) blocked CPP of
morphine (4 mg/kg) while having no effect on its own (Chaperon et al., 1998) and cannabinoid
mediation of opioid CPP has reported elsewhere (Mas‐Nieto et al., 2001; Singh et al., 2004).
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Although cannabinoids and opioids appear to interact in reward processes as measured by
CPP, we observed no effect of endocannabinoid catabolic inhibition on acquisition of naloxoneprecipitated morphine withdrawal CPA. This suggests different mechanisms may contribute to
reward related aspects of acute opioid exposure and negative motivational aspects of opioid
withdrawal. The opponent process theory of addiction suggests two processes: the positive
hedonic response and the affective/hedonic withdrawal response to drugs of abuse (Koob et al.,
2008b; Solomon et al., 1974). Initially, the hedonic response (in this case the CPP to opioids)
produces a rewarding state which in humans drives initial drug taking and undergoes tolerance
such that a fixed amount of drug becomes less rewarding over time. The other response, the
affective/hedonic withdrawal response, which occurs later and becomes more intense following
continued exposure to drug, becomes the main driving force of drug taking later on (Koob et al.,
2008b; Solomon et al., 1974). These two opponent processes are thought to be mediated by
separate systems (Koob et al., 1988) and while the endocannabinoid system appears to be
involved in the reward aspects of opioids (Caille et al., 2003; Chaperon et al., 1998; Mas‐Nieto
et al., 2001; Navarro et al., 2001; Singh et al., 2004) our data suggest it is not involved in the
negative motivational response of opioid withdrawal as measured by CPA. This could be due to
distinct mediators of these two aspects of the opponent processes. While the rewarding aspects of
morphine are mediated by mu opioid receptors in the nucleus accumbens and VTA (Le Merrer et
al., 2009), there is a postulated “anti-reward” system which compensates for over activation of
the reward system. The affective withdrawal response is suggested to involve this “anti-reward
system” (Koob et al., 2005) and has been suggested to include corticotropin-releasing factor
(CRF), norepinephrine and dynorphin systems (Koob et al., 2008a). Indeed, increased dynorphin
has been observed in the amygdala of rats that underwent morphine withdrawal (Rattan et al.,
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1992) and kappa agonism is known to be aversive to humans (Pfeiffer et al., 1986) and rodents
(Mucha et al., 1985). Furthermore, CRF mRNA levels are increased during morphine withdrawal
in the central nucleus of the amygdala of rats (Maj et al., 2003) and CRF is known to be involved
in fear and anxiety (Takahashi, 2001). Consistent with this idea, CRF1 knockout mice display a
reduced CPA to opioid withdrawal and the increased dynorphin expression in the nucleus
accumbens shell region following opioid withdrawal is reduced to control levels in CRF1
knockout mice (Contarino et al., 2005). Furthermore, CRF1 antagonism has been shown to block
acquisition of morphine withdrawal CPA in rats (Stinus et al., 2004) and these effects appear
mediated in the central nucleus of the amygdala (Heinrichs et al., 1995).
Interestingly, CRF1 antagonism has also been shown to block the anxiogenic effects of
CB1 agonism in rats in the defensive withdrawal test (De Fonseca et al., 1996). Additionally,
AEA and THC have been shown to increase adrenocorticotropic hormone (ACTH) and
corticosterone (Weidenfeld et al., 1994). Thus, it might be that while cannabinoids are reducing
the somatic signs of opioid withdrawal they are producing similar effects to those of withdrawal
in regions that mediate the negative motivational aspects through modulation of the HPA axis.
Additionally, the negative motivational effects of THC are absent in dynorphin deficient mice
(Zimmer et al., 2001), suggesting that the aversive effects of cannabinoids are kappa mediated.
Considering the data which suggest dynorphin involvement in the aversive aspects of opioid
withdrawal, this commonality between cannabinoid agonism and opioid withdrawal presents a
problem for use of cannabinoids for the treatment of opioid dependence.
In conclusion, cannabinoid receptor agonism either directly with THC or indirectly via
inhibition of endocannabinoid catabolism does not appear effective at reducing the negative
motivational consequences of opioid withdrawal in mice using the CPA paradigm. This assay
161

represents one among many in which opioid withdrawal produces effects which may reflect an
aversive state. For example, opioid withdrawal elevates reward-thresholds in intracranial selfstimulation which may indicate an anhedonic-like effect (Altarifi et al., 2011b; Kenny et al.,
2006; Liu et al., 2004; Schaefer et al., 1986; Schaefer et al., 1983). Furthermore, opioid
withdrawal produces anxiogenic-like effects in rats in the elevated plus maze (Schulteis et al.,
1998b; Zhang et al., 2008). Future studies should examine the effects of cannabinoids on these
behaviors related to opioid withdrawal as CPA represents only one measure of negative
motivational aspects and endocannabinoid catabolic inhibitors may exhibit efficacy in these
other measures. However, despite the reductions in somatic withdrawal signs by cannabinoids,
the lack of effects of cannabinoids in morphine withdrawal CPA suggests that these may have
limited efficacy in reducing affective withdrawal symptoms in humans. The lack of cannabinoid
effects on opioid withdrawal CPA could be due to the effects of CB1 agonism on CRF and
dynorphin that are similar to those accompanying opioid withdrawal and/or insufficient CB1 colocalization with mu opioid receptors in particular regions that mediate the negative motivational
withdrawal response.
5.4. Possible mechanism for reductions in somatic withdrawal signs
We have shown that dual inhibition of the endocannabinoid catabolic enzymes FAAH
and MAGL is effective at reducing the somatic aspects opioid withdrawal via CB1 mechanism of
action. Since CB1 and mu opioid receptors are both G-protein coupled receptors that couple with
Gi/o proteins, they share common downstream signaling events including mutual inhibition of
adenylyl cyclase (Childers et al., 1992) via activation of Gi/o proteins (Robledo et al., 2008).
Opioid withdrawal involves superactivation of adenylyl cyclase which results in cAMP
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overshoot (Avidor-Reiss et al., 1995) in regions (i.e. LC and PAG) known to mediate somatic
signs of opioid withdrawal (Guitart et al., 1992; Nestler et al., 1988) and these changes are
associated with the expression of physical signs of opioid withdrawal (Shaw-Lutchman et al.,
2002). This upregulation of the cAMP pathway leads to the hyper-excitability of LC neurons
during withdrawal (Lane-Ladd et al., 1997; Widnell et al., 1994). This resulting hyperexcitability
leads to increased noradrenergic outflow which largely contributes to the physical withdrawal
signs (Crawley et al., 1979; Van Bockstaele et al., 2008). The ability of CB1 receptors through
activation of Gi/o proteins to inhibit adenylyl cyclase (Matsuda et al., 1990; Vogel et al., 1993)
provides a means by which superactivation of adenylyl cyclase could be throttled, and the
colocalization of CB1 with mu opioid receptors in LC (Scavone et al., 2010) and PAG (WilsonPoe et al., 2012) neurons demonstrates that CB1 receptors are localized to important regions for
the mediation of these withdrawal signs. Thus, inhibition of adenylyl cyclase resulting in a
reduction in the cAMP overshoot that accompanies opioid withdrawal seems a likely mechanism
through which cannabinoids attenuate the physical signs of opioid withdrawal. In addition, CB1
receptors are located presynaptically on glutamatergic afferents to LC neurons and thus could
inhibit glutamate release onto noradrenergic neurons, thereby inhibiting the release of
norepinephrine (Scavone et al., 2010).
5.5. Overall conclusions
These studies suggest that endocannabinoid catabolic inhibitors reduce the somatic signs,
but not a negative motivational aspect of opioid withdrawal in the CPA paradigm. While the
alpha-2 adrenergic agonists clonidine and fexofenadine are currently in use as non-opioid
treatments for withdrawal, they have side effects such as hypotension, sedation and cognitive
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impairment and in some patients are not fully effective at lessening the withdrawal symptoms
(Gerra et al., 2001; Gossop, 1988; Lobmaier et al., 2010). Better treatment options are needed to
assist patients undergoing detoxification from opioids and to improve patient retention in these
programs. The efficacy of the endocannabinoid catabolic inhibitors at reducing somatic signs of
opioid withdrawal in mice suggests they may be effective at reducing physical aspects of opioid
withdrawal in humans (e.g. diarrhea). However, the lack of effects of endocannabinoid catabolic
inhibitors on the acquisition of CPA suggests that their efficacy may not extend to affective
aspects of opioid withdrawal, though these results are from a single experimental assay (CPA)
and tested in a single mouse strain. Regardless, the observations that endocannabinoid catabolic
enzyme inhibitors reduce somatic withdrawal signs argue for further investigation of these drugs.
The ability of endocannabinoids to attenuate the expression of diarrhea also suggests that these
effects are not simply non-specific reductions in behavior and a previous study demonstrating
that endocannabinoid catabolic inhibitors reduce naloxone-precipitated increases in contractions
of morphine treated ilea supports this (Ramesh et al., 2011). Future studies should examine the
ability of these compounds to reduce other behaviors that may reflect affective components of
opioid withdrawal and also examine them in other models of drug abuse such as reinstatement of
opioid self-administration in dependent rodents. Additionally, determination of the downstream
signaling events which may mediate their effects will provide further evidence for interactions
between endocannabinoid and opioid systems during opioid withdrawal. Conditional knockout
of CB1 receptors on mu opioid receptor containing neurons would provide a means for
determining the mechanism of cannabinoid action on reducing somatic withdrawal signs. In
conclusion, inhibition of endocannabinoid catabolism is effective at attenuating somatic opioid
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withdrawal signs and further studies on their effects on other aspects of opioid withdrawal are
warranted.
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